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Summary (English)
Data analysis of medical images is an important and growing area, as systems
for imaging becomes still more available and complex.
The goal of this thesis is to demonstrate solutions to data analysis problems in
a cross disciplinary context. Further, to develop methods for analysis of new
imaging modalities and to combine cross disciplinary knowledge from various
ﬁelds to ﬁnd new solutions to existing problems.
More speciﬁcally this thesis shows segmentation of images, classiﬁcation and
statistics used on a variety of quite diﬀerent problems. Active Appearance
models, Chan-Vese and graph-cut has been used, as well as a variety of statistical
tools centred on the General Linear Model.
The point of departure for the thesis is the NanoGuide project, in which gel
based x-ray markers for use in radiotherapy has been developed. Two diﬀerent
types of gels has been analysed using segmentation of micro-CT images followed
by a statistical analysis of homogeneity, contrast, degradation, and other qual-
ities. By combining knowledge from the diﬀerent professions in the project, a
new application for one of the developed gels - in-vivo dosimetry in radiotherapy
- has been studied.
Analysis of diﬀerences between groups and of correlations between brain regions
and cognitive tests in alzheimers patients is another contribution. Segmentation
of fat in abdominal MRI-scans has also been studied and a robust algorithm
based on graph-cut is presented.
ii
A relatively new modality  phase-contrast x-ray and dark-ﬁeld  has shown
promise for diagnosis of a variety of diseases in the lungs. A classiﬁcation algo-
rithm for diﬀerentiation of healthy, emphysematous and ﬁbrotic lung tissue on
pixel level is presented.
Resumé
Dataanalyse af medicinske billeder er et vigtigt og voksende område, da systemer
til billeddannelse bliver stadig mere udbredte og komplekse.
Målet for denne afhandling er at demonstrere løsninger på dataanalyseproble-
mer af medicinske billeder i en tværfaglig sammenhæng. Endvidere, at udvikle
metoder til analyse af billeder fra nye billeddannede modaliteter og kombinere
tværfaglig viden fra forskellige felter til at ﬁnde nye løsninger på eksisterende
problemer.
Mere speciﬁkt viser denne afhandling segmentering af billeder, klasiﬁkation og
statistik anvendt på en række - ret forskellige - problemer. Active Apperance
Models, Chan-Vese og graph-cut er blevet brugt, og en række statistiske meto-
der, centreret omkring den Generelle Lineære Model er blevet anvendt.
Udgangspunktet for afhandlingen er NanoGuideprojektet, i hvilket gelbaserede
røntgenmarkører til brug i stråleterapi er blevet udviklet. To forskellige typer af
geler er blevet analyseret ved hjælp af segmentering i mikro-CT billeder og en
efterfølgende statistisk analyse af homogenitet, kontrast, nedbrydelse og andre
egenskaber. Ved at kombinere viden fra de forskellige faggrupper i projektet, er
en ny anvendelse - in-vivo dosimtry i stråleterapi - for de udviklede geler blevet
undersøgt.
Analyse af forskel mellem grupper og korrelation mellem segmenterede hjernere-
gioner og kognitive test i alzheimerspatienter udgør et andet bidrag. Segmente-
ring af fedt i abdominale MR-scaninnger er også blevet undersøgt, og en robust
algoritme baseret på graph-cut præsenteres.
iv
En relativt ny modalitet  fasekontrast-røntgen og mørkefelt  har vist sig loven-
de til diagnoisticering af en række sygdomme i lungerne. En klassiﬁkationsal-
goritme til at diﬀerentiere sundt, emfysemt og ﬁbrøst lungevæv på pixelniveau
præsenteres.
Preface
This thesis was prepared at the department of Applied Mathematics and Com-
puter Science at the Technical University of Denmark in fulﬁlment of the re-
quirements for acquiring an PhD in Applied Mathematics with an emphasis on
Mathematical Image Analysis. The thesis was part of the NanoGuide project
and was prepared with funding from the Danish Council for Strategic Research.
Professor Knut Conradsen started as co-supervisor and ended as the main su-
pervisor and vice versa for professor Rasmus Larsen.
The thesis deals with data analysis of medical images, namely CT, MRI, Phase
Contrast X-ray and PET.
The thesis consists of a part with the general methodology that was applied and
a part summarising the scientiﬁc contributions of the thesis.
Lyngby, 01-October-2015
Anders Nymark Christensen
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Chapter 1
Introduction
Data analysis of medical images are an important and growing ﬁeld. With the
advent and wide spread use of diverse systems for medical imaging, we face
an increasing demand for automation and quantitative analysis. Both to save
valuable time in the clinic, to extract information not apparent to a human ob-
server, and to interpret results rigorously to avoid spurious conclusions. Further
by combining physical knowledge of the various systems, we may develop new
applications to solve current problems.
The objectives of this thesis are:
• To engineer solutions to data analysis problems of medical images in cross
disciplinary settings
• To develop methodologies for new medical imaging techniques
• To combine data analysis with physical knowledge of imaging modalities
to achieve new solutions to exiting problems
2 Introduction
1.1 NanoGuide project
Cancer is diagnosed in more than 14.1 million people each year and 8.2 million
die from it 1. With the ageing populations and better diagnostics this number
is increasing.
For the treatment more than 50 % of cancer patients receive radiotherapy. Ra-
diotherapy uses ionising radiation to kill the cancerous cells. This treatment is
highly dependent on advanced imaging techniques such as CT, PET and MRI
for the location of the cancer. A major challenge is the movement of both
tumours and normal tissue during the radiotherapy.
These problems can potentially be alleviated by image-guiding during the treat-
ment. However, the tumours are often diﬃcult to visualise and track with the
imaging apparatus available in connection with the treatment. To increase the
image contrast, solid markers of e.g. gold are implanted in or around the tu-
mours. This requires large diameter needles and adverse side-eﬀects are rela-
tively common.
The goal of the NanoGuide project was thus to develop new markers and tracers
for use in the treatment of cancer, based on nano-technology, that did not have
the short-comings of the existing markers and were better than existing tracers.
This thesis is part of NanoGuide project and the ﬁrst three contributions also
come from this project. The project is cross-disciplinary in nature and has con-
tributions from DTU Nanotech, DTU Chemistry, DTU Nutech and DTU Com-
pute through yours truly and my supervisors. Also contributing are Copenhagen
University Hospital, Rigshospitalet, Gentofte and Bispebjerg and the industry
in the form of the companies Nanovi and GE Healthcare. In this setting the
demands of the project took precedence, with regard to the tasks and scientiﬁc
work that were pursued.
It was originally envisioned, that a systemic marker for intra-venous injection
was going to be developed. The nano-particles in this marker would then cir-
culate with the bloodstream and bind to any cancerous tissue, marking them
for radiotherapy. In that regard my task would have been analysis of CT- and
PET-images investigating the biodistribution of the tracer. Unfortunately, this
part of the project met unforeseen challenges and has not yet come to fruition.
A second marker for local injection through a thin ﬂexible needle was pur-
sued concurrently with the systemic marker. This marker - based on gold-
1http://www.cancerresearchuk.org/health-professional/cancer-statistics/
worldwide-cancer
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nanoparticles (paper A) and later iodine (paper B) - was much more successful.
It was originally envisioned that shape-statistics of the marker would be hugely
relevant. Both for the characterisation of the marker in terms of stability and
for its use in radiotherapy. This turned out to be of very little practical im-
portance, and the eﬀort was put into general characterisation of the gels with
regard to stability and visibility.
The iodine based gel-marker is in the ﬁnal stages of regulatory approval, and
has been tested in-vivo in both mice, pigs and patients. It was decided in the
project not to publish results along the way to avoid damaging the novelty value.
As such all the results are being collected into a single high-impact article,
describing the full process from bench-to-bedside. In this thesis a technical
report has been included (paper B), exemplifying the work I have contributed.
Many other tasks have been performed with regard to statistical analysis of
results and general modelling, both for regulatory approval and for other smaller
experiments.
As often seen in science within engineering the work was thus problem driven
and had to be adjusted to the requirements of the NanoGuide-project. While
little new methodology has been developed, existing techniques has been applied
in new settings and for new purposes.
1.1.1 Motivating examples
In external beam radiotherapy we rely on accurate and precise targeting of the
tumour. Even with precise delineation and alignment of the patient, breathing
and bowel movements will lead to possible errors. More over, with conven-
tional 2D x-ray imaging the contrast is too low to track the tumour on-line
while treating. One of the goals in the NanoGuide project was to develop a
nanoparticle-hydrogel marker for local administration (ﬂuid that gels upon in-
jection) with good contrast. Thus allowing for online tracking of the tumor while
treating. This has been achieved, see paper A, where gold nano-particles were
used to achieve the necessary contrast. For the analysis we needed to quantify
the inhomogeneity in the gels. The gels were placed in mice and imaged on a
micro-CT scanner. The analysis was made more complicated by the fact, that
gels with diﬀerent contrast levels were compared.
A second even more promising gel is in the ﬁnal stages of regulatory approval,
see paper B. It uses iodine instead of gold, and has very good characteristics
with regard to stability and contrast. An important subtask for me, has been
statistical analysis of results for regulatory approval of the developed markers.
In the paper we had a situation with multiple measurements on the same mice.
4 Introduction
Figure 1.1: Maximum Intensity Projection of two gels in a mouse, paper B
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Figure 1.2: Volume data over time from mice in paper B
We ﬁrst needed to segment the gel, see ﬁg. 1.1, and could then extract volume
information, see ﬁg. 1.2. Here the main interest was the degradation rate of
diﬀerent formulations of the gel. A Repeated Measurements Model was used to
quantify the results.
Through this collaboration another possible application for the gels developed
was envisioned, namely as an in-vivo dosimeter, see paper C.
By combining knowledge about nuclear physics with knowledge about problems
in radiotherapy and the capabilities of the diﬀerent imaging modalities available,
we can reach new solutions. One is to measure the dose delivered through radio-
therapy in-vivo, by activating silver nano-particles embedded in a gel through a
(γ,n)-reaction. By measuring the resulting activity level in a PET scanner, we
can estimate the dose. The activation of the silver gels are shown in ﬁg. 1.3.
1.2 Brains, Abdominal Fat and Mice
Although this thesis took its point of departure in the NanoGuide-project, the
basic methodology, image-analysis and statistical analysis could be readily ap-
plied to other areas. This exempliﬁes the general use of the approach.
6 Introduction
Figure 1.3: Maximum intensity projections. From left to right CT, PET/CT,
and PET. The silver gels are clearly activated by the photon irra-
diation used in radiotherapy. See paper C.
(a) Segmentation of abdominal fat, pa-
per E
(b) Lung segmentation in a mouse using
a dark-ﬁeld image, paper F
Figure 1.4: Diﬀerent segmentation problems
In paper D the eﬀect of exercise on alzheimers disease was investigated through
MRI-scans of the brain. To quantify changes between two groups a Hotellings
T2 test was performed. As several outliers were present in the data, the results
were further conﬁrmed by a non-parametric test. In the same paper it was
investigated whether there was any correlation between cognitive test scores
and the changes in speciﬁc brain regions. A statistical test for this special
situation was employed.
In paper E we had a segmentation problem: How to quantify the amount of ab-
dominal fat from a MRI-scan. Faced with a segmentation problem, the standard
approach outside the image analysis community is nearly always manual segmen-
tation. This is slow, tedious work, and suﬀers from both inter- and intra-observer
variance. By making these segmentations automatic, we can both reduce the
variance stemming from the observer and drastically reduce the required time
for analysis. See ﬁg. 1.4 (a) for an example of the segmentation.
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In paper F we were presented with the challenge of classifying diseases in mice,
based on absorption, dark-ﬁeld and diﬀerential phase images. First the lungs
needed to be segmented, see ﬁg. 1.4 (b), to extract the relevant parts. Fig.
1.5 illustrates a classiﬁcation on the basis of only two of the images available:
absorption and dark-ﬁeld.
1.3 Reading Guidelines
Part I serves as a common reference and introduction to the methodologies used
in this thesis. This part assumes a basic knowledge of physics, image analysis
and statistics.
Part II summarises the contributions and puts them in context.
The contributions are included in part III.
The thesis can either be read from the beginning, or one can start with part II
and refer back to part I to clarify details in the applied methodology.
8 Introduction
(a) Absorption image (b) Dark-ﬁeld image
(c) Classiﬁcation
Figure 1.5: Illustration of classiﬁcation. Green is healthy, blue is emphysema
and red is ﬁbrotic. The marked regions are classiﬁed as ﬁbrotic by
a radiologist.
Part I
Methodology

Chapter 2
Imaging, Radiotherapy and
Related Physics
This chapter is meant as a short overview of the imaging modalities used in this
thesis, as well as the basic principles behind radiotherapy and some of the related
physics. References are given if the reader want a more in-depth treatment.
2.1 Computed tomography
Computed tomography (CT) uses an X-ray tube and detector panel mounted
around an axis where the object or subject to be imaged are placed. By rotating
the tube and detector together, images are taken at diﬀerent angles. Given
enough of these angular projections a 3D image can be reconstructed using
Filtered Back Projection (FBP), see section 2.4.1.1. While having a rather poor
contrast in soft tissue, CT has excellent contrast between soft tissue and bone.
A CT scan is quantitative and the unit of the images are normally given in
Hounsﬁeld Units (HU) deﬁned by:
HU = 1000 ·
(
µ
µwater
− 1
)
(2.1)
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where µ is the linear attenuation coeﬃcient. Table 2.1 shows the HU values in
various tissues.
Table 2.1: HU values in diﬀerent substances and organs [Jørgensen, 2005]
Substance HU
Air -1000
Lung -900 to -500
Fat -100 to -85
Water 0
Kidney 20 to 40
White matter 20 to 40
Grey matter 35 to 55
Blood 50 to 60
Muscle 40 to 50
Liver 60 to 70
Spongious bone 30 to 230
Compact bone 250 to 3000
Both resolution, energy of the x-rays (kV) and the amount of photons used
(mAs) can be varied. This gives a trade-oﬀ between image quality and the dose
delivered to the subject. The typical dose can range from about 1 mSv to more
than 10 mSv depending on much of the body is covered by the scan and the
quality of the scan [Elliott, 2011].
See e.g. [Bushberg et al., 2011] for a more in-depth treatment of CT. Examples
of uses can be seen in paper A where it was used to quantify the contrast level,
volume, and homogeneity in a gold-based NanoGel. In paper B it was used to
extract volumetric information about a iodine-based NanoGel, and in paper C
it was used for location of gels, dose planning and attenuation correction.
2.1.1 Cone Beam Computed Tomography
A Cone Beam Computed Tomography (CBCT) integrated with a radiotherapy
treatment apparatus, was ﬁrst introduced in 2002 [Jaﬀray et al., 2002]. The
principle is the same as for CT, but a cone beam geometry is used. It allows for
in-situ control of the patient placement, by comparing a planning CT with the
CBCT images.
The geometry with a cone of X-rays hitting a ﬂat-panel detector, does not
allow for the resolution of quantitative units (HU). The geometry also induces
a number of artefacts [Schulze et al., 2011]. Iterative reconstruction algorithms
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that can correct for some of these artefacts exists. They are, however, rather slow
for clinical use. Instead a variation of the FBP called the Feldkamp algorithm
is used [Feldkamp et al., 1984]. Even with these drawbacks, CBCT is still a
valuable tool for quality control in radiotherapy.
Examples of uses can be seen in papers A and C.
2.2 Phase Contrast X-ray
CT and normal x-ray images rely only on the absorption of the x-rays. In phase
contrast imaging  as the name implies  the phase is also used.
Several techniques exists, but only grating based imaging (GBI) will be treated
here. See [Bech, 2009, Nesterets and Wilkins, 2008] for an overview of the diﬀer-
ent techniques. The review here for GBI is based on [Bech, 2009, Jensen, 2010].
The complex refractive index is given by:
n = 1− δ + iβ (2.2)
where δ is the normal refractive index determining the phase shift and β is the
attenuation, see ﬁg. 2.1.
Figure 2.1: Illustration of the complex refractive index. We see the resulting
phase shift and attenuation by passing through a medium. From
[Bech, 2009]
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We want an imaging technique that, in addition to measuring β, the attenuation,
measures the phase shift δ. The grating based imaging can do that, and more.
The basic mechanism is given by ﬁg. 2.2.
Figure 2.2: Illustration of the two gratings that make detection of phaseshift
possible. From [Bech, 2009]
By introducing the g1 grating, we get a diﬀraction pattern. However, to resolve
that we would need very high resolution in our detector. By introducing the
second grating g2 we can sample the wavefront, by shifting the g2 grating, thus
measuring the phase shift at several positions and resolve it.
However, this setup needs coherent x-rays, but it is possible to insert a grating
array that acts as many thin slits, enabling the use of standard x-ray tubes. In
that case we have a setup like the one seen in ﬁg. 2.3.
The positions and the characteristics of the gratings needs to be matched to the
x-ray energy, and the distance from the source to g1.
When shifting the g2 grating the signal can be written as:
Ipx,py (xg) = a0(px, py) +
∞∑
m=1
am(px, py)cos
(
2pimxg
g2
+ φm(px, py)
)
(2.3)
where xg is the shifting, Ipx,py is the measured intensity in pixel x, y.
Instead of ﬁtting the intensities directly to this equation to resolve, a0, am and,
φm, we can simply take the Fourier transform. In addition to the sample scan
s, a reference scan r is acquired, to correct for inhomogeneities.
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Figure 2.3: GBI setup with incoherent x-ray source. From [Bech, 2009]
We can now recover the absorption or transmission image by:
a0 =
as0
ar0
(2.4)
the diﬀerential phase is given by:
φ1 = φ
s
1 − φr1 (2.5)
and the visibility  normally known as darkﬁeld  as:
V =
as0
ar0
∑
m odd
asm
arm
(2.6)
examples of the three images can be seen in ﬁg. 2.4. Examples of uses can be
seen in paper F, where the modality was used to classify between diseased and
healthy lung in a murine model.
2.3 Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) is a versatile imaging technique that utilises
nuclear magnetic resonance (NMR). While the images are not quantitative in
nature like CT, it can be used to get quantitative results, especially with regards
to volume. The following review is based on [Nishimura, 2010, Hanson, 2009].
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(a) Absorption image (b) Dark-ﬁeld image (c) Diﬀ. phase image
Figure 2.4: The three image types obtainable using grating based imaging.
The images are of the same mouse.
In relation to imaging of humans, it is the hydrogen content of the body that is
used, as it has non-zero spin. Associated with the spin is the magnetic moment
M. Given a huge magnet, that generates a magnetic ﬁeld B, the moment and
ﬁeld will reach an equilibrium over time and point in the same direction.
If we now perturb the moment by a radio frequency (RF) pulse we get:
dM
dt
= M×B (2.7)
Remembering the right hand rule, we see that M will precess around B. The
frequency is given by: f = γ2piB Hz, where γ is the gyromagnetic ratio and the
frequency is known as the Larmor frequency.
To do imaging we use RF pulses to introduce speciﬁc ﬂips in the magnetic
moment. Further we use gradient coils to introduce a gradient in the magnetic
ﬁeld B across the subject. As the frequency is dependant on B f will vary
across the subject and a roll pattern will develop. The returned signal is now
dependent on how much this roll pattern is similar to the subject. In eﬀect we
sample the subject in the Fourier domain or k-space, as it is called within MRI.
An illustration can be seen in ﬁg. 2.5.
This gives us a trade-oﬀ between scan time and resolution. If we only cover the
central parts of k-space, we will get a blurred image. If we want to cover k-space
more extensively it increases the scan time.
Many diﬀerent scans can be performed that weigh the subject diﬀerently. The
three most used sequences are T1, T2 and proton-density. But other sequences
are also used, i.e. Dixon [Ma, 2008, Dixon, 1984] which is very fast and gives
two images: one of the water content and one of the fat content, but at the cost
of poor resolution. If not constrained by speed T1 with water suppression seems
the best for imaging fat.
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Figure 2.5: Row 1: More and more detailed roll patterns are added. Row
2: The resulting image as more patterns are added. Row 3: The
parts of k-space that have been sampled. From [Hanson, 2009]
As the scans are relatively long, a common artefact is subject movement. An-
other common artefact is a bias-ﬁeld. This is due to inhomogeneities in the
18 Imaging, Radiotherapy and Related Physics
magnetic ﬁeld B, and leads to varying intensity across the images.
Examples of uses can be seen in paper D where it was used to extract volumetric
information about the brain in alzheimers patients and in paper E where the
modality is used for quantiﬁcation of abdominal fat.
2.4 Positron emission tomography
Positron emission tomography (PET) detects the γ-photons that are emitted
following the annihilation of a positron from a β+ decay and an electron. The
following is based on [Knöß, 2004].
A ring of detectors are placed around the subject, and when two photons are
detected at approximately the same time (within approx. 6 ns [Knöß, 2004]),
we know that a decay has happened on the line between the two detectors: The
line of response (LOR). The newer PET scanners can even resolve the time at
a level detailed enough (picosecond level!) to give information about where on
the line the decay has occurred.
The source of the β+-decays are a radioactive tracer injected into the subject.
Some of the more commonly used isotopes are 18F, 11C and 15O.
Several sources of errors must be considered and corrected for PET scans to
yield quantitative results. Three of the most important are:
• Attenuation: The subject scanned attenuates the γ-photons. If no at-
tenuation correction is made, the signal for superﬁcial parts will be over-
estimated compared to deeper lying parts. To correct for the attenua-
tion most newer systems use a CT scan, integrated into the PET scanner
[Kinahan et al., 2003]. Some systems use a radioactive line or point source
that are rotated around the subject to estimate it.
• Scatter: The γ-photons may be scattered on their way to the detectors.
This means that the decay has not taken place on the LOR. If not cor-
rected, this will lead to a blurring of the entire image. Newer systems use
model based, monte-carlo simulations incorporating information from the
CT scan that was also used for attenuation correction [Siemens, 2009].
• Decay: The tracer injected decays while the scan is performed. Typically
the scan is decay corrected to the start of the scan. The decay formula is:
A(t) = A0e
−λt (2.8)
where A0 is the initial activity and λ the decay constant.
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Figure 2.6: The sinogram is formed from the diﬀerent angles φ and positions
s. Copyright c© 2013, Milan Zvolský 1
An example of uses can be seen in paper C, for the measurement of radioactive
silver used for in-vivo dosimetry.
2.4.1 Reconstruction algorithms
The detected events are collected into a sinogram. The sinogram has angles
along one axis and position perpendicular to the given angle along the other
axis , see ﬁg. 2.6. For reconstructing the sinograms into images, two main
groups of algorithms exist. The ﬁltered backprojection (FBP) and the iterative
reconstructions.
2.4.1.1 Filtered Backprojection
The FBP is generally the most reliable algorithm, but also yields more noisy
images than the iterative methods.
If we just back-projected these data, we would get a heavy blurring in the
middle. Instead we take the Fourier transformation, apply a ﬁlter to avoid the
1http://www.desy.de/~garutti/LECTURES/BioMedical/Lecture7_ImageReconstruction.
pdf
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blurring, and ﬁnally apply the inverse Fourier transformation.
f(x, y) = F−1{h(ω)F(vx, vy)} (2.9)
where F is the Fourier transform, h is the ﬁlter, and vx, vy are polar coordinates.
2.4.1.2 iterative reconstruction
The iterative reconstruction method derive from the Ordered Subset Expecta-
tion Maximisation method [Hudson and Larkin, 1994]. They have been devel-
oped to incorporate the points-spread function and other corrections, to increase
the resolution and reduce noise, see e.g. [Comtat et al., 2008]. The forward
model is given by:
y = Aλ+ b (2.10)
where y is the sinogram, λ is the image we want to estimate, and b is the noise
and scatter. A is a system matrix that contains both geometric information,
but also information about the blurring eﬀects. Because of this the backwards
model can get quite complicated.
A speciﬁc problem with iterative methods are, that they tend to overestimate
low activities [van Velden et al., 2009, Boellaard et al., 2001]. For uses where
we want quantitative results the FBP should thus be preferred.
2.5 Radiotherapy
Radiotherapy aims at destroying cancerous tissue by delivering doses of ionising
radiation, while minimising side eﬀects on healthy tissue. The ionising radiation
induces DNA damage, and as cancerous tissue has a higher rate of cell division,
is is more susceptible to the damage.
While particle based radiation has seen growing use, it is still very specialised
and expensive. Most commonly used is high-energy photons, which are gener-
ated by Bremsstrahlung from linear accelerators. By using a multi-leaf collima-
tor, the x-ray beam can be precisely shaped, see ﬁg. 2.7.
A CT scan is used for the dose plan. Radiographers will outline the tumor
or tissue to be targeted, and medical physicists will make a dose-plan using
2http://filecache.drivetheweb.com/mr5mr_varian/154577/MLC+-+gold.jpg
http://filecache.drivetheweb.com/mr5mr_varian/154631/clinac+dose+shaping.jpg
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Figure 2.7: Beam forming using a multi-leaf collimator. Copyright c© Varian
Medical 2
advanced monte-carlo based models. By irradiating from multiple angles at
varying intensities and shapes, a suﬃcient dose can be delivered to the target
tissue, while minimising dose to vulnerable tissue. An example can be seen in
ﬁg. 2.8.
Examples of uses can be seen in paper A and C.
2.5.1 Targeting
A very important subproblem in radiotherapy is accurate targeting. If we as-
sume the radiographers have contoured the cancerous tissue correctly, we need
to target it precisely.
CBCT is a big help here, as it can be used to verify correct patient placement
in the accelerator. However, for tumours in thorax or abdomen we have dis-
placements due to breathing and bowel movements. Unfortunately the 2D x-ray
3http://filecache.drivetheweb.com/mr5mr_varian/154488/Base+of+Tongue+RapidArc+
Axial.jpg
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Figure 2.8: Dose plan for a mouth cancer. We note how the spinal cord is
spared for excissive radiation, and receives a low dose by using the
entire arc of angles. Copyright c© Varian Medical 3
images that we can record online while treating cannot be used to distinguish
the tumour, as the contrast is too low. It has been one of the aims of the
NanoGuide-project to rectify this by injectable x-ray markers.
2.6 Photo-nuclear reactions
In the context of radiotherapy the (γ,n)-reaction has interesting applications.
A high energy photon can knock a neutron out of the nucleus, producing a new
isotope. If the produced isotope decays via β+, it can be imaged in a PET
scanner and potentially be used for dosimetry.
The required energy for the reaction to take place varies from isotope to isotope.
Of interest are the isotopes naturally occurring in the body and silver, which has
a high cross-section and produces a high fraction of β+ decay. Other materials
have been investigated, but silver was the most promising [Hansen et al., 2008].
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However, the energies required for the isotopes naturally occurring in the body
 12C: 20.7 MeV, 14N: 17.5 MeV, 16O: 15.7 MeV  are higher than normally used
in radiotherapy and the cross sections are small [Fuller, 1985]. Further even if
activated, we have no ground truth of the amount of the isotope present, which
makes quantiﬁcation very diﬃcult.
In contrast silver can be placed in the subject in a known amount. Natural
silver consists of the isotopes 106Ag and 108Ag, and the energy threshold is only
9.5 MeV [Diven and Almy, 1950]. Their decay is outlined in ﬁg. 2.9.
Figure 2.9: Decay of 106Ag and 108Ag. From [Hansen et al., 2008]
An example of uses can be seen in paper C, where the reaction is used for in-vivo
dosimetry.
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Chapter 3
Image Analysis
This chapter will give a brief overview of the image analysis techniques used in
this thesis. Further details can be found in the references.
3.1 Segmentation
Segmentation is a basic problem in image analysis, and depending on the con-
text, many algorithms are available, ranging from a simple threshold to complex
models. Below we will review some techniques of importance to this thesis.
3.1.1 Active Appearance Models
The Active Appearance Model (AAM) has seen widespread applications since
its introduction in 1998 [Cootes et al., 1998]. The idea is to ﬁt a model or
shape to an image by using not only the shape but also the appearance of
the image. This makes it a more robust alternative to active shape models
[Cootes et al., 1995, Cootes and Taylor, 2001].
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We start with a training set of images with annotated landmarks of a shape and
all in the same coordinate system. Let each shape be represented by a vector
x. Then applying a principal component analysis (PCA) on the training set, we
can describe each shape as:
x = x¯ + Psbs (3.1)
where x¯ is the overall mean shape, Ps is the principal components, in this
context often referred to as modes of variation, and bs is the shape parameters.
We can now warp each shape x to the mean shape x¯, thus shape normalising
them. Given the shape normalised images we extract the convex hull of the
shape and the appearance - or image intensity - can now be modelled equiva-
lently:
g = g¯ + Pgbg (3.2)
where g is the mean and intensity normalised image patches.
By including scaling, translation, rotation, and intensity scaling oﬀset in the
parameters, the shape of a new image can be estimated. To do it eﬃciently
all the parameters are systematically perturbed from their empirical optimal
values and averaged over the dataset. Having this change matrix precomputed
speeds up the estimation signiﬁcantly. In addition a multi-scale approach is
used: Starting at a coarse level and then reﬁning.
An example of the model used to segment the lungs in a mouse can be seen in
ﬁg. 3.1. The model was trained by Hildur Einarsdottir [Einarsdottir et al., 2015]
and used in paper F.
3.1.2 Chan-Vese
Chan and Vese proposed to attack the segmentation problem through a level-
set approach [Chan and Vese, 2001]. Let u denote the image we are trying to
segment and let φ be a level-set function describing a curve and thus partitioning
our image. Further, let H be the Heaviside function:
H(x) =
{
1 if x ≥ 0
0 if x < 0
(3.3)
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Figure 3.1: AAM used for lung segmentation in a mouse
The method then seeks to minimise an energy functional given by:
F (φ) =µ
∫
Ω
|∇H(φ(x, y))| dx dy
+ ν
∫
Ω
H(φ(x, y)) dx dy
+ λ1
∫
Ω
|u(x, y)− c1|2H(φ(x, y)) dx dy
+ λ2
∫
Ω
|u(x, y)− c2|2(1−H(φ(x, y)))dx dy
(3.4)
where Ω describes the entire image. The ﬁrst term is the length of the curve
weighted by µ. The second term is the area enclosed by the curve weighted by
ν. The two last terms are the homogeneity of the area inside and outside the
curve, where c1, c2 are the mean value of the areas, weighted by λ1 λ2.
Often ν is set to 0, and the two last terms concatenated into one with equal
weighting. In addition some degree of smoothing is often applied to counter the
eﬀects of noise. This is the case in the implementation1 used to segment gels in
mice in paper B.
1http://www.mathworks.com/matlabcentral/fileexchange/
24998-2d-3d-image-segmentation-toolbox
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3.1.3 Graph-Cut
Graph-cut allows for 'optimal` segmentations as graph-cut algorithms can be
used to ﬁnd the optimum cut in a graph. The problem is how to formulate ones
segmentation problem as a graph.
Boykov and Kolmogorov published an eﬃcient algorithm in 2004 [Boykov and Kolmogorov, 2004]
for graph-cuts in vision, although graph-cuts had seen application before, see
e.g. [Ishikawa, 2003, Ebastien, 1999].
We denote a directed graph G = 〈V, E〉, which consists of nodes with individual
costs V and directed edges also with individual costs E . Further, the graph has
a source t and a sink s. The task is now to ﬁnd the minimum s/t-cut, that
partitions the graph into two subsets. This is done by the min-cut / max-ﬂow
property. Looking at the graph as a set of pipes with diﬀerent capacity, it seems
obvious that the pipes saturated and thus determining the max-ﬂow across the
graph, will be the same pipes that lead to a minimum cut.
To utilise it in segmentation we need to formulate the image as a graph, see ﬁg.
3.2.
This is the most basic formulation. Often the node and edge weight are given by
the Gibbs model [Geman and Geman, 1984] leading to Markov Random Fields
[Greig et al., 1989], but can be extended in several diﬀerent ways [Boykov and Kolmogorov, 2003].
In this thesis a method for multi-layer segmentation proposed by Li et al.
[Li et al., 2006] was used.
Given a 3D image we can view it as a matrix I(x,y, z). If the orientation is as
in ﬁg. 3.3 (a) the surface will only intersect each (x,y) column of voxels once.
To ensure connectivity we have intracolumn edges Ea given by:
Ea = {〈V (x, y, z), V (x, y, z − 1)〉|z > 0} (3.5)
To incorporate smoothness constraints ∆x and ∆y we add intercolumn edges
given by:
Er =

{〈V (x,y, z), V (x+ 1,y,max(0, z −∆x))〉 | x ∈ {0, . . . , X − 2}, z ∈ z}∪
{〈V (x,y, z), V (x− 1,y,max(0, z −∆x))〉 | x ∈ {1, . . . , X − 1}, z ∈ z}∪
{〈V (x, y, z), V (x, y + 1,max(0, z −∆y))〉 | y ∈ {0, . . . , Y − 2}, z ∈ z}∪
{〈V (x, y, z), V (x, y − 1,max(0, z −∆y))〉 | y ∈ {1, . . . , Y − 1}, z ∈ z}
(3.6)
The intercolumn edges guarantee, that if voxel I(x, y, z) is on the the surface N ,
then the neighboring voxels on N in the x-direction, cannot be lower than than
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Figure 3.2: Typical grid-like graph for segmentation in images. While shown
as uni-directional here, the image edges (red arrows) would typical
be bidirectional. The cut is the dashed line. From: Graph cuts
via l1 norm minimization, Bhusnurmath et al, IEEE transactions
on pattern analysis and machine, 2008, Copyright c© 2008, IEEE
I(x, y,max(0, z −∆x)) and similar for the y-direction. The setup is illustrated
in ﬁg. 3.3 (b).
This can be generalised to 4D, when we have multiple surfaces. The constraints
now ensure that we have minimum and maximum distance between the surfaces.
The node weights or energies are set depending on what we want to segment.
If it is layers in a 3D volume, it could e.g. be the inverse of the gradient. Often
the surface we want to segment is folded or circular. The above method can
still be used after an unrolling.
In paper E the method was used for segmentation of subcutaneous fat and in F
it was used to identify the spine of mice on x-ray images.
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Figure 3.3: (a) Surface orientation. (b) Two adjacent columns with edges.
[Li et al., 2006], Copyright c© 2006, IEEE
3.2 Image Filters
An image can be treated as a matrix, and we can perform the same operations
on an image as on a matrix, even though a lot of them might not be sensible.
We will look at some of the more common ﬁlters, that have also been applied
in the contributions of this thesis.
By kernel we mean a mask, that we center on each pixel or element in the image,
calculate the value from element-wise multiplication of the kernel and image and
then replace the pixel we have centred on with the resulting value.
3.2.1 Image smoothing
An image can be smoothed, i.e. noise removed or reduced. The most common
 and some of the most simple  methods are Gaussian and median smoothing.
We start by choosing a 2D-Gaussian kernel:
G(x, y) =
1
2piσ2
e−
x2+y2
2σ2 (3.7)
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with a given σ. This function is discretised and made into a n×n matrix. This
size will depend on the size of σ. A larger standard deviation needs a larger
matrix.
The median smoothing is a non-linear ﬁlter, and cannot be formulated as a
kernel ﬁlter. Within the kernel area the median value is calculated and that
value returned to the centre pixel. The degree of smoothing is now directly
dependant on the size of the matrix.
For both types of kernel we have assumed symmetry. This needs not be the
case. If we want a heavier smoothing in one direction, we can make the kernel
larger in that direction and vice versa. The methods saw use in paper E and F.
3.2.2 Texture ﬁlters
To describe a local feature like texture, we can also use ﬁlters.
The range ﬁlter is given by a kernel of size n×m. Within that kernel, the range
is calculated and the values returned. The same for the standard deviation
ﬁlter except the standard deviation is returned. The entropy ﬁlter is a bit more
complicated. It calculates the entropy E in the kernel given by:
E = −
∑
kernel
p · log2(p) (3.8)
where p is the histogram approximation to the probability density function from
the kernel region.
The texture ﬁlters were used in paper F to extract information from the diﬀer-
ential phase image.
3.2.3 Feature extraction
We can also use ﬁlters to extracts features from the image, i.e. edges or ridges.
A very versatile ﬁlter is the Laplacian of Gaussian (LoG) ﬁlter. The kernel is
given by:
LoG(x, y) = − 1
4piσ4
[
1− x
2 + y2
2σ2
]
e−
x2+y2
2σ2 (3.9)
which is simply the Laplacian of the Gaussian kernel. The ﬁlter can be used to
identify blobs, holes, ridges and valleys, depending on the sign.
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The gradient can be used to detect edges. A simple kernel is given by:
Gx =
[− 12 0 12] (3.10)
Gy =
− 120
1
2
 (3.11)
which is simply the central diﬀerence in the x and y direction.
An example of the two ﬁlters is given in ﬁg. 3.4. In addition to paper F, the
ﬁlers were also used extensively in paper E for the estimation of energies for
segmentation.
(a) Absorption image of mouse
(b) LoG (c) Gradient
Figure 3.4: Example of gradient and LoG ﬁlter used in paper F. (b) The LoG
ﬁlter is with a kernel of 25× 25 and with a σ of 8. (c) Sum of the
absolute value of the gradients in the x- and y-directions.
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3.3 Histogram equalisation
When posed with an image with poor contrast, we can enhance it by histogram
equilisation. The basic idea is that by making the histogram of the image more
uniformly distributed, we use more colours and the contrast is increased.
Since the contrast is not globally dependant, but is local feature, it also makes
sense to do this in local areas of the image instead of globally.
One method is the Contrast Limited Adaptive Histogram Equilisation (CLAHE)
[Zuidervel, 1994]. The image is partitioned into 8x8 regions, and a histogram
equilisation is performed in each region. Since this alone often leads to noise in
homogeneous regions and many bins 'wasted' on homogeneous regions, a clipping
factor is introduced. This clipping factor determines when the histogram should
be `clipped' and bins with values above are thus redistributed equally. See ﬁg.
3.5. The eﬀect can be seen in ﬁg. 3.6. Both the number of regions and the
clipping factor can be varied.
Figure 3.5: Clipping and redistribution procedure in CLAHE 2
3.4 Bias Correction
Bias ﬁeld correction has a very important role in MRI, but also has applications
in other areas e.g. to correct for unequal illumination in vision systems. Using
a generative model [Larsen, 2015] we can estimate and model the bias-ﬁeld by
a sum of basis functions.
2 https://upload.wikimedia.org/wikipedia/commons/thumb/5/5f/Clahe-redist.svg/
600px-Clahe-redist.svg.png
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(a) Absorption image of mouse (b) CLAHE
Figure 3.6: Example of the eﬀect of contrast equalisation. Used in paper F
for identiﬁcation of ribs
The image is assumed to consist of a number of Gaussian classes, which can be
set depending on the scan. By tuning this and other hyperparameters such as
a smoothing distance controlling how ﬂexible the bias-ﬁeld is and a regularisa-
tion parameter punishing curvature of the bias-ﬁeld, we can achieve very good
corrections. For an example see ﬁg. 3.7.
(a) MRI with bias-ﬁeld (b) MRI corrected for bias-ﬁeld
Figure 3.7: Example of a MRI before and after bias-correction. Used in paper
E
Chapter 4
Statistics
This chapter is meant to give an overview and a common reference for the
statistical methods used in this work. Although it is very brief it has more of a
survey character then the preceding chapters. Further details may be found in
the references.
4.1 General Linear Model
The general linear model is a powerful framework that encompasses many dif-
ferent tests, see the ﬂowchart on page 37. The basic formulation is
Y = XB +  (4.1)
where Y is a matrix of measurements, X is our model/design matrix, B is a
matrix of coeﬃcients to be estimated and  is a matrix of noise or errors. The
errors are assumed to be normally distributed N (0, σ2Σ) with covariance Σ.
We will return to the model where Σ is structured with unknown parameters
in the section about Repeated Measurement Models 4.2.
In the following only the one-way tests are shown. The review is based on
[Johnson et al., 2007] and [Ersbøll and Conradsen, 2012].
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Table 4.1: Analysis of Variance table
Source of variation Sums of Squares Degrees of freedom
Treatments
∑k
i=1 ni(y¯i − y¯)2 k − 1
Error
∑k
i=1
∑ni
i=j(yij − y¯i)2
∑
ni − k
Total
∑k
i=1
∑ni
i=j(yij − y¯)2
∑
ni − 1
4.1.1 Analysis of variance
Analysis of variance (ANOVA) is a subset of the GLM. Here the left hand side
is univariate and we have i treatment eﬀects:
Yij = µ+ τi + ij (4.2)
where Yij is the measurement from sample j belonging to treatment i for a total
of N samples, µ is the overall mean, τi is the treatment eﬀect of treatment i
and ij is the errors that are N (0, σ2) distributed. Let ni denote the number of
samples in treatment i, it then follows that
∑
i niτi = 0.
The null-hypothesis, that we see no eﬀects of the k treatments:
H0 : τ1 = τ2 = . . . = τk (4.3)
can then be tested be dividing the variation into three eﬀects. We consider the
sum of squares (SS) of the eﬀect, the error and the total. Those are given by:
SStreatment =
k∑
i=1
ni(y¯i − y¯)2 (4.4)
SSerror =
k∑
i=1
ni∑
i=j
(yij − y¯i)2 = SStotal − SSeﬀect (4.5)
SStotal =
k∑
i=1
ni∑
i=j
(yij − y¯)2 (4.6)
It is customary to write this as a table, see Table 4.1.
From these we construct the F-test, which will reject the null-hypothesis at level
α if fulﬁlled.
SStreatment/(k − 1)
SSerror/(N − k) > F (k − 1, N − k)1−α (4.7)
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where F is the cumulative F-distribution F (v1, v2)1−α with signiﬁcance level
1− α and v1, v2 degrees of freedom.
This methodology was applied in paper B, C, and D. In the ﬁrst to assess various
models describing the degradation of two types of gels. In the second to assess
the signiﬁcance of various factors that could inﬂuence the measured activity of
106Ag used for in-vivo dosimetry. In the latter to assess the impact of physical
exercise on the brain volume of alzheimers patients.
4.1.2 t-test
The t-test can be formulated as a subset of the ANOVA model and hence the
GLM, but may be used completely independent here oﬀ. Here we are restricted
to max two levels or treatments. While it can formulated as a GLM it is custom-
ary to use a more direct notation and tests. For the 2 sample case (y1,y2) with
the same variance, we can test the hypothesis H0 : µ1 = µ2 against H1 : µ1 6= µ2
with the test statistic:∣∣∣∣∣ y¯1 − y¯2sp√1/n1 + 1/n2
∣∣∣∣∣ > t(n1 + n2 − 2)1−α/2 (4.8)
where y¯ is the mean and sp is the pooled sample standard deviation given by:
sp =
√
(n1 − 1)s21 + (n2 − 1)s22
n1 + n2 − 2 (4.9)
where s1 and s2 are the sample standard deviations, and n1, n2 the sample sizes.
t(v)1−α/2 is the cumulative t-distribution with signiﬁcance level α and degrees
of freedom v.
This test was applied in paper D to assess whether signiﬁcant diﬀerences were
present between a test and a control group of patients.
4.1.3 Welch's t-test
In the 2 sample case (y1,y2) we again wish to test the hypothesis H0 : µ1 = µ2
against H1 : µ1 6= µ2. If we cannot assume equal variances of the samples we
use Welch's t-test instead:∣∣∣∣∣∣ y¯1 − y¯2√ s21
n1
+
s22
n2
∣∣∣∣∣∣ > t(DF )1−α/2 (4.10)
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where the degrees of freedom DF is estimated by the Welch-Satterthwaite equa-
tion:
DF =
(s21/n1 + s
2
2/n2)
2
(s21/n1)
2/(n1 − 1) + (s22/n2)2/(n2 − 1)
(4.11)
This test was applied in paper D to assess whether signiﬁcant diﬀerences were
present between a test and a control group of patients. The test was applied,
when the data could not be assumed to have equal variance.
4.1.4 Multivariate analysis of variance
Multivariate analysis of variance (MANOVA) can be considered as a subset of
the GLM, but may be used independently. We look at the one-way test, but it
can be easily extended to two or more eﬀects. Here we have multi dimensional
measurements on the left hand side:
Yij = µ+ τ i + ij (4.12)
where Yij is the measurements from sample j belonging to treatment i for a
total of N samples, µ is the overall mean, τ i is the treatment eﬀect of treatment
i and ij is a matrix of errors that is N (0, σ2Σ) distributed. It follows that∑
i niτ i = 0.
The SS used in the ANOVA generalises to the multivariate case. We look at
the between (B), within (W), and total (T) variation in the data. That is the
variation between the treatments (eqv. to SStreatment), the variation within the
treatment groups (eqv. to SSerror) and the total variation in the data (eqv. to
SStotal). Given k treatments we get:
B =
k∑
i=1
ni(Y¯i − Y¯)(Y¯i − Y¯)T (4.13)
W =
k∑
i=1
ni∑
j=1
(Yij − Y¯i)(Yij − Y¯i)T (4.14)
T =
k∑
i=1
ni∑
j=1
(Yij − Y¯)(Yij − Y¯)T (4.15)
Instead of the F-test we can use Wilks Λ (Andersons U):
Λ = U =
|W|
|T| =
|W|
|B + W| ≤ Λ(p, k − 1, N − k)1−α (4.16)
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where | | denotes determinant, and Λ(p, k − 1, N − k)1−α is the cumulative
Λ-distribution at signiﬁcance level α, and p is the dimensionality of Y.
This methodology was applied in paper D, to assess the impact of physical
exercise in brain regions of alzheimers patients.
4.1.5 Hotellings T2
Equivalent to the situation with ANOVA, the test is equivalent to a simpler
formulation when we only have 2 levels. For this situation we use Hotelling
T2-test. Given two samples (Y1i, i = 1, · · · , n1) , (Y2j , j = 1, · · · , n1) and
assuming equal covariance the formulation is:
T 2 =
(
1
n1
+
1
n2
)−1/2
(Y¯1 − Y¯2)T S−1pooled
(
1
n1
+
1
n2
)−1/2
(Y¯1 − Y¯2) (4.17)
where n1, n2 are the sample sizes and Spooled is the pooled covariance given by:
Spooled =
n1 − 1
n1 + n2 − 2S1 +
n2 − 1
n1 + n2 − 2S2 (4.18)
where S1 and S1 are the sample covariances. We reject the null-hypothesis,
that H0 : µ1 = µ2 against H1 : µ1 6= µ2 if:
T 2 > c2 =
(n1 + n2 − 2)p
(n1 + n2 − p− 1)F (p, n1 + n2 − 1)α (4.19)
where F is the cumulative F-distribution at signiﬁcance level α with p, n1+n2−1
degrees of freedom.
Like the t-test the T2-test can be extended to unequal covariances for the 2
samples, see e.g. [Johnson et al., 2007].
Indirectly this test was applied in paper D, to assess the impact of physical
exercise in brain regions of alzheimers patients. Although the test were formu-
lated as a MANOVA 4.1.4, this reduces to Hotellings T2 when we only have two
classes.
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4.1.6 Estimation in the General Linear Model
To estimate the parameters in the GLM, we rely on either the inverse or the
pseudo inverse of the model matrix. We recall that the GLM was:
Y = XB +  (4.20)
where Y is a matrix of measurements, X is our model matrix, B is a matrix of
coeﬃcients to be estimated and  is a matrix of noise or errors.
Without loss of generality, we look at the univariate case, i.e. Y is a vector
distributed Y ∼ N (XB, σ2) and B is a vector of coeﬃcients to be estimated. B
can be estimated using a least squares approach:
Bˆ = (XTX)−1XTY (4.21)
If XTX is not full rank we use the pseudo inverse instead.
In practice SAS, R or another statistical language is used for the computations.
SAS has been used in this thesis and in PROC GLM it utilises the generalised
g2-inverse of XTX [SAS, 2008].
As long as the experiment is balanced, no problems arises. However, as soon
as we have missing data or for some other reason have an unbalanced experi-
ment our coeﬃcients and thus sums of squares are not uniquely identiﬁable. In
that context diﬀerent types of SS are reported. The following review is based
on [Iacobucci, 1995, Driscoll and Borror, 2000], but the SAS notation is used
[SAS, 2008]. We distinguish between four types of layout, with the notation
n( , ) denoting number of samples in a cell:
1 Balanced layout: Equal cell frequencies, n(i, j) constant for all i,j combi-
nations
2 Proportional layout: n(i,j)n(i,l) =
n(k,j)
n(k,l) for all i,j,k,l combinations
3 Unbalanced layout: n(i, j) > 0 for all i,j, but [2] does not hold for all
i,j,k,l combinations
4 Missing cells: n(i, j) = 0 for some i,j
We will use a model with an overall mean µ, eﬀects A, B, and interaction AB:
Y = µ+A+B +AB +  (4.22)
to describe the diﬀerent types of SS. The notation will be as follows: SS(A|B) =
SS(B,A)− SS(B).
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4.1.6.1 Type I
Type I is a sequential estimation, and thus dependant on the order of the eﬀects
in the model.
SS(A|µ)
SS(B|µ,A)
SS(AB|µ,A,B)
A nice property of Type I is that the eﬀects SS sum up to the model SS.
Appropriate for:
• purely nested models (speciﬁed in the proper sequence)
• polynomial regression models (in the proper sequence)
4.1.6.2 Type II
Type II estimates the SS after all other eﬀects have been added to the model
except those that contain the given eﬀect.
SS(A|µ,B)
SS(B|µ,A)
SS(AB|µ,A,B)
Appropriate for:
• any main-eﬀects model
• any pure regression model
• an eﬀect not contained in any other eﬀect (regardless of the model)
4.1.6.3 Type III
Type III estimates the SS after controlling for all other eﬀects.
SS(A|µ,B,AB)
SS(B|µ,A,AB)
SS(AB|µ,A,B)
Appropriate for:
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• Unbalanced layout
• Missing cells
4.1.6.4 Type IV
Similar to Type III but handles missing cells diﬀerently.
Appropriate for:
• Unbalanced layout
• Missing cells
To summarise the diﬀerent properties see table 4.2.
Table 4.2: Equalities in Type I-IV SS
Eﬀect Balanced Proportional Unbalanced Missing cells
A I=II=III=IV I=II, III=IV III=IV (all unequal)
B I=II=III=IV I=II, III=IV I=II, III=IV I=II
AB I=II=III=IV I=II=III=IV I=II=III=IV I=II=III=IV
The literature favours using Type III in general. However, in practical work one
tries to obtain the simplest possible model that describe the observations. Then
it will often be necessary to perform a sequential testing based on successively
simpler and simpler models. In that case one must set up the test statistics
manually.
This section is included for completeness and Type III was used in the included
works, e.g. in paper C to assess the signiﬁcance of various factors that could
inﬂuence the measured activity of 106Ag used for in-vivo dosimetry.
4.2 Repeated Measurements Model
In the repeated measurements models (RMM) we use the same structure as the
in the GLM:
y = Xβ +  (4.23)
where y is a vector of measurements, X is our model matrix, β is a vector of
coeﬃcients to be estimated and  is a vector of noise or errors. The change
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is, that the errors now are assumed to have a speciﬁc structure. They are
still normally distributed N (0, σ2Σ) but the covariance Σ now has a speciﬁc
structure and additional parameters that has to be estimated.
By letting the errors be correlated, we can use the information in a longitudinal
study. A subject with a higher value than the mean, is likely to also have a
higher value on the next measurement as the measurements are on the same
subject and thus correlated.
PROC GLM allows for RMM to some degree, but a more ﬂexible framework is
found in PROC MIXED [SAS, 1999]. The documentation for PROC MIXED is
used in the following. As opposed to PROC GLM the procedure PROC MIXED
uses a restricted maximum likelihood estimate (REML) instead of a generalised
inverse.
As PROC MIXED also allows for random eﬀects the model changes to:
y = Xβ + Zγ +  (4.24)
where Z is a known matrix and γ is a vector of unknown random eﬀects to be
estimated.
Further we have the assumptions that γ and  are normally distributed with:
E
[
γ

]
=
[
0
0
]
(4.25)
Var
[
γ

]
=
[
G 0
0 R
]
(4.26)
The general linear model is then simply a special case with Z = (0) and R =
σ2Σ.
The variance of y is then V = ZGZT + R. The restricted maximum likelihood
can then be formulated as:
`(G,R) =− 1
2
log|V| − −1
2
log|XTV−1X|
− 1
2
rTV−1r− n− p
2
log(2pi)
(4.27)
where r = y −X(XTV−1X)− XTV−1y, p is the rank of X, and (−) denotes
the generalised inverse. A rather ugly equation but nonetheless solvable using
a ridge stabilised Newton-Raphson algorithm. When we have estimated Rˆ, Gˆ
and thus Vˆ, the parameters B and γ can simply be found using least square:
Bˆ =(XTVˆ−1X)−XTVˆ−1Y (4.28)
γˆ =GˆZTVˆ−1(Y −XBˆ) (4.29)
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The special case for Gˆ singular is treated in [SAS, 1999].
The model was used in paper B to assess degradation over time in gels. The
gels were placed in mice that were measured repeatedly.
4.2.1 Covariance structure in the errors
A wide variety of covariance structures are possible in PROC MIXED. In this
thesis only the autoregressive structure was used - see paper B where a RMM
was used to estimate degradation of two types of gels. Diﬀerent subjects are
assumed uncorrelated, while the measurements within one subject has a time
dependent correlation. This gives the following variance-covariance matrix:
D(jk) = σ
2
 1 · · · ρ
|t(k)1j−t(k)Ij |
...
. . .
...
ρ|t(k)1j−t(k)Ij | · · · 1
 (4.30)
where t is time and I is the last observation for subject j group k. It has the
interpretation that the correlation between two measurements decrease with
time between the measurements. This seems like a sensible assumption.
4.3 Assumption tests
All of the tests presented in the previous sections hinge on the assumption of
normality. Several of them also depend on the variance or covariance to be
equal. Finally, a given model can be evaluated be inspecting the residuals.
In this section we will start with the inﬂuence statistics and residuals, before
moving to more rigorous tests of equality of variance or covariance.
For this section it is convenient to deﬁne the hat matrix:
H = X(XTX)−XT (4.31)
where X is our model matrix.
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Figure 4.1: Example of ﬁt diagnostics from SAS
4.3.1 Inﬂuence statistics and residuals
An example of the standard ﬁt diagnostics output by SAS can be seen in ﬁg.
4.1.
These were used to assess model adequacy in papers B, C, and D. For examples
see the sections below and appendix C to paper B.
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Figure 4.2: Example of residual plots in diﬀerent situations
4.3.1.1 Residual plots
The upper left ﬁgure in ﬁg. 4.1 shows a residual plot. This can be used to
diagnose any potential lacks in the ﬁtted model. Six examples are given in ﬁg.
4.2. The residuals in A) are quite like those in ﬁg. 4.1. We see no trend in the
residuals, and it appears we have an unbiased estimate. In subplot B) we need
a linear and in C) a quadratic term in our model, to ﬁt the trend adequately. In
subplots D)-F) we have a growing variance. In those situations we would often
resort to a variance stabilising transformation of the data.
4.3.1.2 RSTUDENT
RSTUDENT is a normalisation of the residual and is deﬁned as:
RSTUDENTi =
ri
σˆ(i)
√
1− hii
(4.32)
48 Statistics
where σˆ(i)2 is the variance estimated without the ith observation and hii is ele-
ment i, i in the hat matrix. If RSTUDENT is larger than ± 23 the observation
warrants extra scrutiny.
Examples can be seen in ﬁg. 4.1 in the top middle and right ﬁgures.
4.3.1.3 Leverage
Leverage is a measure of how far from the mean the ith independent variable is
and is deﬁned as:
hii = Xi(X
TX)−XTi (4.33)
Since such a measure or observation - given a high leverage - can force or inﬂu-
ence the regression to lie closer to this observation they are worth considering.
As a rule of thumb observations with a leverage > 2p/n should be investigated,
where p is the parameters in the model and n the total number of observations.
An example can be seen in ﬁg. 4.1 in the top right ﬁgure.
4.3.1.4 Cook's D
Cook's distance is a measure of the eﬀect of deleting a given observation and is
deﬁned as:
Di =
1
pσˆ2
(Bˆ− Bˆ(i))TXTX(Bˆ− Bˆ(i)) (4.34)
where Bˆ(i) is the parameter estimates without observation i.
An example can be seen in ﬁg. 4.1 in the middle right ﬁgure.
4.3.1.5 Fit-mean and Residual plot
In bottom middle in ﬁg. 4.1 a Fit-Mean (pronounced ﬁt minus mean) and resid-
ual plot can be seen.
It is used to compare the spread of the ﬁt to the spread of the residuals. If the
spread of the residuals is not much smaller than the spread of the mean, our
model is not very good and much of the variance is not explained by the model.
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4.3.2 Normality tests
While more rigorous normality tests exist it is often suﬃcient to inspect residual
plots. Examples of these tests are [Shapiro and Wilk, 1965, Anderson, 1962,
Anderson and Darling, 1952, Lilliefors, 1967], we will, however, limit ourselves
to the residual plots.
The methods below were used to assess normality in paper B, C, and D.
4.3.2.1 Q-Q plot
A Q-Q plot can be seen in the middle left of ﬁg. 4.1. It is generated by plotting
the ordered residuals against the quantiles of a normal distribution. If the
residuals are normal they will follow a straight line. In the example in ﬁg. 4.1,
the residuals look normal except perhaps for the two lowest observations.
4.3.2.2 Histogram plot
A Histogram plot with normal distribution overlaid can be seen in the bottom
left of ﬁg. 4.1. The distribution is clearly unimodal, and we see nothing that
would lead us to reject the normality assumption.
4.3.3 Variance tests
When considering the most common case for a general linear model, namely
Σ = I, equality of variance or homoscedascity becomes an assumption. As
mentioned earlier, we can evaluate homoscedascity from the residual plots but
more rigorous tests are available when we are in doubt.
4.3.3.1 Univariate: Levene
Levene's test for equal variance is given by [Brown and Forsythe, 1974]:
W =
∑
i ni(z¯i − z¯..)2/(g − 1)∑
i
∑
j(z¯i − z¯i.)2/
∑
i(ni − 1)
(4.35)
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where:
zij =|yij − y¯i| (4.36)
z¯i =
∑
j
zij/ni (4.37)
z¯.. =
∑
i
∑
j
zij/
∑
i
ni (4.38)
The critical value is found by using the cumulative F-distibution: F (g−1,∑i(ni−
1))1−α. Unfortunately the test is very sensitive to departures from normality.
This test was used in paper C to assess variance between the diﬀerent dose levels
delivered to the Ag-nanogel. See paper C supplementary material.
4.3.3.2 Multivariate: Box's M
Box's M test [Box, 2015, Johnson et al., 2007] is used to test for equal variance
in the multivariate case. It is available in SAS through the PROC DISCRIM
procedure. It is also sensitive to departures from normality. In addition it is
quite powerful and may detect diﬀerences that are trivial.
This was used to assess possible diﬀerences in variance between control and
test-group in the alzheimers study in paper D.
4.4 Model Selection
In the GLM framework we can test sequentially for nested submodels by using
the F-test. However, it is often the case that models are not nested or we do
not test sequentially. In these situations where no direct test is available other
criteria are more ﬁtting.
The information criteria described below was used in paper B to select between
various RMMs describing the degradation of two types of gel.
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4.4.1 R2 and adjusted R2
A very useful - although a bit crude - measure for a model, is the multiple
correlation coeﬃcient [Ersbøll and Conradsen, 2012]:
R2 =
SStotal − SSerror
SStotal
=
SSeﬀect
SSTotal
(4.39)
As can be seen R2 is a measure for the amount of variance explained by our
model.
This - in itself - is a poor measure of how good a model is. R2 tends to increase
as parameters are added to the model, and a very complex model can achieve a
high R2 - but we need to weigh that against the complexity. For that we have
the adjusted R2:
R2adj = 1−
(n− i)(1−R2)
n− p (4.40)
where n is the number of observations, p is the number of parameters, and i is
equal to 1 if an intercept is included in the model and 0 otherwise.
4.4.2 Information Criteria
The information criteria are a relative measure of the quality of a model. It
provides a trade-oﬀ between the information lost in a given model and the
complexity of said model
4.4.2.1 Akaikes information criterion
Akaikes information criterion [Akaike, 1974] is deﬁned as:
AIC = 2k − 2log(L) (4.41)
where k is the number of parameters and L is the maximised values of the
likelihood function of the model. The preferred model is then the one that has
the lowest AIC. As we have ﬁnite sample sizes a correction is needed, the AICC
[Hurvich and Tsai, 1991]:
AICC = AIC +
2k(k + 1)
n− k − 1 (4.42)
where n is the sample size and k is again the number of parameters.
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If we have equal variance among the models, AIC reduces to a very convenient
form:
AIC = 2k + n log(RSS/n) + C1 = 2k + n log(RSS) + C2 (4.43)
where RSS is the residual sum of squares and C1 and C2 are constants across
the models and can be ignored.
As AICC converges to AIC as the sample size increases, it should generally be
preferred [Burnham, 2004].
4.4.2.2 Bayesian information criterion
The Bayesian information criterion was originally formulated by [Schwarz, 1978]
but is now used in a slightly diﬀerent formulation [Burnham, 2004] is deﬁned
as:
BIC = −2 log(L) + k log(n) (4.44)
where k is the number of parameters, L is the maximised values of the likelihood
function of the model and n the sample size. BIC penalises models more heavily
than AIC but is comparable to AICC.
Like AIC it reduces to a simple form when the variance is equal over the models:
BIC = n log(RSS/n) + k log(n) (4.45)
Whether AICC or BIC should be preferred is still not settled.
4.5 Non-parametric methods
When presented with non-normal data we may be able to model and test in
the Generalised Linear Model. However, even that is not always possible. To
accommodate the general case, where we make no - or only weak - assumptions
on the distribution of data we have the non-parametric models.
4.5.1 Mann-Whitney-U
For univariate distribution the Mann-Whitney-U test [Johnson and Gibbons, 1973],
equivalent to the Wilcoxon rank-sum test, can be used to test whether two sam-
ples come from the same population.
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Given two samples X = X1, X2, . . . , Xm and Y = Y1, Y2, . . . , Yn we start by
ordering the samples in ascending order and then merge them into a single
sequence of m+ n = N variables. We can then form an indicator variable:
Dij =
 1 if Yj < Xifor i = 1 . . .m, j = 1 . . . n
0 if Yj > Xi
(4.46)
and the test statistic is then:
U =
m∑
i=1
n∑
j=1
(1−Dij) (4.47)
The critical value for U can be tabulated for small values of m and n or approx-
imated by a normal distribution for larger values.
This test was applied in paper A to test for possible diﬀerences in variance -
and thus inhomogeneity - between two diﬀerent formulations of a Ag-nanogel.
It was also used to assess whether signiﬁcant diﬀerences were present between
a test and a control group of patients in paper D.
4.5.2 Multivariate rank tests
For the multivariate case the Oja rank tests can be used [Oja and Randles, 2004,
Oja, 2010]. Naturally, they are somewhat more complicated than the univariate
case but quite elegant.
Let X1, . . . ,Xn be identically, independently distributed matrices of p dimen-
sional measurements sampled from F (x + µ) with a total of N samples. F (·)
represents a continuous p-dimensional distribution with location parameters µ.
We deﬁne the spatial sign function:
Sign(x) =
{ ‖x‖−1x x 6= 0
0 x = 0
(4.48)
The multivariate rank is then:
Sij = Sign(Ax(Xi −Xj)), i, j = 1, . . . , n (4.49)
where Ax is a transformation matrix, that we will return to shortly. From this
we form the centered rank:
Ri =
1
n
∑
j
Sij (4.50)
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Returning to Ax we choose it to make the rank aﬃne invariant. This can be
achieved by satisfying the property:
p
1
n
∑
i
RiR
T
i = (
1
n
∑
i
RTi Ri)I (4.51)
where I is the identity matrix.
The transformation can be found iteratively. Let ATxAx = V
−1
x , we then ini-
tialise V = I and use the update:
V+1 =
p
1
n
∑
i R
T
i Ri
V 1/2
1
n
∑
i
RiR
T
i V
1/2 (4.52)
Unfortunately the convergence of this algorithm has yet to be proofed, but it
seems to work well in practice.
The several sample spatial rank test with c groups is then:
U2 =
p
1
n
∑
i R
T
i Ri
c∑
i=1
ni‖R¯i‖2 (4.53)
The p-value can be found by permuting the data:
Eγ
[
U2γ ≥ U2
]
(4.54)
where γ = (γ1, . . . , γN ) is a uniform distributed sample of the N ! possible per-
mutations and U2γ is the test statistic of the permuted sample.
This test was used in paper D to conﬁrm the results obtained from a Hotellings
T2-test, as there were several outliers present in the data.
4.6 Variance stabilising transforms
If - as we saw in ﬁg. 4.2 (d-f) - the data are heteroscedastic, we can try to stabilise
the variance by using various transforms. Some of the most commonly employed
are to take the logarithm for log-normally data and the square root for Poisson
distribution. A more general transformation is the Box-Cox transformation.
4.6.1 Box-Cox
The Box-Cox transformation [Box and Cox, 1964] in addition to being variance
stabilising, is also able to correct for skewness and make the data more normal.
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The transformation is deﬁned as:
y′λ =
{
yλ−1
λ λ 6= 0
log(y) λ = 0
(4.55)
the question is now how to choose the parameter λ. For a single variable we do
that by maximising the log-likelihood function [Johnson et al., 2007]:
L = −n
2
log(σ2(
yλ − 1
λ
))− (λ− 1)
∑
y
(log(y)) (4.56)
In the GLM framework, the log-likelihood function can be extended to incorpo-
rate the design matrix X.
The Box-Cox transform was used in paper A for variance stabilisation allowing
for comparison of variance betweens gels with diﬀerent contrast level.
4.7 Correlation tests
For test of structure in correlation and covariance matrices PROC CALIS [Sas, 2007]
was used. It allows for the speciﬁcation of a constrained covariance matrix to
be tested against the unconstrained matrix.
Let p be the number of variables, S the sample p × p covariance matrix, x¯ the
vector of sample means, Σ the ﬁtted constrained covariance matrix and µ the
vector of ﬁtted means.
We now minimise a discrepancy function, which when using the likelihood prin-
ciple is:
F = Tr(SΣ−1)− p+ log(|Σ|)− log(|S|) (4.57)
The test statistic is then simply:
C = (N − k − l) · Fmin (4.58)
where N is the number of observations, k is the number of groups and l is
the number of variables used as covariates that we have partialled against, i.e
variables we have controlled for 1. This value can then be tested in cumula-
tive χ2(C,m) with degrees of freedom m which is the number of parameters
constrained in Σ.
1The SAS documentation does not mention that we need to subtract the number of vari-
ables partialled against, which can be rather confusing...
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The covariance test was used in paper D to assess correlation between several
brain regions and a single test score. The test score could e.g. be cognitive
performance and it was of interest whether this was couples to the development
in certain regions of the brain.
4.8 Performance measures
To assess performance of a segmentation or classiﬁcation, we can use the con-
fusion/error matrix [Fawcett, 2006, Labatut and Cheriﬁ, 2011, Liu et al., 2007]:
Table 4.3: Confusion Matrix
Actual
Positive Negative
Predicted
Positive True Positive (TP) False Positive (FP)
Negative False negative (FN) True negative (TN)
Based on these four labels we can generate a variety of measures:
Table 4.4: Performance measures
Performance measures
sensitivity or true positive rate (TPR) TPTP+FN
speciﬁcity (SPC) or true negative rate (TNR) TNFP+TN
precision or positive predictive value (PPV) TPTP+FP
negative predictive value (NPV) TNTN+FN
fall-out or false positive rate (FPR) FPFP+TN
false discovery rate (FDR) FPFP+TP
miss rate or false negative rate (FNR) FNFN+TP
accuracy (ACC) TP+TNTP+FP+FN+TN
F1-score or Sørensen/Dice-score 2TP2TP+FP+FN
Accuracy gives a good overall measure of the performance, if the categories are
balanced, i.e. have approximately the same number of samples. If this not the
case, the accuracy is a poor measure as we can obtain a high score by simply
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always guessing at the dominant class. In cases like that one needs to consider
other measures such as sensitivity, speciﬁcity and precision. A nice alternative
to assessing performance by evaluating several measures is to use Matthew's
correlation coeﬃcient [Matthews, 1975]:
MCC =
TP · TN − FP · FN√
(TP + FP )(TP + FN)(TN + FP )(TN + FN)
(4.59)
which is a balanced measure that can be used even if the classes diﬀer markedly
in size.
This was used in paper E to quantify segmentation errors.
4.9 Classiﬁcation
In the preceding chapter we went through various measures of how good perfor-
mance a classiﬁer has. Now for the actual classiﬁers. A classiﬁer is a function
that maps an input into discrete classes. An example is a simple threshold: If
higher than: then one label. If not higher: then another label. We brieﬂy go
through some of the most prominent classiﬁcation algorithms.
In this thesis only quite simple methods have found use. It is possible, but
not probable, that the more advanced methods also presented here could have
increased the performance.
Naive Bayes sec. 4.9.1 was used in paper F to classify between healthy, emphy-
sematous and ﬁbrotic lung tissue in mice. The quadratic classiﬁer described in
sec. 4.9.2 was then used to assess whether the classiﬁcation could be improved
by considering the correlation between the various features used. The rest are
included for completeness.
4.9.1 Naive Bayes
Given a sample x = (x1, x2, . . . , xn) we want to ﬁnd p(Ck|x) for each of the k
classes. For that purpose we use Bayes' theorem [Pitman, 1993, Ersbøll and Conradsen, 2012]:
p(Ck|x) = pikp(x|Ck)
p(x)
(4.60)
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As the term p(x) is equal over all classes k we can ignore it. pik is the prior
probability of a class. Often this will simply be 1k if we have no additional
information. p(x|Ck) can be inferred from our training data.
The name `Naive' Bayes, derive from the rather naive assumption that the
distribution of the features are independent.
4.9.2 Discriminant Analysis
Instead of looking at the individual frequencies as in Naive Bayes, we can make
use of the correlation between the variables through Linear and Quadratic Dis-
criminant Analysis [Hastie et al., 2009]. For each k out of a total of p classes,
we model the distribution as:
fk(x) =
1
(2pi)p/2|Σk|1/2 e
− 12 (x−µk)Σ−1k (x−µk) (4.61)
We can then apply Bayes theorem to get P (Ck|x). For the case where Σ is equal
over the the p classes we get the linear discriminant function:
δk(x) = x
TΣ−1µk − 1
2
µTkΣ
−1µk + log(pik) (4.62)
If, however, the Σ is not equal over the classes we get the quadratic discriminant
function:
δk(x) = −1
2
log|Σk| − 1
2
(x− µk)TΣk(x− µk) + log(pik) (4.63)
The sample x then belongs to the class with the highest value of δ. The Σk and
µk are estimated from training data and pik is the prior probability for class k.
The names linear and quadratic derive from the fact, that when solving and eq.
4.62 and eq. 4.63 respectively for x to get the decision boundary between each
pair of classes we get a linear and a quadratic equation.
4.9.3 Logistic Regression
Logistic regression classiﬁes by using the log-ratios between the probability of
groups given the data. For two groups g1 and g2 we have:
log
P (G = g1|X = x)
P (G = g2|X = x) = β0 + xβx = 0 (4.64)
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Our decision boundary is the value where the probability of the group given the
data is equal.
To ﬁnd it we maximise the likelihood function of β:
`(β) =
N∑
i=1
logPgi(xi|β) (4.65)
Logistic regression can easily be extended to more than two groups. It has
fewer assumptions than LDA or QDA and is generally more robust. How-
ever, it breaks down if the classes are perfectly separable by a hyperplane. See
[Hastie et al., 2009] for more details.
4.9.4 Random forest
Random forest is a collection of decision tress, which - together - forms a forest.
The method aims at averaging many approximately unbiased but noisy trees to
obtain low variance results. The following is based on [Hastie et al., 2009].
The procedure is as follows:
1. Draw a bootstrap sample from the training data
2. Grow a tree to the bootstrap sample until the minimum node size is
reached by:
(a) Selecting m variables at random
(b) Pick the best split and split the node
3. Repeat until you have a forest
The classiﬁcation is then a majority vote in the forest.
4.9.5 Support Vector Machines
Support Vector Machines (SVM) are a powerful type of classiﬁers. They are are
a generalisation of support vector classiﬁers, which are again a generalisation of
optimal separating hyperplanes. This review is based on [Hastie et al., 2009].
The optimal separating hyperplane, ﬁnds the optimal linear separation of two
non-overlapping classes and maximises the distance to the closest point from
each class.
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Let us deﬁne a hyperplane by
f(x) = xTβ + β0 = 0 (4.66)
where β is a unit vector and we classify based on the sign of f(x). Our training
data are N pairs of (x, y) where x is a measure and y is the classiﬁcation (-1,1).
The hyperplane can be found by maximising the margin M = 1/‖β‖:
maximise
β,β0
M
subject to yi(x
T
i β + β0) ≥M, i = 1, · · · , N
‖β‖ = 1
or more conveniently formulated:
minimise
β,β0
‖β‖
subject to yi(x
T
i β + β0) ≥ 1, i = 1, · · · , N
The support vector classiﬁer extends this to the case where the classes overlap
by modifying the constraint:
yi(x
T
i β + β0) ≥M(1− ζi) (4.67)
where ζ > 0 is a so called slack variable. Without going into too much detail,
this can be formulated as a convex problem of which the dual can be solved
eﬃciently by maximising:
LD =
N∑
i=1
αi − 1
2
N∑
i=1
N∑
i′=1
αiαi′yiyi′x
T
i xi′ (4.68)
subject to a number of constraint (see [Hastie et al., 2009] p. 420).
The extension to SVM is now simple. We choose a suitable basis expansion h(x)
for x . The beauty is, that they only appear through their inner product in the
dual function:
LD =
N∑
i=1
αi − 1
2
N∑
i=1
N∑
i′=1
αiαi′yiyi′ 〈h(xi), h(xi′)〉 (4.69)
and the decision border is now:
f(x) =h(x)Tβ + β0 (4.70)
=
N∑
i=1
αiyi 〈h(x), h(xi)〉+ β0 (4.71)
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4.9.6 Sparse methods
It should be mentioned, that in addition to those methods already mentioned, a
large number of sparse methods exist e.g. lasso, least angle regression [Hastie et al., 2009],
and Sparse discriminant analysis [Clemmensen et al., 2011]. As more classical
methods worked adequately on the problems in this thesis they are, however,
outside the scope here.
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Part II
Scientiﬁc Contributions

Chapter 5
NanoGuide project:
Paper A, B, and C
One of the goals of the NanoGuide project was to develop gel based injectable
markers for use in radiotherapy. It was successful in that regard, see paper A
and B. The gel described in paper A was further developed for use in in-vivo
dosimetry, see paper C.
5.1 Paper A
Paper A presents a gel-based x-ray marker based on gold nano-particles. It was
demonstrated that the marker had a high contrast, was stable and biocompati-
ble. The gel was tested in both mice for stability and biocompatibility and in a
dog with a spontaneous tumour as proof of concept for guidance in radiother-
apy. The mice experiment consisted of repeated measurements on 5 mice using
a micro-CT scanner. My task was analysis of stability and homogeneity of the
gel.
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Figure 5.1: A slice in a mouse showing the Au-nanoparticle gel. The gel is the
bright structure to the right.
5.1.1 Methods and Results
The gels were quite inhomogeneous and a manual segmentation was necessary.
Fig. 5.1 should help illustrate why. The volume showed no major changes once
the ethanol that makes the gel liquid had diﬀused out. By inspecting the cumu-
lative histograms it was clear that the inhomogeneity increased over time, see
ﬁg. 5.2. To test if the gels were more inhomogeneous than an earlier formula-
tion with less contrast [Jølck et al., 2014], a common Box-Cox transformation
(sec. 4.6.1) for the two groups was performed to obtain approximate normal-
ity followed by a Wilcoxon rank-sum test (sec. 4.5.1) of the variances of the
two groups. The variances of the gels were found not to diﬀer signiﬁcantly
(P=0.0734). Thus, even with more contrast the new formulation was not more
inhomogeneous than the old.
5.1.2 Contributions
• Segmenting gels
• Presented data visually to establish that the volume and overall contrast
was stable and the heterogeneity of gel increased
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Figure 5.2: Cumulative histogram from a representative mouse. The colours
represent diﬀerent days.
• Statistical analysis of inhomogeneity compared to older formulation
5.2 Paper B
Although the gel described in paper A, worked well, an even better formulation
was found. An in-vivo test of the degradation rate of this gel is described in
paper B. By using iodine instead of gold particles, the contrast level could be
increased and the homogeneity and stability were even better. With regards to
production, storage and use the gel also had favourable qualities. This paper
investigated the degradation rate of two groups with diﬀerent contrast levels.
5.2.1 Methods and Results
As the gels were much more homogeneous it was easy to segment them using
a Matlab implementation of Chan-Vese (sec. 3.1.2). This performed very well,
see ﬁg. 5.3. To analyse both group diﬀerence and degradation a repeated mea-
surements model (sec. 4.2) was used. The data from the two groups are shown
68
NanoGuide project:
Paper A, B, and C
Figure 5.3: A slice in a mouse showing the iodine gel. The red curve is the
segmentation using Chan-Vese
in ﬁg. 5.4. A clear downwards trend is seen, but apart from that it is diﬃcult
to make conclusions.
A number of models were tested, to see which one most adequately described
the data. k is the group, j is the mouse and i is the observation. The errors were
Table 5.1
Model overview
M1 α(k)j + β(k)j t(k)ij Individual intercept and slope
M2 α(k)j + β(k) t(k)ij Individual intercept and group slope
M3 α(k)j + β t(k)ij Individual intercept and common slope
M4 α(k)j Individual intercept
M5 α(k) Group intercept
modelled as autoregressive, giving the following variance-covariance matrix for
a single mouse:
D(jk) = σ
2
 1 · · · ρ
|t(k)1j−t(k)Ij |
...
. . .
...
ρ|t(k)1j−t(k)Ij | · · · 1
 (5.1)
where I is the last observation.
Using Akaikes information criterion corrected for ﬁnite sample size (sec. 4.4.2.1)
M3 found to be an appropriate model, i.e. individual intercept and common
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Figure 5.4: Volume data over time from mice. 1-8 is one group and 9-25
another group.
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slope. Thus concluding that the two groups did not diﬀer in degradation rate.
The degradation of the gels were simulated with a simple physical model as-
suming that the degradation only occurred in the surface. With this model an
approximate time to total degradation could be made.
5.2.2 Contributions
• Segmenting gels
• Statistical analysis of diﬀerence in two formulations
• Statistical analysis of degradation rate
• Simple physical model for the degradation of the gels
5.3 Paper C
Returning to the ﬁrst gel (paper A), I got an idea to use it in in-vivo dosimetry.
Based on this paper [Hansen et al., 2008], the gold nano-particles could be ex-
changed with silver. When irradiated with high-energy photons a (γ,n)-reaction
can occur and the silver can become β+ active (sec. 2.6). The amount of ra-
dioactivity can then be measured in a PET scanner and the dose calculated on
basis of the activity.
5.3.1 Methods and Results
Gels with silver were prepared and stored in plastic cylinders ﬁlled with gelatine.
They were inserted into a thorax phantom, and irradiated at three diﬀerent dose-
levels. 2 Gy, 10 Gy, and 22 Gy. Immediately afterwards they were transported
to a PET-scanner and scanned for half an hour.
The scannings were reconstructed using a Filtered Back-Projection (FBP). While
generally more noisy than iterative methods it does not suﬀer from bias in low
activity regions (sec. 2.4.1). The activities of the gels were manually extracted
by centring a ball with radius 20 mm on each gel and taking the mean value.
We then wanted to establish whether the position, the individual gels and the
dose had any inﬂuence on the measured activity. Obviously we had an expec-
tation that the dose might had something to say. The ﬁrst model were with all
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Figure 5.5: The activities of the gels plotted against the eﬀective dose
eﬀects and their pairwise interaction. Then all the eﬀects, then the dose and
intersect and ﬁnally only the dose.
By successive testing we showed that the data could be described using a simple
proportionality model, see ﬁg. 5.5.
5.3.2 Contributions
• Conceiving experiment
• Performing PET/CT scan
• Extracting activity from scans
72
NanoGuide project:
Paper A, B, and C
• Statistical analysis of eﬀects
Chapter 6
Paper D
In this paper the data were MRI-scans of the brains of alzheimers patients. The
hypothesis was that exercise delayed the progression of alzheimers disease. For
that purpose the subjects were divided into an intervention group that exer-
cised and a control group that did not. All subjects were scanned twice with
16 weeks in between and the brains were segmented using FreeSurfer software
[Reuter et al., 2012, Fischl et al., 2002]. The resulting segmentation gave volu-
metric measures and the thickness of various gyri and sulci.
6.1 Methods and Results
To cancel within subject correlations, the relative change from pre-scan to post
scan were used. Age and sex were used as covariates in all tests. The group
diﬀerences were investigated using Hotellings T2-test (sec. 4.1.5). As outliers
were present the results were validated by a non-parametric method, the Oja
rank test (sec. 4.5.2).
Several cognitive measures were investigated through tests. It was hypothesised,
that they each correlated with speciﬁc brain regions. To investigate a potential
correlation of a single test score with multiple brain regions we tested the co-
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variance matrix (sec. 4.7). If we have a test score x and a brain region with two
subﬁelds y1,y2 the null-hypothesis was:
H0 :
 cov(x,x) cov(x,y1) cov(x,y2)cov(y1,x) cov(y1,y1) cov(y1,y2)
cov(y2,x) cov(y2,y1) cov(y2,y2)
 =
cov(x,x) 0 00 cov(y1,y1) cov(y1,y2)
0 cov(y2,y1) cov(y2,y2)
 (6.1)
against all alternatives. If we rejected the null-hypothesis a post-hoc test of the
individual correlations was performed.
6.2 Contributions
• Statistical analysis of diﬀerence in groups - both parametric and non-
parametric
• Statistical analysis of correlation between cognitive test-scores and brain-
regions
Chapter 7
Paper E
The distribution of abdominal fat has been linked to various metabolic risk fac-
tors and is of great clinical interest. We wanted to make an integrated software
solution that could segment a MRI scan fully automatically. Further it should
be robust to changes in sequence and across diﬀerent population groups.
7.1 Methods and Results
The scans were bias-corrected using a generative model (sec. 3.4). By formu-
lating the segmentation as a graph-cut problem (sec. 3.1.3), we can utilise the
information in adjacent slices and achieve a globally `optimal' segmentation of
the subcutaneous fat. The visceral fat was segmented using the inner surface
of the subcutaneous fat as a mask. A dynamic threshold based on k-means
clustering was used.
A set of settings for the bias-correction and energies for the graph-cut problem
was found, that performed robustly. These energies consist of a weighting of
various gradient and surface based costs. In the same framework a method for
exclusion of the non-visceral fat around the spine was implemented. When eval-
uated against an expert observer the method performed very well. An example
of the segmentation of subcutaneous fat can be seen in ﬁg. 7.1.
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Figure 7.1: An example of segmentation of the subcutaneous fat
7.2 Contributions
• Integrated bias-correction and graph-cut in the pipeline
• Found energies and settings that worked robustly
• Method for spine extraction
• Demonstrated usefulness in three diﬀerent studies with diﬀerent sequences
and population segments
Chapter 8
Paper F
Phase-contrast imaging is an emerging imaging modality for medical use. It al-
lows for imaging of absorption, dark-ﬁeld and diﬀerential phase. The dark-ﬁeld
in particular shows a superior sensitivity to changes in the lungs. While both
emphysema and ﬁbrosis can be detected using the dark-ﬁeld, it has been ques-
tioned whether they can be separated as they exhibit the same characteristics.
The focus of paper F was to investigate this and if possible classify between
healthy, emphysematous, and ﬁbrotic lung tissue. In addition we investigated if
the diﬀerential phase image had information that could contribute to diﬀeren-
tiation.
8.1 Methods and Results
By using an Active Appearance Model (AAM) (sec. 3.1.1) the lungs were seg-
mented and deformed to a standard shape. This allowed for comparisons across
diﬀerent mice. A medical doctor contoured diseased region for use in a training
and test set. Methods for automatic extraction of the ribs and spine were im-
plemented. By excluding the ribs and spine, a model of the healthy lung was
generated by averaging a set of healthy mice. By normalising with the healthy
lung model we could incorporate regional information.
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With regards to the diﬀerential phase we tested three texture ﬁlters (sec. 3.2.2)
as a mean to extract information: The range, standard deviation, and entropy
ﬁlter. Each with various diameter kernels. The marginal probabilities for the
three classes (healthy, emphysematous, and ﬁbrotic) were estimated for ab-
sorption, dark-ﬁeld, diﬀerential phase, and the ﬁlters applied to the diﬀerential
phase. Using the healthy lung-model, a Naive Bayes classiﬁer (sec. 4.9.1) could
diﬀerentiate and classify with an accuracy of 84.05 %. An example can be seen
in ﬁg. 8.1.
8.2 Contributions
• Method for rib and spine removal
• Implemented classiﬁcation algorithms and performed all analysis in that
regard
• Statistical analysis of the results
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Figure 8.1: An emphysematous lung showing good agreement with classiﬁca-
tion. Green: healthy. Blue: Emphysema. Red: ﬁbrosis. The
yellow line is the region demarcated as emphysema by an expert.
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Chapter 9
Conclusion
As demonstrated in this thesis data analysis of medical images is a wide topic
with many problems. Here a small subset of them have been tackled. In all the
papers contributing to this thesis, segmentation was the ﬁrst step in the analysis
if not the end-goal. When having extracted data through a segmentation or
other means, statistical analysis is often required.
In the NanoGuide project two gels were developed to function as x-ray markers
for radiotherapy. The necessary data analysis for both publications and regula-
tory approval was performed. This demonstrates the need for both extraction
data, though segmentation, and rigorous analysis through the use of statistics.
The statistical analysis was used to conﬁrm that gold-nanoparticle gels with
diﬀerent contrast levels did not diﬀer in inhomogeneity. For the iodine based
gels with diﬀerent contrast levels it was conﬁrmed that the degradation rate did
not diﬀer through the use of a RMM.
The gel with gold-nanoparticles was tested for a new application in in-vivo
dosimetry with the gold exchanged with silver. This use was successfully demon-
strated in a thorax-phantom. It was shown that neither position nor inter-gel
variance had any practical eﬀect on the results.
The analysis of MRI brain scans of alzheimer patients also started with a seg-
mentation. Statistical analysis was applied to make conclusion about group
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diﬀerences and correlation between cognitive test-scores and changes in brain
regions.
A software package in development for segmentation of abdominal was pre-
sented. The method works robustly across diﬀerent sequences and population
groups.
The eﬃcacy of phase-contrast x-rays in diﬀerentiation diﬀerent lung diseases
was demonstrated. In a murine model we successfully classiﬁed between healthy,
emphysematous, and ﬁbrotic tissue.
Through solutions to this diverse set of problems the objectives of the thesis
was met.
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 In the western world, approximately 50% of all cancer patients receive radio-
therapy alone or in combination with surgery or chemotherapy. Image-guided 
radiotherapy (IGRT) has in recent years been introduced to enhance precision 
of the delivery of radiation dose to tumor tissue. Fiducial markers are often 
inserted inside the tumor to improve IGRT precision and to enable monitor-
ing of the tumor position during radiation therapy. In the present article, a 
liquid fi ducial tissue marker is presented, which can be injected into tumor 
tissue using thin and fl exible needles. The liquid fi ducial has high radio-
opacity, which allows for marker-based image guidance in 2D and 3D X-ray 
imaging during radiation therapy. This is achieved by surface-engineering 
gold nanoparticles to be highly compatible with a carbohydrate-based gela-
tion matrix. The new fi ducial marker is investigated in mice where they are 
highly biocompatible and stable after implantation. To investigate the clinical 
potential, a study is conducted in a canine cancer patient with spontane-
ous developed solid tumor in which the marker is successfully injected and 
used to align and image-guide radiation treatment of the canine patient. It is 
concluded that the new fi ducial marker has highly interesting properties that 
warrant investigations in cancer patients. 
 1.  Introduction 
 Nanomaterials offer unique properties 
that can provide society with new health-
care technologies for treatment of disease. 
With the increasing aging of the popula-
tion in the western world, cancer inci-
dence continues to rise creating a crucial 
demand for effi cient and cost-effective 
therapies. Radiation therapy is a cost-effec-
tive treatment modality and approximately 
50% of cancer patients receive radia-
tion therapy after being diagnosed with 
cancer. [ 1 ] Modern radiation oncology relies 
on advanced, high-precision imaging tech-
niques such as computed tomography 
(CT), positron emission tomography 
(PET), and magnetic resonance (MR) to 
enable the delivery of high radiation doses 
to defi ned targets. [ 2–4 ] However, tumors 
rarely display a fi xed position during irra-
diation or within the treatment period 
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due to breathing motion, changes in organ fi lling, and tumor 
size. [ 5–7 ] To compensate for variations in tumor position fre-
quent imaging (kilovoltage radiographs or fl uoroscopy—also 
referred to as 2D X-ray imaging) during the course of treatment 
or image-guided radiation therapy (IGRT) is now being used in 
the clinic to improve radiation precision and accuracy, thereby 
reducing the treatment toxicity and optimizing therapeutic effi -
cacy. [ 2,6,8 ] When the tumor position cannot be correlated with 
internal reference points such as the skeleton, tumor localiza-
tion can be enhanced by alignment to radiographic markers 
implanted in or near the tumor. [ 9–11 ] Such markers can improve 
treatment through optimized planning, tumor positioning 
accuracy, and tumor tracking resulting in more precise dose 
delivery and enable treatment of cancers, which are presently 
not eligible for radiotherapy. [ 12,13 ] Tissue markers currently used 
in the clinic are metal-based solid implants with large physical 
dimensions, which require complicated insertion procedures 
and therefore the risk of complications. Lung tumor inser-
tion is especially problematic, with pneumothorax (reported 
in 33%–68% of patients) as well as bleeding being reported as 
primary complications. [ 14–16 ] In order to increase the usability 
and patient compliance of radiographic markers, we recently 
described the concept of a liquid injectable fi ducial marker by 
exploiting polyethylene glycol (PEG)-coated gold nanoparticles 
(AuNPs) in a nonsolvent-induced phase separation (NIPS) 
gelation matrix. [ 17 ] This system was found to be biocompatible 
and clearly visible on 3D X-ray imaging, However, due to the 
chemical properties of the encapsulated AuNPs only 10 mg 
AuNPs mL −1 providing approximately 200 Hounsfi eld units 
(HU) of contrast could be included, which is insuffi cient for 
2D X-ray visualization. For gating-based radiation procedures, 
often exploited in for example lung cancer patients, 2D X-ray 
visualization is required for intrafractional real-time imaging of 
moving tumors. [ 6,18–20 ] Additionally, fi ducial marker visualiza-
tion using 2D X-ray techniques lowers the X-ray exposure level 
to the patients and may reduce treatment time compared to 
3D X-ray-based procedures. [ 2 ] Furthermore, with the increasing 
focus on stereotactic radiation procedures and the clinical intro-
duction of proton therapy, visualization of tumor position and 
motion becomes crucial to optimize irradiation of cancerous 
tissue. [ 21,22 ] Therefore, radiopaque fi ducial markers continue to 
be in high demand and development of new marker systems is 
of paramount importance. 
 In the present work, we have investigated a novel liquid 
fi ducial marker (nanogel) system based on sucrose acetate 
isobutyrate (SAIB) and uniform poly( N -isopropyl acrylamide) 
(PNIPAM)-coated AuNPs with radio-opacity adequate for 2D 
X-ray visualization. SAIB, a fully acylated derivative of sucrose, 
is a biodegradable nonpolymeric compound, which has been 
approved for oral consumption and is generally regarded as safe 
(GRAS) by the FDA. SAIB mixtures with ethanol (EtOH) behaves 
as Newtonian liquids and have a low viscosity (50–200 mPa s) 
suited for injection using thin hypodermic needles. [ 23–25 ] Upon 
hydration, an amorphous (gel-like) solid is formed, which effi -
ciently encapsulate high concentrations (>100 mg Au mL −1 ) 
of PNIPAM-coated AuNPs providing contrast levels suffi cient 
for visualization in 2D X-ray imaging techniques such as 
fl uoroscopy and ExacTrac imaging (Brainlab AG, Feldkirchen, 
Germany). The developed nanogel has been characterized in 
vitro and the in vivo stability and visibility was evaluated in 
immunocompetent mice over a period of 8 weeks. Proof-of-
concept in a clinical canine cancer patient with a spontaneous 
growing tumor was additionally established and the developed 
nanogel with PNIPAM-coated AuNPs was applied in IGRT in 
a canine cancer patient where marker visibility, stability, and 
marker migration were evaluated over time during the course 
of radiotherapy. The developed nanogel fulfi lls the require-
ments for use in guidance of radiation therapy as it is easy to 
inject, remains stable over the full time course of radiation 
treatment (6 weeks), shows no sign of migration, and is the 
fi rst liquid fi ducial marker to enable visualization using both 
2D and 3D X-ray-based imaging techniques. 
 2.  Results and Discussion 
 Visualization of fi ducial markers in 2D X-ray imaging requires 
high electron density within the nanogel to possess effi -
cient X-ray attenuation/radio-opacity, which can be achieved 
by doping the injectable gel with colloid AuNPs. We recently 
exploited the use of PEG-coated AuNPs but due to the high 
hydrophilicity of the PEG-coated AuNPs only 10 mg AuNPs 
mL −1 could be included in the liquid marker, which was insuf-
fi cient for 2D X-ray visibility. Higher AuNP-concentrations 
resulted in a signifi cant burst release due to the higher prefer-
ence of the hydrophilic PEG-coated AuNPs for the surrounding 
aqueous phase. [ 17 ] 
 2.1.  Engineering AuNPs for Enhanced Nanogel Compatibility 
 In order to increase the concentration of AuNPs and enhance 
the compatibility of the AuNPs with the hydrophobic SAIB-
based gelation matrix, two different strategies were investi-
gated: i) Masking the AuNPs by chemisorption of a dithiolane 
SAIB derivate ((SH) 2 -SAIB) ( 5 ) (see Section 2.1.1, and Sup-
porting Information) and ii) using commercially available thiol-
functionalized PNIPAM with a molecular weight of 3.500 Da 
(SH-PNIPAM 3.500 ). Both strategies resulted in hydrophobic 
AuNPs, which was anticipated to reduce the previously 
observed AuNP burst release from the nanogels. Hence, we 
hypothesized that realization of one or both of these strategies 
should enable formulation of nanogels with higher concentra-
tions of AuNPs resulting in higher X-ray contrast levels. 
 2.1.1.  Synthesis of SAIB-Based Capping Agent for AuNP 
Functionalization 
 The dithiolane-functionalized SAIB derivate  5 was prepared as 
outlined in Scheme S1 (Supporting Information) starting from 
sucrose ( 1 ). Mono silyl protection of the 6′-OH position of the 
fructofuranose unit was achieved using  tert -butyl(chloro)diphe-
nylsilane (TBDPS-Cl) and 4-dimethylaminopyridine (DMAP) 
yielding 6′-O-TBDPS-sucrose ( 2 ). [ 26 ] The remaining hydroxyl 
groups were isobutyrylated using isobutyric anhydride and 
DMAP resulting hepta-isobutyryl-6′-O-TBDPS-sucrose ( 3 ). 
Initial attempts of deprotection of the TBDPS group using 
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 tetra - n -butylammonium fl uoride (TBAF) indicated a high 
degree of isobutyryl migration; fortunately, this could be sup-
pressed by addition of acetic acid leading to hepta-isobutyryl-
sucrose ( 4 ). Finally, the dithiolane moiety was introduced by 
 N -(3-dimethylaminopropyl)- N′ -ethylcarbodiimide (EDC) activa-
tion of lipoic acid in the presence of DMAP yielding the dithi-
olane-functionalized SAIB derivate  5 (a detailed description of 
synthesis and compound characterization is available as Sup-
porting Information). 
 2.1.2.  AuNP Synthesis, Functionalization, and Characterization 
 Citrate-stabilized AuNPs were synthesized using a seeding 
procedure as previously described resulting in uniform elec-
trostatic-stabilized AuNPs with a diameter of approximately 
40 nm. [ 17 ] Subsequently, chemisorption of SH-PEG 5000 , SH-
PNIPAM 3500 or (SH) 2 -SAIB ( 5 ) to the citrate-stabilized AuNPs 
was conducted in aqueous solution in order to increase the col-
loid compatibility with SAIB-based gels ( Figure  1 A). Increasing 
the compatibility of the AuNPs with the SAIB-matrix includes 
increasing the hydrophobicity of the particles. However, a deli-
cate balance exists where the hydrophobicity of the particles is 
increased without compromising their stability in aqueous solu-
tion during synthesis. As evident from the UV–vis (Figure  1 B) 
and dynamic light scattering (DLS) (Figure  1 C) analysis, AuNP 
coating with PEG and PNIPAM was successful. Only a slight 
increase in the surface plasmon resonance was observed, 
which is expected due to the microenvironmental changes on 
the surface of the particles. Additionally, DLS confi rmed the 
presence of the two polymers at the colloid interface since an 
increase of 15.1 and 12.9 nm was observed for the PEG-coated 
and PNIPAM-coated AuNPs, respectively. However, chem-
isorption of (SH) 2 -SAIB ( 5 ) to the surface of the electrostatic-
stabilized AuNPs caused considerably aggregation due to the 
poor aqueous solubility of the formed particles, even under 
the very diluted conditions used. The aggregates formed from 
SAIB-coated AuNPs were isolated but redispersion in organic 
solvents such as absolute ethanol was not possible; thus, this 
class of particles was not investigated further. Synthesis and 
 Figure 1.  A) Synthesis protocol for obtaining PEG-, PNIPAM, and SAIB-coated AuNPs based on a three steep seeding protocol using chloroauric acid as 
Au 3+ source and trisodium citrate as reductant and stabilizer; B) UV–vis characterization of PEG-, PNIPAM-, and SAIB-coated AuNPs in aqueous solu-
tion; C) DLS characterization of PEG-, PNIPAM-, and SAIB-coated AuNPs in aqueous solution; and D) ζ-potential characterization of PEG-, PNIPAM-, 
and SAIB-coated AuNPs in aqueous solution. E) Nanogel composition and preparation procedure.
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subsequently coating of AuNPs with (SH) 2 -SAIB ( 5 ) in pure 
organic solvent using the Burst–Shiffi n method may be fea-
sible, but this was not attempted due to the small size of 
particles formed by this method (<10 nm) and the fact that non-
biocompatible solvents such as toluene and toxic phase-transfer 
agents have to be used, which could limit their use in biological 
settings. [ 27 ] 
 Additionally, handling of PNIPAM-coated AuNPs was found 
to be superior compared to PEG-coated AuNPs as these could 
be lyophilized and stored for prolonged time as an air stabile 
nanopowder, which readily dispersed into MQ-H 2 O and a wide 
range of protic- and aprotic organic solvents including anhy-
drous ethanol without causing any changes to particle mor-
phology (Figure S1, Supporting Information). This enabled 
easy up-concentration, storage, and nanogel formulation com-
pared to the previous described method where AuNPs were 
transferred into anhydrous EtOH by centrifugation prior to use. 
 2.2.  Contrast Evaluation for 2D X-Ray Visualization of Nanogel 
in Humans 
 In order to evaluate the required concentration of AuNPs within 
the nanogel for visibility on 2D X-rays images in humans, a 
simulation of 2D digitally reconstructed radiographs (DRRs) 
was performed based on clinical 3D CT-data for a patient diag-
nosed with lung cancer. A lung tumor model was chosen as 
this region is considered as a worst-case scenario due to the 
high concentration of bone structure in the thoracic region. 
A simulated nanogel (500 µL) was digitally placed inside the 
lung tumor of the patient and the specifi ed HU contrast level 
was varied from 500 to 2000 HU with increments steps of 500 
HU on the 3D CT-data. 2D DRRs were created for all angles 
entering perpendicular around the patient in steps of 5° using 
a ray-tracing algorithm [ 28,29 ] resulting in 72 simulated projec-
tions for each contrast level ( Figure  2 ). The center position 
of the DRRs was chosen to be in the center of the simulated 
nanogel placed centrally within the lung tumor of the patient. 
On the resulting DRRs, the visibility for each contrast level was 
evaluated by a contrast-to-noise ratio (CNR) approach, where a 
region of interest (ROI) for one projection and contrast level 
was contoured to defi ne the nanogel and then transferred to all 
other projections. The mean intensity ( M m ) and standard devia-
tion ( σ m ) of ROIs were calculated and compared to the mean 
( M b ) and standard deviation ( σ b ) from a ROI on a DRR with 
no simulated nanogel present according to a CNR evaluation 
(Equation  ( 1) ).
 
M M
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−
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m
2
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 The CNR level can be considered a quantitative measurement 
of the visibility of the object measured compared to the back-
ground contrast from the surroundings. Generally, high CNR 
translate to increased visibility of the marker. We considered 
the simulated nanogel visible in the 2D DRR if CNR > 2. This 
value corresponds to a signifi cance level of 0.05 obtained from 
a two-tailed  t -test with a large number of degrees-of-freedom. [ 30 ] 
As evident from Figure  2 , some angles requires a higher X-ray 
contrast level of the nanogel in order to obtain a CNR > 2 as 
these penetrates bone structure prior to reaching the nanogel. 
Other angles are more easily accessible and thereby result in 
lower background contrast, thus making the nanogel more vis-
ible on the 2D DRRs. Based on the lung cancer patient projec-
tion simulation on the DRRs, it was evident that the contrast 
level required for CNR > 2 in 95% of all perpendicular angles 
was approximately 1000 HU (spherical nanogel with a total 
volume of 500 µL) corresponding to a nanogel with approxi-
mately 30 mg AuNPs mL −1 . A comparison of the 2D X-ray 
contrast level from PNIPAM-coated AuNPs (10, 30, 60, and 
90 mg mL −1 ) and clinically used solid fi ducial markers is 
provided in Figure S2, Supporting Information. 
 2.3.  In Vitro Evaluation of Nanogel Performance 
 In vitro release kinetics of encapsulated PEG-coated and 
PNIPAM-coated AuNPs in SAIB nanogels doped with polylactic 
acid (PLA) with the composition SAIB/EtOH/PLA (75:20:5) + 
30 mg AuNPs mL −1 were examined by placing small droplets 
(200 µL) of nanogels into MQ-H 2 O at physiological tempera-
ture. Small aliquots of MQ-H 2 O were removed at specifi c time 
intervals and replaced with fresh MQ-H 2 O to mimic the sink 
effect in vivo. The amount of released AuNPs was determined 
by UV–vis spectroscopy using a standard curve of individual 
synthesized and coated AuNPs with a known concentration 
(Figure S3, Supporting Information). Injection of nanogel into 
aqueous solution causes an effl ux of EtOH from the nanogel 
into the aqueous compartment. Effl ux of EtOH results in rapid 
increase in gel viscosity, [ 24 ] but may also induce a burst release 
of encapsulated AuNPs. [ 24 ] Indeed, a rapid burst release of PEG-
coated AuNPs from nanogels composed of SAIB/EtOH/PLA 
(75:20:5) + 30 mg PEG-coated AuNPs mL −1 was observed. In 
contrast, the use of PNIPAM-coated AuNPs resulted in highly 
stable nanogels with no (<1%) AuNP release over time in vitro 
despite the high AuNP concentration in the gel (Figure S3, 
Supporting Information). Concentrations as high as 100 mg 
PNIPAM-coated AuNPs mL −1 were evaluated without induced 
burst release of encapsulated PNIPAM-coated AuNPs (data not 
shown). The enhanced compatibility of the PNIPAM-coated 
AuNPs with the SAIB matrix compared to the PEG-coated 
counterpart can be explained by the enhanced hydropho-
bicity and potential hydrogen bonding interactions between 
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 Figure 2.  Contrast to noise (CNR) level versus angle of entrance for a 
simulated nanogel (500 µL) with various contrast levels (500–2000 HU) 
placed digitally inside a lung tumor.
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the PNIPAM-coating polymers and the polyester backbone of 
SAIB. The positive in vitro stability results and known target 
AuNP concentration for 2D X-ray visibility encouraged us to 
further evaluate the nanogels composed of SAIB/EtOH/PLA 
(75:20:5) + 30 mg PNIPAM-coated AuNPs mL −1 in vivo using 
immunocompetent mice. 
 2.4.  In Vivo Evaluation of Nanogel Performance 
 2.4.1.  Evaluation of Nanogel in Immunocompetent Healthy 
NMRI-Mice 
 Nanogels (200 µL) composed of SAIB/EtOH/PLA (75:20:5) + 
30 mg PNIPAM-coated AuNPs mL −1 were injected subcutane-
ously in immunocompetent NMRI-mice ( n = 5) at the upper left 
fl ank using a 25G needle under general anesthesia. The nanogel 
was visualized using micro-CT imaging over a period of 8 weeks 
(images acquired directly after injection and again after 24, 48 h, 
1, 2, 4, and 8 weeks) using a dedicated small-animal scanner 
( Figure  3 ). Based on the recorded micro-CT images, the nanogel 
X-ray contrast level, degradation rate, and homogeneity were eval-
uated as a function of time ( Figure  4 ). No signifi cant changes in the 
nanogel volume were observed after the initial EtOH effl ux phase, 
which caused approximately 20% reduction of nanogel volume in 
good correlation with the known EtOH content of the nanogel 
prior to injection. The nanogel doped with 30 mg PNIPAM-
coated AuNPs mL −1 provided a mean X-ray contrast level in the 
range of 1200 HU, which is suffi cient for 2D X-ray visualization 
as previously described. A reduction of the mean contrast level of 
the nanogel was observed over time possible due to some AuNP 
leakage or aggregation of particles within the nanogel. Figure  4 B 
clearly displays the increased maximum contrast level within 
the nanogel during the fi rst week following intra-gel AuNP 
aggregation resulting in very high contrast levels (>15.000 HU) 
(Figure S4, Supporting Information). The homogeneity of the 
nanogel in terms of PNIPAM-coated AuNP distribution within 
the gel matrix was analyzed further by investigating each voxel 
of the micro-CT images as illustrated in Figure  4 C. As evident 
from the cumulative histograms for a representative mouse, the 
PNIPAM-coated AuNPs were found to gradually aggregate within 
the nanogel as previously observed for PEG-coated AuNPs within 
the same gel matrix. [ 17 ] In fact, no signifi cant difference was found 
in the variance of the PEG-coated and PNIPAM-coated AuNPs 
within the nanogels as analyzed by the Wilcoxon rank-sum test 
( p = 0.0734). [ 31 ] The inhomogeneous PNIPAM-coated AuNPs 
distribution within the nanogel could be visualized in the mice 
due to the high resolution and small slice thickness (0.092 × 
0.092 × 0.092 mm 3 ) of the micro-CT scanner. The aggregation 
phenomenon of the PNIPAM-coated AuNPs within the nanogel 
has no clinical impact as human clinical scanners operate with 
signifi cant larger slice thickness (2–3 mm) and lower resolution 
(1 × 1 mm 2 ) causing the AuNP microstructure aggregation to be 
below the resolution of recorded images. 
 2.4.2.  Evaluation of Nanogel in a Canine Cancer Patient with 
Spontaneously Developed Solid Tumor 
 In order to fully validate the concept of liquid injectable fi du-
cial markers for IGRT, the nanogel was evaluated in a canine 
cancer patient suffering from spontaneously developed malig-
nant solid tumor (mast cell tumor). Solid tumors often show 
an increased interstitial fl uid pressure (IFP) possibly due to 
vessel abnormalities, fi brosis, and contraction of the intersti-
tial matrix mediated by stromal fi broblasts. [ 32,33 ] Increased IFP 
may serve as an obstacle for intratumoral injection of the devel-
oped nanogel as the available intracellular space for marker 
assembly post-injection is limited and the increased IFP may 
repel the nanogel into adjacent areas. Additionally, migration of 
the nanogel over time may compromise the accuracy of fi ducial 
Adv. Healthcare Mater. 2015, 4, 856–863
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 Figure 3.  Representative 3D reconstruction from micro-CT images of 
mouse. Nanogel composed of SAIB/EtOH/PLA (75:20:5) + 30 mg PNIPAM-
coated AuNPs mL −1 administered subcutaneously to immunocompetent 
mice at the upper left fl ank. Nanogel visualized from different angles.
 Figure 4.  In vivo characteristics of nanogel composed of SAIB/EtOH/PLA (75:20:5) + 30 mg PNIPAM-coated AuNPs mL −1 administered subcutane-
ously to immunocompetent mice at the upper left fl ank. A) Nanogel degradation over a period of 8 weeks (mean ± SEM,  n = 5); B) Mean (left axis) 
and maximum (right axis) X-ray contrast level of nanogel over a period of 8 weeks (mean ± SEM,  n = 5) and C) Accumulated histogram of nanogel 
contrast level within each pixel from a representative mouse over a period of 30 d.
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marker-based IGRT and potentially result in misguidance of 
the external radiation beam, which, in turn, leads to poor tumor 
coverage and increased radiation to healthy adjacent tissue. [ 16,34 ] 
Such obstacles are not encountered for subcutaneous injections 
of the nanogel as evaluated in immunocompetent NMRI-mice, 
hence the canine cancer patient with a spontaneously devel-
oped solid tumor (mast cell tumor) served as a clinical animal 
model with high translational value for evaluating the clinical 
potential of the developed nanogel. 
 A companion dog (Male, Rhodesian Ridgeback, 10 years, 
body weight 38 kg) diagnosed with a subcutaneous mast cell 
tumor (maximum distance ( x ×  y ×  z ); 1.82 × 5.81 × 5.32 cm 3 , 
CT volume; 31.64 cm 3 ) adherent to the underlying soft tissue 
located over the dorsal aspect of the left shoulder blade was 
given an intratumoral injection of nanogel (300 µL) composed 
of SAIB/EtOH/PLA (75:20:5) + 30 mg PNIPAM-coated AuNPs 
mL −1 under general anesthesia ( Figure  5 ) prior to radiation 
therapy. Approximately 24 h after the injection of the nanogel, a 
diagnostic planning CT-scan of the tumor/nanogel region was 
performed and the therapeutic regimen consisting of four frac-
tions of 6 Gy radiation therapy planned accordingly. Radiation 
therapy was delivered over 16 d on a clinical linear accelerator 
equipped with on-board imaging (OBI) capabilities (3D cone 
beam CT (CBCT) and 2D X-ray imaging). 
 Prior to each fraction of radiotherapy, CBCT ( Figure  6 ) 
images and 2D X-ray imaging  ( Figure S5, Supporting Informa-
tion) were acquired and used for positioning based on nanogel 
and tumor. Radiation therapy was delivered according to the 
nanogel position. The size ( Table  1 ) and stability of the nanogel 
in terms of migration and deformation were evaluated based on 
the recorded CBCT images (Figure  6 ) by manually contouring 
the nanogel using 300 HU as a lower threshold. The nanogel 
size remained constant over the time of treatment with no 
change in overall volume was observed. The small variations 
observed in Table  1 are a consequence of motion artifacts from 
respiratory movement on the recorded CBCT images. Addition-
ally, image analysis revealed that the nanogel retained its 3D 
shape and was found to be immobilized/associated with the 
tumor as no migration of the nanogel was observed during 
the course of radiation therapy despite the canine patient exer-
cising and resting on the tumor inducing mechanical stress on 
the nanogel. Finally, exposure to four fractions of 6 Gy each was 
not found to alter the nanogel morphology as evaluated based 
on the CBCT images. The nanogel was well tolerated and no 
clinical side effects were observed throughout the study. 
 3.  Conclusion 
 A novel nanogel composition based on PNIPAM-coated AuNPs 
formulated in a mixture of SAIB/EtOH/PLA (70:20:5) has been 
developed. PNIPAM-coated AuNPs were found to be highly 
compatible with the hydrophobic SAIB-based gel matrix facili-
tating encapsulation of high concentration of colloidal gold, 
which enables 2D X-ray visualization of the nanogel. This was 
confi rmed by a simulation of 2D DRRs of a patient suffering 
from lung cancer. The developed nanogel is the fi rst inject-
able fi ducial marker that can be visualized in 2D X-ray imaging 
thereby enabling intra- and interfractional IGRT by referencing 
the nanogel position. The nanogel performance was evaluated 
Adv. Healthcare Mater. 2015, 4, 856–863
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 Figure 5.  3D reconstruction based on CT images of canine patient with injected nanogel. Nanogel composed of SAIB/EtOH/PLA (75:20:5) + 30 mg PNIPAM-
coated AuNPs mL −1 administered intratumorally into a canine suffering from an intermediate-grade subcutaneous mast cell tumor (maximum distance 
( x ×  y ×  z ); 1.82 × 5.81 × 5.32 cm 3 , CT volume; 31.64 cm 3 ) adherent to the underlying soft tissue located over the dorsal aspect of the left shoulder blade. 
A) Full-body scan of the canine. Area of interest indicated with a red box. B–D) Nanogel visualized from different angles.
 Figure 6.  Nanogel composed of SAIB/EtOH/PLA (75:20:5) + 30 mg PNIPAM-coated AuNPs mL −1 administered intratumorally into a canine mast 
cell tumor visualized by CBCT imaging. A) Transversal plane (day 0); B) frontal plane (day 0); C) sagittal plane (day 0). Contours in A–C represent the 
nanogel on day 6 (green), day 9 (yellow), day 13 (blue), and day 16 (red). The light blue contour represents the gross tumor volume. D) 3D renderings 
of all the four surfaces represent the nanogel from each day of treatment.
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in vivo in immunocompetent mice by subcutaneous injection. 
Excellent visibility of the nanogel by micro-CT imaging was 
observed with a mean contrast level of 1200 HU after injec-
tion. Over time, the PNIPAM-coated AuNPs were found to 
form microaggregates within the gel matrix as confi rmed by 
image analysis of the high-resolution micro-CT images. This 
phenomenon was found to have no clinical impact due to the 
larger slice thickness of human clinical scanners and lower res-
olution compared to small animal micro-CT scanners. 
 The concept of an injectable fi ducial marker for use in IGRT 
was fi nally validated in a canine cancer patient with a large spon-
taneous solid tumor. The canine patient provides translational 
understanding and allowed us to evaluate the clinical potential 
of the nanogel. The nanogel displayed high image contrast on 
both conventional CT and CBCT images and could addition-
ally be identifi ed by 2D X-ray imaging, thus providing suffi cient 
radiographic properties for visualization with all the imaging 
modalities associated with modern linear accelerators. Further-
more, the nanogel retained its size and 3D structure within 
the tumor microenvironment and no migration of the nanogel 
was observed within the time period for the radiotherapy treat-
ment procedure. The developed nanogel was utilized to align 
the canine patient prior to external beam radiation therapy, was 
found to be unaffected by the deposited radiation dose within the 
tumor, and no side effects were observed in neither the murine 
nor the clinically relevant canine model. However, it should be 
noted that AuNPs are currently not approved for human use and 
the knowledge about the potential short- and long-term toxico-
logical effects after AuNP exposure is still limited. [ 36 ] 
 The developed nanogel presented in this article is the fi rst 
liquid fi ducial marker, which can be inserted using thin and 
fl exible needles and with a high enough contrast to make it vis-
ible in 2D X-ray imaging, which is an important feature for use 
in IGRT. Furthermore, active pharmaceutical ingredients may 
be included in the nanogel formulation to improve the thera-
peutic benefi t for the patient, and the AuNPs may enhance 
the effect of the radiation therapy if the gel is injected directly 
into tumors. [ 37,38 ] In conclusion, the nanogel may provide both 
human and veterinary radiation oncologists with a new tool for 
improving planning, alignment, and tumor tracking in radio-
therapy and could improve treatment outcome by providing a 
more precise delivery of the radiation dose to tumors. 
 4.  Experimental Section 
 Materials : Tetrachloroauric acid trihydrate was purchased from Wako 
Chemicals GmbH (Neuss, Germany) and MeO-PEG 5000 -SH was purchased 
from Rapp Polymere (Tuebingen, Germany). SH-PNIPAM ( M w = 3500Da, 
PDI = 1.24) was purchased from Polymer Source Inc. (Dorval, Canada). 
All other chemicals including SAIB, PLA ( M w = 10–18 kDa), trisodium 
citrate dihydrate, Au-standard for inductively coupled plasma atomic 
emission spectroscopy (ICP-AES) (1000 mg L −1 ), hydrochloride acid and 
nitric acid were purchased from Sigma–Aldrich (Schnelldorf, Germany). 
All chemicals were used as received from the manufacturer. 
 Synthesis of (SH) 2 -SAIB ( 5 ) : (SH) 2 -SAIB ( 5 ) was synthesized over four 
steps starting from sucrose ( 1 ) in an overall yield of 27%. Full synthetic 
procedure including chemical characterization ( 1 H NMR,  13 C NMR, 
HRMS, and FTIR) is available in the Supporting Information. 
 AuNP Synthesis and Characterization : AuNPs were synthesized as 
previously described using a two-step seeding procedure resulting 
in citrate-stabilized AuNPs with an average diameter of 40 nm. [ 17 ] 
The citrate-stabilized AuNPs were subsequently coated with either 
SH-PEG 5000 , SH-PNIPAM 3500, or (SH) 2 -SAIB ( 5 ) using eight molecules 
per nm 2 surface area. Chemisorption of coating materials was in all 
cases conducted overnight at RT after which the volume was reduced 
to approximately 15 mL by centrifugation (9.500 RPM, 15 min). The 
PEG-coated AuNPs, PNIPAM-coated AuNPs, and SAIB-coated AuNPs 
colloid solutions were washed with MQ-H 2 O (3 × 15 mL) and the 
fi nally up-concentrated to approximately 75 mg Au mL −1 as determined 
by ICP-MS using an ICP-MS Au standard (1000 mg L −1 ) as reference. 
Colloid solutions (citrate-stabilized AuNPs, PEG-, PNIPAM-, and SAIB-
coated AuNPs) were furthermore characterized by UV–vis spectrometry, 
DLS, and ζ-potential measured. PNIPAM-coated AuNPs were fi nally 
characterized by TEM (Figure S2, Supporting Information). 
 Nanogel Formulation : SAIB (1.75 g, 90 w/w% in EtOH) and PLA 
(105 mg) were mixed and homogenized by a ball homogenizer 
(frequency 30 s −1 , 30 min) to give a clear homogenous solution. 
Lyophilized PNIPAM-coated AuNPs (63 mg) was weighed off and 
redispersed into anhydrous EtOH (310 µL) by extensive vortexing and 
added to the SAIB/PLA mixture to give a fi nal nanogel forming matrix 
composed of SAIB/EtOH/PLA (75:20:5) with 3.0 w/w% (30 mg mL −1 ) 
PNIPAM-coated AuNPs. Formed nanogels were stored at RT and used 
within 4 h from preparation with vortexing prior to use. Nanogels with 
PEG-coated AuNPs were prepared as described elsewhere. [ 17 ] 
 In Vitro Release of PNIPAM -  and PEG -Coated  AuNPs from Nanogel : 
Nanogels composed of SAIB/EtOH/PLA (75:20:5) with 3.0 w/w% 
(30.0 mg mL −1 ) of either PEG- or PNIPAM-coated AuNPs were prepared 
as described above. Nanogels (200 µL) were added to glass vials 
containing MQ-H 2 O (10.0 mL, 37 °C) and aliquots (1.0 mL) were removed 
as a function of time and replaced with an equal amount of MQ-H 2 O. 
The release profi le from both nanogels was measured by correlating the 
UV–vis absorbance of the individual AuNPs with a standard curve based 
on Au-standards of known concentration (5.0–50.0 µg mL −1 ). 
 Simulation of CNR in Lung Cancer Patient : 2D DRRs were performed 
based on clinical 3D CT-data for a patient diagnosed with lung cancer. 2D 
DRRs were created using the drrCode ray-tracing algorithm available online 
(https://code.google.com/p/drrsuite/downloads/list). 2D DRRs were 
created using a source to detector distance of 150 cm and a detector size of 
768 × 1024 pixels (identical to a clinical settings). For conversion from HU to 
attenuation coeffi cient, a μρ for water was used assuming monochromatic 
photons of 120 kV. ROI contouring and CNR calculations for the simulated 
projections were performed in MATLAB (The MathWorks Inc., Natick, MA, 
USA) using an in-house-developed simulation and analysis tool. 
 Animal Models (Mice) : Immunocompetent 7-week-old female NMRI 
mice ( n = 5) were given a subcutaneous injection (200 µL) of SAIB/
EtOH/PLA (75:20:5) + 30 mg mL −1 PNIPAM-coated AuNPs using 
a 25 G needle in the upper left fl ank of the anesthetized mice. The 
animals were given free access to food and water and micro-CT scans 
were recorded over a period of 8 weeks (24, 48 h, 1, 2, 4, and 8 weeks) 
using a dedicated small-animal MicroCAT II system (Siemens Medical 
Solutions, Malvern, PA, USA). Micro-CT images were recorded using 
the following settings; tube voltage of 67 kVp, tube current of 500 µA, 
360 rotation steps, an exposure time of 400 ms, and a voxel size of 
0.092 × 0.092 × 0.092 mm 3 . The animal experiments were approved by 
the Animal Research Committee of the Danish Ministry of Justice. 
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 Table 1.  Nanogel volume following intratumoral injection in a canine 
model. 
Day # Nanogel volume [cm 3 ]
0 0.20
6 0.18
9 0.21
13 0.22
16 0.19
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 Canine : A privately owned companion dog (Male, Rhodesian 
Ridgeback, 10 years, bodyweight 38 kg) suffering from a spontaneously 
developed subcutaneous mast cell tumor (maximum distance 
( x ×  y ×  z ); 1.82 × 5.81 × 5.32 cm 3 , CT volume; 31.64 cm 3 ) adherent 
to the underlying soft tissue located over the dorsal aspect of the left 
shoulder blade was used as a clinical relevant model. In conjunction 
with the standard diagnostic procedures, nanogel (300 µL) was manually 
injected centrally in the tumor using a 23 G needle and 1 mL syringe. 
Approximately 24 h after the injection of the nanogel, a diagnostic CT 
scan (Biograph 40, Siemens Medical Solutions, Erlangen, Germany) of 
the tumor region was performed with the dog under general anesthesia 
using the following acquisition parameters; 120 kV, 150 mAs, pixel 
size 0.977 × 0.977 × 1.00 mm 3 ). As part of the therapeutic procedure 
radiation therapy was planned according to the tumor histology and 
imaging characteristic, and a therapeutic regimen consisting of four 
fractions of 6 Gy radiation treatments was chosen. Radiation therapy was 
delivered by a linear accelerator (Novalis TX, Varian Medical Systems, 
Palo Alto, CA, USA) with on-board imaging capabilities (Cone Beam CT 
and 2D X-ray imaging) and orthogonal ExacTrac radiography (Brainlab 
AG, Feldkirchen, Germany). No side effects were observed throughout 
the study. The canine cancer patient study was approved by the Ethics 
and Administrative Committee at the Department of Veterinary Clinical 
and Animal Sciences, Faculty of Health and Medical Sciences, University 
of Copenhagen, Denmark. 
 Analysis of Nanogel Homogeneity : The nanogels were delineated by 
hand using ITK-SNAP. [ 35 ] All data analyses were done in MATLAB (The 
MathWorks Inc., Natick, MA, USA) using in-house- developed software. 
Based on the voxel values in the gels mean and max values, as well as 
cumulative histograms were calculated. The cumulative histograms were 
used for homogeneity evaluation, as changes in the AuNP distribution 
are refl ected in the voxels values and thus the histograms. 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
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1. Synthetic Procedure to (SH)2-SAIB and Product Characterization 
 
Scheme  S1. Synthesis scheme for obtaining (SH)2-SAIB (5) over four synthetic steps starting from sucrose (1) 
resulting in (SH)2-SAIB (5) in an overall yield of 27%. 
 
General Information 
Nuclear Magnetic Resonance (NMR) was conducted on a Bruker Ascend
TM
 400 MHz - 
operating at 401.3 MHz for 
1
H and 100.62 MHz for 
13
C - with a 5 mm H – Broadband Dual 
Channel z-gradient Prodigy cryoprobe instrumentation. All spectrums were measured at 298 
K and the spectrums recorded were calibrated according to the solvent residues. Thin Layer 
Chromatography (TLC) analysis was conducted by use of TLC Silica gel 60 F254 aluminum 
sheets, Merck KGaA, 64271 Darmstadt, Germany. As developing agent a mixture (Cemol-
dip) consisting of 9 g cerium sulfate, 47 g ammonium molybdate, 849 mL H2O and 94 mL of 
sulfuric acid was applied on the TLC plate followed by heat treatment. For dry column 
purification, a silica gel 60 (0.015-0.040 mm) from Merck KGaA, 64271 Darmstadt, Germany 
was used. High Resolution Mass spectroscopy (HR-MS) was conducted on a Bruker 
Daltronics maXis 3G QTOF-MS fitted with a Dionex Ultimate 3000 UHPLC instrumentation. 
Attenuated Total Reflection Fourier Transformation Inferred radiation (ATR-FTIR) analysis 
was conducted on a Bruker Alpha platinum ATR instrumentation with a single reflection 
diamond ATR module. Melting point was measured with a Stuart SMP 30 instrumentation. 
Sucrose (99.5%, 57-50-1), 4-(dimethylamino)pyridine (DMAP, puriss, 1122-58-3), isobutyric 
anhydride (97%, 97-72-3), (R)-(+)-1,2-dithiolane-pentanoic acid (97%, 1200-22-2), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDAC·HCl, 98%, 25952-53-8) 
and tetra-n-butylammoniumfluoride (TBAF, 1.0 M, 429-41-4) in THF were purchased from 
Sigma Aldrich (Steinheim, Germany) and used as received. tert-Butyl(chloro)diphenylsilane 
(TBDPS-Cl, 98%, 58479-61-1) was purchased from ABCR (Karlsruhe, Germany).  
 
(2R,3R,4S,5S,6R)-2-(((2S,3S,4S,5R)-5-(((tert-Butyldiphenylsilyl)oxy)methyl)-3,4-dihydroxy-2-
(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
(2). To a suspension of sucrose (1) (10 g, 29.2 mmol) in pyridine (100 mL) was added DMAP 
(0.36 g, 2.92 mmol). The reaction mixture was stirred at room temperature for 1 h followed 
by addition of TBDPS-Cl (4.65 mL, 17.5 mmol) and heated to 70 ⁰C for 3 h. Another portion 
of TBDPS-Cl (4.65 mL, 17.5 mmol) was added to the reaction mixture at room temperature 
and then left stirred overnight. The reaction was followed by TLC. Pyridine was then 
removed in vacuo and the crude compound was purified by dry column vacuum 
chromatography (EtOH in EtOAc with 2% increments). Yield: 6.8 g amorphous solid; 40%. 
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Mp: 174 °C. 
1
H-NMR (400 MHz, MeOD): δ = 1.04 (s, 9H), 3.25-3.35 (m, 2H), 3.50-3.68 (m, 
5H), 3.72-3.79 (m, 1H), 3.84-3.99 (m, 3H), 4.01-4.13 (m, 2H), 5.44 (d, J=3.9 Hz, 1H), 7.35-
7.46 (m, 6H), 7.67-7.77 (m, 4H).
 13
C-NMR (100 MHz, MeOD): δ = 20.0, 27.3 (3C), 62.4, 
64.3, 66.5, 71.4, 73.2, 73.9, 74.9, 76.2, 79.0, 83.7, 93.0, 105.6, 128.8 (2C), 128.8 (2C), 130.8 
(2C),  134.5, 134.6, 136.8 (2C), 136.8 (2C);  HR-MS. Calculated adducts: [M+H
+
] = 
581.2413, [M+Na
+
] = 603.2232, [M+K
+
] = 619.1971. Observed adducts, [M+H2O] = 
598.2675, [M+Na
+
] = 603.2226, [M+K
+
] = 619.1952. ATR-FTIR (cm
-1
): 507.18, 701.83, 
805.57, 930.50, 994.46, 1043.53, 1067.96, 1111.82, 1390.34, 1428.36, 1470.26, 2857.74, 
2930.17, 3285.79. 
   
(2R,3R,4S,5R,6R)-2-(((2S,3S,4R,5R)-5-(((tert-Butyldiphenylsilyl)oxy)methyl)-3,4-bis(iso-
butyryloxy)-2-((isobutyryloxy)methyl)tetrahydrofuran-2-yl)oxy)-6-((isobutyryloxy)methyl-
)tetrahydro-2H-pyran-3,4,5-triyl tris(2-methylpropanoate) (3). 6’-O-TBDPS-sucrose (2) (2.00 
g, 3.44 mmol) was dissolved into pyridine (40 mL) together with DMAP (0.114 g, 0.924 
mmol). Isobutyric anhydride (11.4 mL, 66.7 mmol) was added and the reaction mixture was 
stirred at room temperature overnight. The reaction was followed by TLC. At the point of 
reaction completion, the reaction mixture was concentrated in vacuo and diethyl ether (200 
mL) was added followed by extraction with saturated aqueous sodium bicarbonate solution 
(5×200 mL). The organic phase was subsequently collected and concentrated in vacuo. The 
crude product was purified by dry column purification (EtOAc in heptane with 2% 
increments). Yield = 2.97 g transparent oily texture; 80%.
1
H-NMR (400 MHz, DMSO): δ = 
0.94-1.07 (m, 39H), 1.08-1.16 (m, 12H), 2.32-2.48 (m, 4H), 2.52-2.62 (m, 3H), 3.75-3.86 (m, 
2H), 3.90 (dd, J = 13 Hz, 2 Hz, 1H), 4.02-4.20 (m, 4H), 4.24 (ddd, J =  10.3 Hz, 4.4 Hz, 1.8 
Hz, 1H), 4.86 (dd, J =  10.6 Hz, 3.6 Hz, 1H), 5.04 (t, J = 10.0 Hz, 1H),  5.35 (t, J = 10.0 Hz, 
1H); 5.46-5.49 (m, 2H); 5.62 (d, J = 3.7 Hz, 1H),  7.37-7.50 (m, 6H), 7.56-7.64 (m, 4H).
13
C-
NMR (100 MHz, DMSO): δ = 18.0-19.0 (14C), 26.4 (3C), 30.7, 32.9-33.3 (7C), 61.2, 63.3, 
63.8, 67.1, 68.1, 69.1, 69.2, 73.5, 75.3, 80.0, 89.1, 102.4, 127.9 (4C), 130.0 (2C), 132.3, 132.4, 
135.0 (4C), 174.6, 175.0 (3C), 175.2, 175.3, 175.6,. HR-MS. Calculated adducts: [M+H
+
] = 
1071.5343, [M+Na
+
] = 1093.5163, [M+K
+
] = 1109.4902. Observed adducts, [M+H2O] = 
1088.5609, [M+Na
+
] = 1093.5175, [M+K
+
] = 1109.4892. ATR-FTIR (cm
-1
): 504.26, 702.23, 
742.56, 823.65, 1030.51, 1071.63, 1111.82, 1139.69, 1186.65, 1247.91, 1388.47, 1470.12, 
1741.41, 2877.85, 2934.80, 2973.83, 3285.44. 
 
(2R,3R,4S,5R,6R)-2-(((2S,3S,4R,5R)-5-(hydroxymethyl)-3,4-bis(isobutyryloxy)-2-(iso-
butyryloxy)methyl)tetrahydrofuran-2-yl)oxy)-6-((isobutyryloxy)methyl)tetrahydro-2H-pyran-
3,4,5-triyl tris(2-methylpropanoate) (4). 
Hepta-isobutyryl-6’-O-TBDPS-sucrose (3) (1.032 g, 0.95 mmol) was dissolved in dry THF 
(20 mL) under inert atmosphere. Acetic acid (0.082 mL, 1.43 mmol) was added to the stirred 
mixture followed by the addition of a 1.0 M TBAF solution in THF (1.2 mL, 1.2 mmol). The 
reaction mixture was stirred at room temperature overnight. The reaction was followed by 
TLC. The reaction mixture was directly purified by dry column purification (EtOAc in 
heptane with 4% increments). Yield: 0.768 g transparent oily texture; 97%. 
1
H-NMR (400 
MHz, DMSO): δ = 0.95-1.21 (m, 42 H), 2.34-2.66 (m, 7H (DMSO overlap)), 3.60 (m, 2H), 
4.00-4.12 (m, 4H), 4.21 (dd, J = 13.0 Hz, 4.4 Hz, 1H), 4.34 (ddd, J =  10.4 Hz, 4.5 Hz, 1.8 Hz, 
1H), 4.91 (dd, J = 10.4, 3.6 Hz, 1H), 4.96 (t, J =  5.5 Hz, 1H), 5.11 (t, J = 9.9 Hz, 1H), 5.34 (t, 
J = 7.5 Hz, 1H), 5.40 (t, J = 9.9 Hz, 1H), 5.47 (d, J = 7.5 Hz, 1H), 5.67 (d, J = 3.5 Hz, 1H). 
13
C-NMR (100 MHz, DMSO): δ = 18.0-19.0 (14C), 32.9-33.3 (7C), 61.4, 61.5, 63.3, 67.3, 
68.0, 69.2, 69.3, 73.7, 75.2, 80.8, 89.1, 102.2, 174.6, 175.0 (3C), 175.3, 175.4, 175.8. HR-MS. 
Calculated adducts: [M+H
+
] = 833.4165, [M+Na
+
] = 855.3985, [M+K
+
] = 871.3724. 
Observed adducts: [M+H2O] = 850.4449, [M+Na
+
] = 855.3999, [M+K
+
] = 871.3738. ATR-
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FTIR (cm
-1
): 748.36, 1005.66, 1048.73, 1077.10, 1142.42, 1186.51, 1247.10, 1344.51, 
1388.51, 1470.09, 1739.30, 2878.48, 2939.02, 2974.80, 3531.46. 
 
(2R,3R,4S,5R,6R)-2-(((2S,3S,4R,5R)-5-(((5-((R)-1,2-dithiolan-3-yl)pentanoyl)oxy)methyl)-
3,4-bis(isobutyryloxy)-2-((isobutyryloxy)methyl)tetrahydrofuran-2-yl)oxy)-6-((isobutyryloxy)-
methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2-methylpropanoate) (5). 
Hepta-isobutyryl-sucrose (4) (0.543 g, 0.64 mmol) was dissolved in dry DMF (10 mL) under 
inert atmosphere. In another flask under inert atmosphere, (R)-(+)-1,2-Dithiolane-pentanoic 
acid (0.206 g, 0.96 mmol), DMAP (0.246 g, 1.91 mmol) and EDAC·HCl (0.190 g, 0.96 
mmol) were dissolved in  dry DMF (10 mL) and stirred for 15 min. The mixture, containing 
the activated ester was subsequently transferred to the reaction mixture of hepta-isobutyryl-
sucrose (4). The reaction mixture was left stirred at room temperature for reaction. The 
reaction was followed by TLC. After 24 h a new mixture of activated ester: (R)-(+)-1,2-
Dithiolane-pentanoic acid (0.0706 g, 0.32 mmol), DMAP (0.080 g, 0.64 mmol) and 
EDAC·HCl (0.065 g, 0.32 mmol) dissolved in dry DMF (10 mL) under inert atmosphere was 
added to the reaction mixture. At the point of reaction completion, the reaction mixture was 
concentrated in vacuo followed by addition of diethyl ether (100 mL) and phase extraction 
with water (3×100 mL). The organic phase was collected and finally purified by dry column 
purification (EtOAc in heptane with 4% increment per fraction). Yield: 0.558 g yellowish oily 
texture; 86%. 
1
H-NMR (400 MHz, DMSO): δ = 0.96-1.18 (m, 42H), 1.38 (m, 2H), 1.48-1.72 
(m, 4H), 1.86 (dq, J = 13.4 Hz, 6.4 Hz, 1H), 2.33 (t, J = 7.3 Hz, 2H), 2.36-2.44 (m, 2H), 2.44-
2.66 (m, 6H), 3.14 (m, 2H), 3.59 (dq, J = 8.5 Hz, 6.2 Hz, 1H), 4.03-4.14 (m, 3H), 4.16-4.40 
(m, 5H), 4.91 (dd, J = 10.4 Hz, 3.6 Hz, 1H), 5.10 (t, J = 9.9 Hz, 1H), 5.34-5.43 (m, 2H), 5.52 
(d, J = 7.5 Hz, 1H); 5.64 (d, J = 3.5 Hz, 1H). 
13
C-NMR (100 MHz, DMSO): δ = 18.0-19.0 
(14C), 24.1, 28.1, 33.0-33.3 (8C), 34.1, 38.1, 40.0 (DMSO overlap), 56.0, 61.4, 63.2, 63.3, 
67.3, 68.2, 69.2, 69.2, 73.5, 74.8, 77.5, 89.3, 102.4, 172.4, 174.5, 174.9, 175.0 (2C), 175.2, 
175.4, 175.8. HR-MS. Calculated adducts: [M+H
+
] = 1021.4495, [M+Na
+
] = 1043.4314, 
[M+K
+
] = 1059.4054. Observed adducts, [M+H2O] = 1039.4844, [M+Na
+
] = 1043.4355, 
[M+K
+
] = 1059.4136. ATR-FTIR (cm
-1
): 476.19, 748.51, 849.06, 916.58, 963.11, 1028.24, 
1074.25, 1140.82, 1185.60, 1246.17, 1344.85, 1388.11, 1469.77, 1738.20, 2877.68, 2936.72, 
2974.16. 
 
2. AuNP Characterization and Handling 
General considerations 
The synthesized AuNPs were diluted with MQ-H2O (Au-seeds ×4), citrate stabilized AuNPs 
(×4) and PNIPAM-coated AuNPs (×4000) prior to UV-vis, DLS and ζ-potential 
measurements. 
 
UV-vis Measurements  
The UV-vis absorption spectra of the synthesized AuNPs were measured using a Unicam 
Helios α Uni 9423 UV-vis spectrophotometer by scanning the UV-range from 450-900 nm.  
UV-vis absorption spectra of hydrosols were measured using disposable PS cuvettes whereas 
organosols were measured in quarts cuvettes of identical dimensions (1.0 cm × 1.0 cm). The 
apparent solvent was used in the reference cell for the individual measurements and blanks 
were run prior to AuNP analysis. 
 
Dynamic Light Scattering Measurements  
The hydrodynamic diameter and polydispersity of the synthesized AuNPs were determined 
using a Zeta PALS Analyzer (Brookhaven Instruments, NY, USA). Data was fitted using 
built-in software to calculate the hydrodynamic size of the AuNP-colloids. 
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ζ-potential Measurements 
The ζ-potential was measured in the same sample as the DLS analysis using a Zeta PALS 
Analyzer (Brookhaven Instruments, NY, USA) with a pre-conditioned electrode with 10 sub-
runs while observing a fitting model residual less than 0.04. 
 
ICP-MS Measurements 
The Au-concentration of the purified and up-concentrated PEG- and PNIPAM-coated AuNPs 
stock solutions were determined by ICP-MS using a Thermo Scientific iCAPQ ICP-MS (MA, 
USA) using the following settings; RF Power: 1550 W, Plasma Gas Flow: 14L min
-1
, 
Nebulizer Gas Flow: 0.945L min
-1
, Dwell Time: 0.01 s, Sweeps: 300, Replicates: 3, Delay 
Time: 60 s, Wash Time: 60 s. PNIPAM-coated AuNPs (20.0 μL) was digested using fresh 
prepared aqua regia (400 μL) and the total volume adjusted to 6.00 mL with MQ-H2O (5580 
μL) (× 300 dilution). The ×300 dilution solution (5 μL) was further diluted with HNO3 (4995 
μL, 1% + 0.5 ppb Ir as internal standard) to give a final dilution factor of ×300.000. A 
standard curve covering the concentration range of 62.5 ppb ─ 500 ppb in HNO3 (1% + 0.5 
ppb Ir as internal standard) was prepared using an Au-standard for ICP-MS (1000 mg L
-1
). 
The intensity of 
197
Au (m/z = 196.9666) was measured and the concentration of coated 
AuNPs was determined based on the corresponding standard curve. 
 
Lyophilization and Stability of PNIPAM-coated AuNPs 
The PNIPAM-coated AuNPs stock solution (64 mg Au mL
-1
) was diluted to 1.0- 2.5- and 5.0 
mg Au mL
-1
 with MQ-H2O in glass vials. The samples were snap frozen by submerging the 
samples into liquid nitrogen and lyophilized overnight (p < 6.0 × 10
-2 
mbar) to give an air 
stable black nanopowder which was stored in the dark at 5 °C until further use. The 
lyophilized PNIPAM-coated AuNPs readily re-dispersed in MQ-H2O to form the apparent 
PNIPAM-coated AuNPs hydrosol with no change in particle morphology based on UV-vis 
spectroscopy and DLS analysis. Additionally, the lyophilized PNIPAM-coated AuNP 
nanopowder also readily re-dispersed in various protic- and aprotic organic solvents to form 
stable PNIPAM-coated AuNP organosols (Figure S1). 
 
 
Figure S1. UV-vis spectroscopy analysis of the re-dispersibility of the air stable black nanopowder of PNIPAM-
coated AuNPs obtained by lyophilization in MQ-H2O and various protic- and aprotic polar organic solvents 
covering the relative polarity scale from 0.259 (chloroform) to 1.000 (MQ-H2O). An apparent red-shift of the 
surface plasmon resonance peak is observed following re-dispersion in organic solvent due to the change in 
refractive index of the solvent. 
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Figure S2. A) Characterization of PNIPAM-coated AuNP by TEM; B) Comparison of the obtained contrast 
level in 2D x-ray imaging of AuNPs containing nanogels (10- 30-, 60- and 90 mg AuNP mL
-1
) and solid fiducial 
markers used in the clinic. Markers visualized in a 10 cm solid water phantom using the following settings; 80 
kVp, 80 mA, 80 ms. 
 
 
Figure S3.  A) Standard curve of UV-absorbance at λ = 537 nm as a function of PNIPAM-coated AuNP 
concentration in MQ-H2O (r
2
 = 1.00); B) In vitro release kinetics from SAIB/EtOH/PLA (75:20:5) with either 30 
mg mL
-1
 PEG-coated AuNPs or PNIPAM-coated AuNPs in MQ-H2O at 37 °C. Each point represents the mean ± 
SEM (n = 3). C) Representative image of nanogels containing either PEG-coated or PNIPAM-coated AuNPs 
after 24 h incubation in MQ-H2O. 
 
3. X-ray Visualization of Nanogel in Mice/Canine 
 
Figure S4.  Visualization of nanogel composed of SAIB/EtOH/PLA (75:20:5) + 30 mg PNIPAM-coated AuNPs 
mL
-1
 administered subcutanously injection in immunocompetent mice. Aggregation of PNIPAM-coated AuNPs 
within the gel matrix visualized by reduction of the contrast level on the micro-CT image.  
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Figure S5.  Nanogel composed of SAIB/EtOH/PLA (75:20:5) + 30mg PNIPAM-coated AuNPs mL
-1
 
administered intratumorally into canine suffering from a solid subcutaneous mast cell tumor (maximum distance 
(x × y × z); 1.82 cm × 5.81 cm × 5.32 cm, CT volume; 31.64 cm
3
) adherent to the underlying soft tissue located 
over the dorsal aspect of the left shoulder blade. A) OBI 2D x-ray imaging of nanogel and B) ExacTrac imaging 
of nanogel. Both images recorded prior to the first fraction of radiation therapy 6 days after injection. 
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1 Abstract
An experiment with 24 mice was started to test two formulations of the x-SAIB
gel. The two formulations were injected into 8 mice each, with a third group of
8 mice as a control. The mice were scanned in a micro-CT scanner on day 0, 2,
8, 29, 51, and 98 after injection of the gel. The gel were semi-automatically seg-
mented on the CT-scan using a Chan-Vese segmentation method. A Repeated
Measurements Model (RMM) showed a non-significant difference in the volume
loss of the gel over time between the two groups. The volume loss, with a 95%
confidence interval, was −0.09176µLd , [−0.1134,−0.07009]µLd . This is less than
what was found for the first 6 weeks.
1
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2 Introduction
An experiment with 24 mice in three groups (A, B and control) were initiated
in the Cluster for Molecular Imaging at Copenhagen University on the 10th of
July 2013. Groups A and B were given different formulations of a x-SAIB gel,
while C acted as control. The mice were scanned in a micro-CT six times: on
day 0, 2, 8, 29, 51 and 98 after injection of the gel. The goals of the experiment
were multiple, but this report will focus narrowly on the stability of the gels,
namely the rate with which they were degraded in the mice.
The segmentation process used to delineate the gel will be explained and possible
errors from this process discussed. The statistical analysis of the volume data
arising from the segmentation, will be explained in details and the degradation
results for the different gels presented.
3 Segmentation
Given the CT scannings of the mice, we needed to isolate the gel in some way,
in order to analyse the stability of the gels. As manual delineation is both time
consuming and exhibits a large operator variability, an automatic approach was
chosen.
The problem in image segmentation is to find some defining feature of the area
one wants to segment. In our case the gels have a higher intensity than the
surrounding tissue, and intensity is thus a good feature. Other features could
be e.g. texture, shape or intensity distribution.
3.1 Chan-Vese method
The Chan-Vese method [1] works by supplying an initial guess on a segmenta-
tion, which will then be refined. The method has two components: An intensity
component and a curvature component. The intensity component will try to
align the segmentation along intensity edges in the image, i.e. gel tissue bound-
ary in our case. The curvature component penalizes curvature, i.e. how curved
or bended our segmentation is. This is a reasonable constraint as our gels mostly
have a smooth surface. If we only looked at intensity, noise in the image could
lead to a spiky segmentation and spurious angular edges.
The penalty function is given by
F (φ) = µ
∫
Ω
|∇H(φ(x, y))| dx dy+λ
∫
Ω
|u(x, y)−c1|2−|u(x, y)−c2|2 dx dy, (1)
where H is the Heaviside function, u(x, y) is the image, Ω describes the entire
image, c1 and c2 are respectively the mean value outside and inside the level
set, and µ and λ are weights.
The problem is how much weight to put on the first component µ vs. the second
component λ. If the second component is to large we will cut of areas with high
curvature, e.g. if the gel is flat and thin. If we weigh the second component
3
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too little our segmentation will be too noisy. In this case the problem is not
significant, as our gels have nice smooth borders, and the segmentation works
for a wide range of parameters.
3.2 Implementation
A script for the segmentation was written in Matlab. The procedure is as
follows. The folder containing the scans are selected, and one by one, the scans
are loaded automatically into Matlab.
First a bounding box (BB) are drawn around the gel on Maximum Intensity
Projections (MIP) in all three dimensions, as shown in fig. 1 for one of the
dimensions.
Figure 1: Example of a Bounding Box drawn around two gels for segmentation
This BB was then automatically segmented into gel/non-gel by the Chan-Vese
method, with the smoothing term µ = 0.25 and the image term set to λ =
5−6. The initial guess was obtained by finding the maximum value in the BB,
subtracting 250, and then use that value as a threshold, assigning all voxels
above that value as ‘gel’. If the segmentation touched the edge of the BB that
part of the segmentation was automatically removed. This was often the case
for the spinal bones, as they have an intensity comparable to the gel.
The resulting segmentation was manually inspected on an image as seen in fig.
2. The bright white mass is the gel and the blue line the segmentation border.
If the segmentation is acceptable - i.e. if it follows the outline of the the gel
on each slice - it is saved, otherwise it is possible to change the parameters in
4
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Figure 2: Slices through two gels. The delineation is shown by blue. The images
are individually scaled.
5
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the model. This was necessary on a few scans where the gel was very flat and
elongated. In those cases the curvature parameter was adjusted downwards,
and a satisfactory segmentation achieved.
3.3 Volume results
The volumes for gel A and B can be seen in fig. 3 with the first measurement
omitted. The reason for this, is that it mostly shows the diffusion of the ethanol
from the gel and is not representative for the degradation of the gel. The volumes
are listed in tabular form in Appendix A
Figure 3: Volume plotted over time. We see no apparent differences in the
degradation rate of the two types. Group A: warm colours 1-8. Group B: cold
colours, 9-25.
3.4 Conclusion
The gels can be segmented semi-automatically.
The segmentation is deterministic and we have no ground truth segmentation.
It is therefore not sensible to assign a variance to the segmentation nor to the
volume. If the segmentation for a gel is very dependant on the parameters
chosen for the Chan-Vese model or very sensitive to a small perturbation of
the image, it could be viewed as an “uncertain” segmentation. This degree of
uncertainness might be incorporated into a statistical model. Not much research
have been done is this area.
6
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4 Statistical analysis
If we look at fig. 3 the curves looks mostly linear with a downwards trend. This
is expected, as the gel is biodegradable. We will focus on this part, to see if the
two gels have different properties regarding the degradation.
All data analysis was done in SAS or Matlab. The SAS program can be found
in Appendix B.
4.1 Model type
As a first step, one might be tempted to fit a general linear model (GLM) (think
linear regression with more than one variable). To capture the downwards trend,
it is not far off, but for statistical tests it is inadequate. In GLM we assume
that the measurements are uncorrelated. This is clearly not the case as we have
repeated measurements on the same mice.
Instead we can use a repeated measurements model (RMM). Here we can model
the correlation of the measurements made on the same mouse. This decreases
the errors in the model, and increases the statistical test strength. The mice
are still assumed uncorrelated.
The errors were modelled as autoregressive, giving the following variance-covariance
matrix for a single mouse:
D(jk) = σ
2
 1 · · · ρ
|t(k)1j−t(k)Ij |
...
. . .
...
ρ|t(k)1j−t(k)Ij | · · · 1
 (2)
where I is the last observation for mouse j, group k.
4.2 Model selection
We start by hypothesizing different models which may describe the data. We
expect a different intercept for each mouse, as the amount of gel seems to vary,
and we may also expect a mouse dependent slope, i.e. degradation rate, as each
mouse may have different responses to the gel. A reasonable model may then
be:
Y (k)ij = α(k)j + β(k)j t(k)ij + (k)ij (3)
where Y (k)ij are the volumes at time i for mouse j in group k, α(k)j are the
intercepts for mouse j in group k, t(k)ij are the times, β(k)j are slopes, and
(k)ij are the errors.
We will then successively test if a simpler model may provide a better expla-
nation of the data, when taking into account that we use fewer parameters.
A simpler model, that still adequately describes the data are preferred, as we
have more degrees of freedom (DoF) left to account for the errors. The null
hypothesis is thus, that the current model explains the data best against that
a the previous model explains it just as well, when accounting for fewer free
parameters. An overview of the tested models can found in table 1.
7
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Table 1:
Model overview
M1 α(k)j + β(k)j t(k)ij Individual intercept and slope
M2 α(k)j + β(k) t(k)ij Individual intercept and group slope
M3 α(k)j + β t(k)ij Individual intercept and common slope
M4 α(k)j Individual intercept
M5 α(k) Group intercept
This is done with the usual F-test statistic for the GLM. For the RMM we use
that the -2 log-likelihood ratio is χ2-distributed under the null hypothesis with
DoF corresponding to the decrease in free parameters when moving to a simpler
model. For the RMM we also use the corrected Akaike information criterion
(AICC)[2], which weighs how good the model fits the data against how many
parameters are used (smaller is better). The results are found for the GLM in
table 2 and for the RMM in table 3. We have a total of 65 observations on 14
mice. Each group A and B have 7 mice.
Table 2:
GLM
Model Fixed effects No. par. RSS DoF F-statistic f P(F >f)
M1 α(k)j + β(k)j t(k)ij 28 311.66 37
M2 α(k)j + β(k) t(k)ij 16 520.12 49 2.062347 0.0458
M3 α(k)j + β t(k)ij 15 521.9696 50 0.174126 0.6783
M4 α(k)j 14 1208.80 51 32.43969 1.06·10−9
M5 α(k) 2 10707.70 63 75.05399 4.00·10−28
Table 3:
RMM
Model Fixed effects No. par. -2 log Diff. DoF P(χ2 >Diff.) AICC
M1 α(k)j + β(k)j t(k)ij 28 286.40 387.5
M2 α(k)j + β(k) t(k)ij 16 316.70 30.30 12 2.516 ·10−3 367.6
M3 α(k)j + β t(k)ij 15 317 0.30 1 0.5839 364.0
M4 α(k)j 14 362.10 45.10 1 1.87·10−11 405.4
M6 α(k) 2 409.40 4730 12 4.14·10−6 418.1
We see from table 2 and 3, that the step from M1 to M2 is significant at a 5%
level. Taking statistical methodology very literally, we should thus use the full
model M1. But obviously the superior fit to the model M1 is due to a very
large number of parameters causing ‘overfitting’. In model selection AICC is
counter balancing the fit with the number of parameters used, and using AICC
we should choose M3. To check whether M3 adequately describes the data we
look at the residuals, which are shown in figure 4. As the residuals look random
and as we can see no trend, we choose to accept M3 as an adequate model for
the data. The full SAS-output for the model can be seen in appendix C.
We can thus conclude, that there is no significant difference between group A
and B, as there is no significant difference between M2 where we have group
8
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Figure 4: First line belong to group A (warm colours), second line to group B
(cold colours)
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slopes and M3 where we have a common slope. Using the RMM we find the
slope, i.e. degradation rate, with a 95% confidence interval, to be:
Degradation rate = −0.09176µL
d
, [−0.1134,−0.07009]µL
d
(4)
Based on the likelihood distance 2 observations were found to have a large
influence. This was observation 18 and 65. Observation 18 is mouse 4 at day 51
and observation 65 is mouse 25 at day 98 which is the last for mouse 10. They are
both clearly the result of an unexpected and physically unexplainable behaviour:
That the volume of the gel increases. A full set of influence diagnostics can be
found in appendix B.
4.3 Validation of model
An assumption we made, was that the volume could be described by a linear
model. To test whether this is a reasonable assumption, we construct a physics
model for the gel.
If we assume a that the gel is spherical and is broken down on the surface only,
we can make the following model of the gel volume:
V (t) =
4
3
pi(r − d · t)3 (5)
V (t) is the time dependant volume, r is the initial radius and d is the distance
from the surface that is broken down per time step t.
Using the same equation we find that a gel with a volume of 50 µL has a radius of
2.2854 mm. With a degradation rate of −0.09176µLd as found, this corresponds
to 0.0014 mm of the surface being broken down each day.
This is less than found for the first 51 days alone. The rate estimate there was
−0.1337µLd corresponding to 0.0020 mm surface per day.
How this affects the volume is plotted in fig. 5. The time to complete degradation
with this very simplistic model is more than a year longer. We see that the initial
part is quite linear, at least for the first 100 days. The assumption of linear
volume loss is thus reasonable, even though the gels are not exactly spherical.
If we use the upper and lower bounds on the 95 % confidence interval, we get
the result shown in fig. 6.
4.4 Conclusion
A repeated measurements model was used and the specific model selected was
performed based on AICC. The residuals were evaluated and showed no trend
or organised structure.
Gel A and B experience the same degradation rate, which, with a 95% confidence
interval, was found to be −0.09176µLd , [−0.1134,−0.07009]µLd .
Based on a physics model, the assumption of linear volume loss would seem a
reasonable model.
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Figure 5: Degradation of the gel assuming loss from the surface only, mean
estimate.
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Figure 6: Degradation of the gel assuming loss from the surface only, upper and
lower bound
12
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5 Conclusion
The x-SAIB gels can be semi-automatically segmented, using a Chan-Vese seg-
mentation model. More research is needed before segmentation ‘uncertainty’
can be quantified and incorporated into a statistical model with only a single
measurement per time.
Gel A and B experience the same degradation rate, which, with a 95% confidence
interval, was found to be −0.09176µLd , [−0.1134,−0.07009]µLd . A more robust
estimate would require more mice.
Based on a physics model, the assumption of linear volume loss would seem a
reasonable model.
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NanoGuide - gel volume data from mice
15:49 Sunday, October 6, 2013 1
Obs mouse group time vol
1 1 1 2 35.4257
2 1 1 8 30.0960
3 1 1 29 30.7415
4 1 1 51 28.5923
5 2 1 2 68.3343
6 2 1 8 66.3791
7 2 1 29 59.5002
8 2 1 51 56.9742
9 3 1 2 62.7148
10 3 1 8 60.7109
11 3 1 29 54.5424
12 3 1 51 52.4118
13 4 1 8 42.0277
14 4 1 29 36.2904
15 4 1 51 45.5662
16 5 1 2 40.5240
17 5 1 8 40.7976
18 5 1 29 34.7843
19 5 1 51 31.7808
20 6 1 2 57.4094
21 6 1 8 50.5330
22 6 1 29 45.9641
23 6 1 51 45.2228
24 8 1 2 44.2484
25 8 1 8 42.8600
26 8 1 29 46.9823
27 8 1 51 42.9485
28 9 2 2 37.3119
29 9 2 8 36.8905
30 9 2 29 29.6868
31 9 2 51 22.0560
32 10 2 2 49.9240
33 10 2 8 46.7736
34 10 2 29 41.7671
117
NanoGuide - gel volume data from mice
15:49 Sunday, October 6, 2013 2
Obs mouse group time vol
35 10 2 51 48.8465
36 11 2 2 39.5342
37 11 2 8 38.0792
38 13 2 2 33.5574
39 13 2 8 30.7204
40 13 2 29 29.9555
41 13 2 51 30.5272
42 14 2 2 57.0920
43 14 2 8 55.2756
44 14 2 29 53.0062
45 14 2 51 49.4588
46 15 2 2 66.4628
47 15 2 8 70.8847
48 15 2 29 62.4411
49 15 2 51 59.6805
50 25 2 2 24.5820
51 25 2 8 26.6777
52 25 2 29 23.5443
53 25 2 51 22.4587
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B SAS program code
1
2 Data Nano2 ;
3 input mouse group time vo l i n t e n s i t y var iance s u r f a c e ;
4 cards ;
5 1 1 2 35.42569864 −49.52979601 108669.995 80.04514464
6 1 1 8 30.09601067 51.44175255 106357.0777 78.08688025
7 1 1 29 30.74151676 43.37341856 125521.3162 80.07125483
8 1 1 51 28.59226568 77.53876299 129834.32 69.339966
9 1 1 98 29.29217291 37.0853476 134306.9352 78.07817686
10 2 1 2 68.33432953 109.4608959 109445.8243 122.3784689
11 2 1 8 66.37913626 142.7016342 119861.0259 126.4081419
12 2 1 29 59.5002337 281.1633461 105998.7397 115.9640651
13 2 1 51 56.97423442 275.7991136 117661.6498 91.82084114
14 2 1 98 51.78176725 357.1379716 116923.7708 86.79027752
15 3 1 2 62.7147728 274.0531597 122797.1628 107.6610242
16 3 1 8 60.71086209 303.5634404 110156.1762 96.65122662
17 3 1 29 54.54242219 404.2452735 99903.43663 75.37142031
18 3 1 51 52.41184614 474.9968397 100473.2707 67.62539674
19 3 1 98 49.89640231 504.5179164 86544.34748 61.23710315
20 4 1 8 42.02772375 266.8248102 126420.5463 84.66664858
21 4 1 29 36.2904332 334.9333035 98390.20222 57.98203257
22 4 1 51 45.56623383 225.8813949 187530.8619 72.1946803
23 4 1 98 36.04278621 389.7182248 120846.7979 56.80707394
24 5 1 2 40.52397876 236.1339438 111813.5532 87.66932064
25 5 1 8 40.79760838 219.1499224 120830.9048 82.02951921
26 5 1 29 34.78425234 366.0769374 107422.8303 54.37882611
27 5 1 51 31.78082215 448.4554304 90005.30525 45.25766577
28 5 1 98 31.06792361 446.5332044 91966.81657 42.59442621
29 6 1 2 57.40944355 217.1534121 117999.5588 101.3510611
30 6 1 8 50.53297686 343.3837008 106286.1012 89.94961072
31 6 1 29 45.96409292 427.1831688 90947.86316 60.39287361
32 6 1 51 45.22277587 453.8050129 97421.79974 54.81399597
33 6 1 98 44.11770194 488.9778228 89563.44952 56.39801427
34 8 1 2 44.24842707 238.3314739 111928.0403 95.09331851
35 8 1 8 42.85998002 289.1258857 114325.2922 85.38032716
36 8 1 29 46.98228742 185.7542644 148668.5902 84.13574135
37 8 1 51 42.94848337 246.7547405 145413.9902 72.57762978
38 8 1 98 36.50966168 418.1167797 114538.3369 65.51047121
39 9 2 2 37.31187553 1114.62812 346953.9974 89.34907631
40 9 2 8 36.89046967 1149.053264 386614.6842 88.39170261
41 9 2 29 29.68678418 547.2069088 588556.8859 77.13820995
42 9 2 51 22.05600912 779.5914077 433365.0605 49.33085569
43 9 2 98 18.33805647 996.5273412 459672.9202 43.34291837
44 10 2 2 49.92400886 853.9556647 324428.4407 93.70947834
45 10 2 8 46.77361439 1137.978891 356115.3594 93.33523226
46 10 2 29 41.76708544 1338.703927 302387.6231 65.30158967
47 10 2 51 48.84654147 932.6099835 344337.7039 62.89074863
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48 10 2 98 41.07123801 1293.54629 333557.0259 57.45982874
49 11 2 2 39.53420277 1140.504292 307094.3966
50 11 2 8 38.07917522 1213.068724 332007.4716
51 13 2 2 33.5573848 1055.388758 327783.165 80.7849334
52 13 2 8 30.72040587 1254.557949 339645.6103 67.86909186
53 13 2 29 29.95554205 1229.502914 338112.0166 67.7472443
54 13 2 51 30.52716002 1204.186531 403008.8158 65.24066589
55 13 2 98 27.15266533 1478.579977 400421.6488 58.94810967
56 14 2 2 57.09196823 1161.750846 257795.559 87.26026097
57 14 2 8 55.27561967 1225.739413 282794.6129 88.52225357
58 14 2 29 53.00619891 1320.464845 269595.8769 82.83893516
59 14 2 51 49.4587573 1541.95556 286752.8728 73.27390157
60 14 2 98 49.89071861 1447.94906 297926.6473 73.70907143
61 15 2 2 66.46276787 1241.89777 281731.4135 124.0756314
62 15 2 8 70.88468753 1101.914434 350269.1201 125.6596497
63 15 2 29 62.44114317 1279.102169 321297.2344 101.107366
64 15 2 51 59.68048822 1385.244075 314925.7126 94.21427538
65 15 2 98 57.88768642 1409.830771 306761.2787 87.86079538
66 25 2 2 24.58200839 1241.273658 323114.2292 48.70421109
67 25 2 8 26.67767028 1091.256361 380429.9504 46.20633607
68 25 2 29 23.54432692 1325.256544 356743.8621 41.85463744
69 25 2 51 22.45873996 1459.392589 336672.244 37.01554856
70 25 2 98 24.05910787 1301.038811 427304.5996 37.51164221
71 ;
72 ods g raph i c s on ;
73 ods pdf f i l e =”NanoGuide . pdf ” ;
74
75 t i t l e ’ NanoGuide − g e l volume data from mice ’ ;
76 proc p r in t ;
77 run ;
78
79 /∗ The f o l l o w i n g l i n e s p l o t the data ∗/ ;
80 t i t l e ’ Gel volume from a l l mice ’ ;
81 f i l ename outgraph ’ VolData . png ’ ;
82 gopt ions r e s e t=a l l dev i c e=png GSFNAME=outgraph ;
83 symbol1 i n t e r p o l=j o i n width=2 value=t r i a n g l e h=2 c=
CXFF0000 ;
84 symbol2 i n t e r p o l=j o i n width=2 value=c i r c l e h=2 c=CXFF2A00
;
85 symbol3 i n t e r p o l=j o i n width=2 value=square h=2 c=CXFF5400
;
86 symbol4 i n t e r p o l=j o i n width=2 value=diamond h=2 c=
CXFF7E00 ;
87 symbol5 i n t e r p o l=j o i n width=2 value=x h=2 c=CXFFA800 ;
88 symbol6 i n t e r p o l=j o i n width=2 value=hexagon h=2 c=
CXFFD200 ;
89 symbol8 i n t e r p o l=j o i n width=2 value=s t a r h=2 c=CXFFFF00 ;
90
91 symbol9 i n t e r p o l=j o i n width=2 value=t r i a n g l e h=2 c=
CX0000FF ;
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92 symbol10 i n t e r p o l=j o i n width=2 value=c i r c l e h=2 c=
CX002AD2 ;
93 symbol11 i n t e r p o l=j o i n width=2 value=square h=2 c=
CX0054A8 ;
94 symbol13 i n t e r p o l=j o i n width=2 value=diamond h=2 c=
CX007E7E ;
95 symbol14 i n t e r p o l=j o i n width=2 value=x h=2 c=CX00A854 ;
96 symbol15 i n t e r p o l=j o i n width=2 value=hexagon h=2 c=
CX00D22A ;
97 symbol25 i n t e r p o l=j o i n width=2 value=s t a r h=2 c=CX00FF00 ;
98 Proc gp lo t data = Nano2 ;
99 Plot vo l ∗ time = mouse /name=”VolData ” ;
100 Run ;
101
102 /∗−−−−−−−−−−GLM−−−−−−−−−−∗/ ;
103
104 /∗ I n d i v i d u a l GLM model ∗/ ;
105 t i t l e ’GLM − I n d i v i d u a l s l ope and i n t e r c e p t ’ ;
106 proc glm data=Nano2 p l o t s=a l l ;
107 c l a s s mouse ;
108 model vo l = mouse time ( mouse ) / s o l u t i o n no int ;
109 run ;
110
111 /∗ Group s l ope i n d i v i d u a l i n t e r c e p t GLM model ∗/ ;
112 t i t l e ’GLM − Group s l ope and i n d i v i d u a l i n t e r c e p t ’ ;
113 proc glm data=Nano2 p l o t s=a l l ;
114 c l a s s group mouse ;
115 model vo l = mouse time ( group ) / s o l u t i o n no int ;
116 run ;
117
118 /∗ One s l ope i n d i v i d u a l i n t e r c e p t GLM model ∗/ ;
119 t i t l e ’GLM − Common s l ope and i n d i v i d u a l i n t e r c e p t ’ ;
120 proc glm data=Nano2 p l o t s=a l l ;
121 c l a s s group mouse ;
122 model vo l = mouse time / s o l u t i o n no int ;
123 output out=resGLM r=r e s i d ;
124 run ;
125
126 /∗ I n d i v i d u a l i n t e r c e p t GLM model ∗/ ;
127 t i t l e ’GLM − i n d i v i d u a l i n t e r c e p t ’ ;
128 proc glm data=Nano2 p l o t s=a l l ;
129 c l a s s mouse ;
130 model vo l = mouse / s o l u t i o n no int ;
131 run ;
132
133 /∗ Group s l ope and i n t e r c e p t ∗/ ;
134 t i t l e ’GLM − Group s l ope and i n t e r c e p t ’ ;
135 proc glm data=Nano2 p l o t s=a l l ;
136 c l a s s group ;
137 model vo l = group time ( group ) / s o l u t i o n no int ;
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138 run ;
139
140 /∗ Group i n t e r c e p t ∗/ ;
141 t i t l e ’ Group i n t e r c e p t ’ ;
142 proc glm data=Nano2 p l o t s=a l l ;
143 c l a s s group ;
144 model vo l = group / s o l u t i o n no int ;
145 run ;
146
147 /∗−−−−−−−−−−RMM−−−−−−−−−−∗/ ;
148
149 /∗ I n d i v i d u a l RMM model∗/ ;
150 t i t l e ’RMM − I n d i v i d u a l s l ope and i n t e r c e p t ’ ;
151 proc mixed data=Nano2 method=ml c o v t e s t p l o t s=
RESIDUALPANEL;
152 c l a s s mouse ;
153 model vo l = mouse time ( mouse ) / s outp=pred no int ;
154 repeated / type=SP(POW) ( time ) s u b j e c t=mouse r c o r r ;
155 run ;
156
157 /∗Group s l ope i n d i v i d u a l i n t e r c e p t ∗/ ;
158 t i t l e ’RMM − Group s l ope and i n d i v i d u a l i n t e r c e p t ’ ;
159 proc mixed data=Nano2 method=ml c o v t e s t p l o t s=
RESIDUALPANEL;
160 c l a s s group mouse ;
161 model vo l = mouse time ( group ) / s outp=pred no int ;
162 repeated / type=SP(POW) ( time ) s u b j e c t=mouse r c o r r ;
163 run ;
164
165 /∗One s l ope i n d i v i d u a l i n t e r c e p t ∗/ ;
166 t i t l e ’RMM − Common s l ope and i n d i v i d u a l i n t e r c e p t ’ ;
167 proc mixed data=Nano2 method=ml c o v t e s t p l o t s=
RESIDUALPANEL c l ;
168 c l a s s group mouse ;
169 model vo l = mouse time / s outp=resRMM noint i n f l u e n c e
alpha =0.05 alphap =0.05;
170 repeated / type=SP(POW) ( time ) s u b j e c t=mouse r c o r r ;
171 run ;
172
173 /∗ I n d i v i d u a l i n t e r c e p t ∗/ ;
174 t i t l e ’RMM − I n d i v i d u a l i n t e r c e p t ’ ;
175 proc mixed data=Nano2 method=ml c o v t e s t p l o t s=
RESIDUALPANEL;
176 c l a s s mouse ;
177 model vo l = mouse / s outp=pred no int ;
178 repeated / type=SP(POW) ( time ) s u b j e c t=mouse r c o r r ;
179 run ;
180
181 /∗Group s l ope and i n t e r c e p t ∗/ ;
182 t i t l e ’RMM − Group s l ope and i n t e r c e p t ’ ;
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183 proc mixed data=Nano2 method=ml c o v t e s t p l o t s=
RESIDUALPANEL;
184 c l a s s group ;
185 model vo l = group time ( group ) / s outp=pred no int ;
186 repeated / type=SP(POW) ( time ) s u b j e c t=mouse r c o r r ;
187 run ;
188
189 /∗ Group i n t e r c e p t ∗/ ;
190 t i t l e ’RMM − Group i n t e r c e p t ’ ;
191 proc mixed data=Nano2 method=ml c o v t e s t p l o t s=
RESIDUALPANEL;
192 c l a s s group ;
193 model vo l = group / s outp=pred no int ;
194 repeated / type=SP(POW) ( time ) s u b j e c t=mouse r c o r r ;
195 run ;
196
197 f i l ename outgraph ’ ResData . png ’ ;
198 gopt ions r e s e t=a l l dev i c e=png GSFNAME=outgraph ;
199 symbol1 i n t e r p o l=j o i n width=2 value=t r i a n g l e h=2 c=
CXFF0000 ;
200 symbol2 i n t e r p o l=j o i n width=2 value=c i r c l e h=2 c=CXFF2A00
;
201 symbol3 i n t e r p o l=j o i n width=2 value=square h=2 c=CXFF5400
;
202 symbol4 i n t e r p o l=j o i n width=2 value=diamond h=2 c=
CXFF7E00 ;
203 symbol5 i n t e r p o l=j o i n width=2 value=x h=2 c=CXFFA800 ;
204 symbol6 i n t e r p o l=j o i n width=2 value=hexagon h=2 c=
CXFFD200 ;
205 symbol8 i n t e r p o l=j o i n width=2 value=s t a r h=2 c=CXFFFF00 ;
206
207 symbol9 i n t e r p o l=j o i n width=2 value=t r i a n g l e h=2 c=
CX0000FF ;
208 symbol10 i n t e r p o l=j o i n width=2 value=c i r c l e h=2 c=
CX002AD2 ;
209 symbol11 i n t e r p o l=j o i n width=2 value=square h=2 c=
CX0054A8 ;
210 symbol13 i n t e r p o l=j o i n width=2 value=diamond h=2 c=
CX007E7E ;
211 symbol14 i n t e r p o l=j o i n width=2 value=x h=2 c=CX00A854 ;
212 symbol15 i n t e r p o l=j o i n width=2 value=hexagon h=2 c=
CX00D22A ;
213 symbol25 i n t e r p o l=j o i n width=2 value=s t a r h=2 c=CX00FF00 ;
214
215 T i t l e ’ Res idua l from repeated measurements model ’ ;
216 proc gp lo t data = resRMM;
217 p lo t r e s i d ∗ time = mouse ;
218 run ;
219
220 /∗
20
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221 gopt ions r e s e t=a l l ;
222 symbol1 i n t e r p o l=j o i n width=4 value=t r i a n g l e h=2 c=
CXFF0000 ;
223 symbol2 i n t e r p o l=j o i n width=4 value=c i r c l e h=2 c=CXFF2A00
;
224 symbol3 i n t e r p o l=j o i n width=4 value=square h=2 c=CXFF5400
;
225 symbol4 i n t e r p o l=j o i n width=4 value=diamond h=2 c=
CXFF7E00 ;
226 symbol5 i n t e r p o l=j o i n width=4 value=x h=2 c=CXFFA800 ;
227 symbol6 i n t e r p o l=j o i n width=4 value=hexagon h=2 c=
CXFFD200 ;
228 symbol8 i n t e r p o l=j o i n width=4 value=s t a r h=2 c=CXFFFF00 ;
229
230 symbol9 i n t e r p o l=j o i n width=4 value=t r i a n g l e h=2 c=
CX0000FF ;
231 symbol10 i n t e r p o l=j o i n width=4 value=c i r c l e h=2 c=
CX002AFF;
232 symbol11 i n t e r p o l=j o i n width=4 value=square h=2 c=
CX0054FF ;
233 symbol13 i n t e r p o l=j o i n width=4 value=diamond h=2 c=
CX007EFF ;
234 symbol14 i n t e r p o l=j o i n width=4 value=x h=2 c=CX00A8FF;
235 symbol15 i n t e r p o l=j o i n width=4 value=hexagon h=2 c=
CX00D2FF;
236 symbol25 i n t e r p o l=j o i n width=4 value=s t a r h=2 c=CX00FFFF;
237
238 T i t l e ’ P l o t t i ng with f i t t e d r e g r e s s i o n l i n e s ’ ;
239 proc gp lo t data = resRMM;
240 p lo t r e s i d ∗ time = mouse ;
241 run ;
242 ∗/ ;
243
244 ods pdf c l o s e ;
245 ods g raph i c s o f f ;
C SAS output for chosen RMM model
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RMM - Common slope and individual intercept
18:01 Sunday, November 10, 2013 35
The Mixed Procedure
Model Information
Data Set WORK.NANO2
Dependent Variable vol
Covariance Structure Spatial Power
Subject Effect mouse
Estimation Method ML
Residual Variance Method Profile
Fixed Effects SE Method Model-Based
Degrees of Freedom Method Between-Within
Class Level Information
Class Levels Values
group 2 1 2
mouse 14 1 2 3 4 5 6 8 9 10 11 13 14 15 25
Dimensions
Covariance Parameters 2
Columns in X 15
Columns in Z 0
Subjects 14
Max Obs Per Subject 5
Number of Observations
Number of Observations Read 65
Number of Observations Used 65
Number of Observations Not Used 0
Iteration History
Iteration Evaluations -2 Log Like Criterion
0 1 319.87143872
1 2 317.06209400 0.00068515
2 1 316.98605809 0.00003302
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18:01 Sunday, November 10, 2013 36
The Mixed Procedure
Iteration History
Iteration Evaluations -2 Log Like Criterion
3 1 316.98267987 0.00000010
4 1 316.98266951 0.00000000
Convergence criteria met.
Estimated R Correlation Matrix for mouse 1
Row Col1 Col2 Col3 Col4 Col5
1 1.0000 0.4116 0.01840 0.000710 6.774E-7
2 0.4116 1.0000 0.04472 0.001725 1.646E-6
3 0.01840 0.04472 1.0000 0.03857 0.000037
4 0.000710 0.001725 0.03857 1.0000 0.000954
5 6.774E-7 1.646E-6 0.000037 0.000954 1.0000
Covariance Parameter Estimates
Cov Parm Subject Estimate
Standard
Error
Z
Value Pr Z Alpha Lower Upper
SP(POW) mouse 0.8625 0.06262 13.77 <.0001 0.05 0.7397 0.9852
Residual 7.9545 1.4228 5.59 <.0001 0.05 5.7649 11.6868
Fit Statistics
-2 Log Likelihood 317.0
AIC (smaller is better) 351.0
AICC (smaller is better) 364.0
BIC (smaller is better) 361.8
Null Model Likelihood Ratio
Test
DF Chi-Square Pr > ChiSq
1 2.89 0.0892
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RMM - Common slope and individual intercept
18:01 Sunday, November 10, 2013 37
The Mixed Procedure
Solution for Fixed Effects
Effect mouse Estimate
Standard
Error DF t Value Pr > |t| Alpha Lower Upper
mouse 1 34.4845 1.4417 0 23.92 . 0.05 . .
mouse 2 63.5541 1.4417 0 44.08 . 0.05 . .
mouse 3 59.1857 1.4417 0 41.05 . 0.05 . .
mouse 4 44.3160 1.5271 0 29.02 . 0.05 . .
mouse 5 39.0192 1.4417 0 27.06 . 0.05 . .
mouse 6 51.8735 1.4417 0 35.98 . 0.05 . .
mouse 8 46.4017 1.4417 0 32.18 . 0.05 . .
mouse 9 31.5838 1.4417 0 21.91 . 0.05 . .
mouse 10 49.2355 1.4417 0 34.15 . 0.05 . .
mouse 11 39.7177 2.8205 0 14.08 . 0.05 . .
mouse 13 34.0362 1.4417 0 23.61 . 0.05 . .
mouse 14 56.3982 1.4417 0 39.12 . 0.05 . .
mouse 15 66.6286 1.4417 0 46.21 . 0.05 . .
mouse 25 27.9729 1.4417 0 19.40 . 0.05 . .
time -0.09176 0.01079 50 -8.51 <.0001 0.05 -0.1134 -0.07009
Type 3 Tests of Fixed Effects
Effect
Num
DF
Den
DF F Value Pr > F
mouse 14 0 519.95 .
time 1 50 72.34 <.0001
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The Mixed Procedure
Influence Diagnostics
Deleted
Obs.
Index
Observed
Value
Predicted
Value Residual Leverage
PRESS
Residual
Internally
Studentized
Residual
RMSE
without
deleted
obs
Externally
Studentized
Residual
Cook's
D DFFITS
1 35.4257 34.301 1.1248 0.185 1.6717 0.4633 2.81651 0.4639 0.00969 0.38168
2 30.096 33.750 -3.6543 0.167 -4.4034 -1.4985 2.78103 -1.5197 0.01865 -0.53624
3 30.7415 31.823 -1.0818 0.219 -1.3202 -0.4393 2.83970 -0.4363 0.00200 -0.17223
4 28.5923 29.804 -1.2122 0.227 -1.5535 -0.4918 2.83746 -0.4888 0.00413 -0.24753
5 29.2922 25.492 3.8006 0.280 5.2788 1.5884 2.78661 1.6076 0.06534 1.00203
6 68.3343 63.371 4.9638 0.185 5.6918 2.0444 2.79643 2.0619 0.01717 0.51168
7 66.3791 62.820 3.5592 0.167 3.8480 1.4594 2.83330 1.4528 0.00277 0.20291
8 59.5002 60.893 -1.3927 0.219 -1.7969 -0.5655 2.83477 -0.5627 0.00576 -0.29254
9 56.9742 58.874 -1.8999 0.227 -2.4357 -0.7707 2.83033 -0.7680 0.01019 -0.38964
10 51.7818 54.561 -2.7794 0.280 -3.8594 -1.1616 2.81272 -1.1648 0.03488 -0.72530
11 62.7148 59.002 3.7126 0.185 4.2916 1.5291 2.81338 1.5329 0.01086 0.40449
12 60.7109 58.452 2.2593 0.167 2.4077 0.9264 2.83994 0.9200 0.00073 0.10403
13 54.5424 56.525 -1.9821 0.219 -2.5296 -0.8049 2.82846 -0.8026 0.01057 -0.39709
14 52.4118 54.506 -2.0939 0.227 -2.6802 -0.8494 2.82796 -0.8472 0.01220 -0.42670
15 49.8964 50.193 -0.2964 0.280 -0.4109 -0.1239 2.84199 -0.1229 0.00039 -0.07609
16 42.0277 43.582 -1.5542 0.271 -2.0363 -0.6508 2.83589 -0.6473 0.00688 -0.31953
17 36.2904 41.655 -5.3644 0.244 -7.1019 -2.2192 2.73176 -2.2912 0.09533 -1.23462
18 45.5662 39.636 5.9302 0.251 7.9583 2.4455 2.70231 2.5523 0.13222 1.46979
19 36.0428 35.323 0.7196 0.298 1.0226 0.3046 2.84033 0.3025 0.00258 0.19532
20 40.524 38.836 1.6883 0.185 1.8244 0.6953 2.84073 0.6904 0.00060 0.09418
21 40.7976 38.285 2.5125 0.167 2.8575 1.0302 2.82943 1.0269 0.00396 0.24274
22 34.7843 36.358 -1.5738 0.219 -2.0079 -0.6391 2.83361 -0.6361 0.00665 -0.31424
23 31.7808 34.339 -2.5584 0.227 -3.2847 -1.0379 2.82025 -1.0379 0.01873 -0.53001
24 31.0679 30.026 1.0416 0.280 1.4475 0.4353 2.83816 0.4326 0.00493 0.27017
25 57.4094 51.690 5.7195 0.185 6.9615 2.3556 2.70659 2.4547 0.04998 0.90187
26 50.533 51.139 -0.6064 0.167 -1.1275 -0.2486 2.81283 -0.2493 0.00902 -0.36882
27 45.9641 49.212 -3.2482 0.219 -4.1082 -1.3190 2.80799 -1.3249 0.02608 -0.62827
28 45.2228 47.194 -1.9707 0.227 -2.5075 -0.7995 2.83029 -0.7967 0.01023 -0.39030
29 44.1177 42.881 1.2371 0.280 1.7189 0.5170 2.83646 0.5141 0.00694 0.32082
30 44.2484 46.218 -1.9698 0.185 -2.1392 -0.8113 2.83986 -0.8057 0.00093 -0.11726
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Influence Diagnostics
Deleted
Obs.
Index COVRATIO
Likelihood
Distance
1 1.0784 0.1461
2 0.7223 0.3136
3 1.5350 0.0357
4 1.5335 0.0660
5 0.9675 1.0231
6 0.8701 0.2716
7 1.2627 0.0439
8 1.4571 0.0889
9 1.4220 0.1534
10 1.2798 0.5270
11 1.0431 0.1646
12 1.3546 0.0170
13 1.3628 0.1587
14 1.3866 0.1830
15 1.7459 0.0133
16 1.5928 0.1060
17 0.4945 1.6596
18 0.3653 2.4050
19 1.7594 0.0446
20 1.3943 0.0156
21 1.2120 0.0603
22 1.4394 0.1016
23 1.2776 0.2809
24 1.6767 0.0781
25 0.3267 1.0407
26 1.0159 0.1370
27 1.0960 0.3972
28 1.4213 0.1539
29 1.6468 0.1071
30 1.3815 0.0199
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The Mixed Procedure
Influence Diagnostics
Deleted
Obs.
Index
Observed
Value
Predicted
Value Residual Leverage
PRESS
Residual
Internally
Studentized
Residual
RMSE
without
deleted
obs
Externally
Studentized
Residual
Cook's
D DFFITS
31 42.86 45.668 -2.8076 0.167 -3.1970 -1.1513 2.82589 -1.1490 0.00504 -0.27430
32 46.9823 43.741 3.2417 0.219 4.1495 1.3164 2.80404 1.3241 0.02906 0.66408
33 42.9485 41.722 1.2267 0.227 1.5472 0.4977 2.83804 0.4946 0.00365 0.23240
34 36.5097 37.409 -0.8992 0.280 -1.2492 -0.3758 2.83923 -0.3733 0.00366 -0.23290
35 37.3119 31.400 5.9116 0.185 6.6244 2.4348 2.79835 2.4539 0.01646 0.50059
36 36.8905 30.850 6.0408 0.167 6.6993 2.4770 2.79507 2.4994 0.01441 0.46904
37 29.6868 28.923 0.7641 0.219 0.9503 0.3103 2.84072 0.3081 0.00122 0.13446
38 22.056 26.904 -4.8478 0.227 -6.2643 -1.9666 2.75742 -2.0115 0.07123 -1.05722
39 18.3381 22.591 -4.2529 0.280 -5.9047 -1.7774 2.77259 -1.8080 0.08159 -1.12537
40 49.924 49.052 0.8720 0.185 1.2014 0.3591 2.83299 0.3575 0.00352 0.22852
41 46.7736 48.501 -1.7278 0.167 -2.0783 -0.7085 2.82901 -0.7063 0.00408 -0.24667
42 41.7671 46.574 -4.8073 0.219 -6.1458 -1.9522 2.75842 -1.9960 0.06319 -0.99541
43 48.8465 44.556 4.2910 0.227 5.5919 1.7407 2.77088 1.7718 0.06008 0.96624
44 41.0712 40.243 0.8286 0.280 1.1492 0.3463 2.83973 0.3439 0.00307 0.21325
45 39.5342 39.534 0.0000 1.000 . . . . . .
46 33.5574 33.853 -0.2953 0.185 -0.1356 -0.1216 2.84013 -0.1208 0.00083 0.11047
47 30.7204 33.302 -2.5817 0.167 -3.0241 -1.0586 2.82109 -1.0583 0.00651 -0.31222
48 29.9555 31.375 -1.4195 0.219 -1.7884 -0.5764 2.83603 -0.5732 0.00480 -0.26685
49 30.5272 29.356 1.1709 0.227 1.5266 0.4750 2.83704 0.4722 0.00449 0.25802
50 27.1527 25.043 2.1093 0.280 2.9291 0.8816 2.82531 0.8800 0.02009 0.54806
51 57.092 56.215 0.8773 0.185 1.0931 0.3613 2.83832 0.3590 0.00151 0.14943
52 55.2756 55.664 -0.3885 0.167 -0.5211 -0.1593 2.84042 -0.1582 0.00058 -0.09297
53 53.0062 53.737 -0.7309 0.219 -0.9022 -0.2968 2.84097 -0.2946 0.00104 -0.12370
54 49.4588 51.718 -2.2595 0.227 -2.9088 -0.9166 2.82470 -0.9152 0.01496 -0.47304
55 49.8907 47.405 2.4854 0.280 3.4526 1.0387 2.81861 1.0394 0.02798 0.64819
56 66.4628 66.445 0.0177 0.185 -0.4059 0.0073 2.82686 0.0073 0.00582 -0.29454
57 70.8847 65.894 4.9902 0.167 5.9164 2.0462 2.74808 2.1001 0.02850 0.67092
58 62.4411 63.967 -1.5263 0.219 -1.9806 -0.6198 2.83278 -0.6171 0.00728 -0.32904
59 59.6805 61.949 -2.2681 0.227 -2.9103 -0.9201 2.82508 -0.9186 0.01464 -0.46786
60 57.8877 57.636 0.2520 0.280 0.3508 0.1053 2.84208 0.1045 0.00029 0.06568
131
RMM - Common slope and individual intercept
18:01 Sunday, November 10, 2013 42
The Mixed Procedure
Influence Diagnostics
Deleted
Obs.
Index COVRATIO
Likelihood
Distance
31 1.1674 0.0758
32 1.0507 0.4454
33 1.5429 0.0591
34 1.6957 0.0600
35 0.8882 0.2588
36 0.8401 0.2307
37 1.5517 0.0248
38 0.6499 1.1850
39 0.8316 1.3049
40 1.2847 0.0548
41 1.2067 0.0621
42 0.6423 1.0559
43 0.7522 0.9749
44 1.7047 0.0515
45 . .
46 1.3855 0.0185
47 1.1093 0.0975
48 1.4767 0.0752
49 1.5267 0.0711
50 1.4633 0.3008
51 1.3592 0.0276
52 1.3615 0.0151
53 1.5557 0.0221
54 1.3395 0.2241
55 1.3627 0.4202
56 1.2040 0.0875
57 0.5052 0.5395
58 1.4267 0.1108
59 1.3449 0.2193
60 1.7475 0.0119
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The Mixed Procedure
Influence Diagnostics
Deleted
Obs.
Index
Observed
Value
Predicted
Value Residual Leverage
PRESS
Residual
Internally
Studentized
Residual
RMSE
without
deleted
obs
Externally
Studentized
Residual
Cook's
D DFFITS
61 24.582 27.789 -3.2074 0.185 -3.8267 -1.3210 2.80919 -1.3263 0.01243 -0.43329
62 26.6777 27.239 -0.5611 0.167 -0.4100 -0.2301 2.83985 -0.2285 0.00076 0.10594
63 23.5443 25.312 -1.7674 0.219 -2.2350 -0.7177 2.83221 -0.7147 0.00771 -0.33870
64 22.4587 23.293 -0.8342 0.227 -1.0583 -0.3384 2.84023 -0.3360 0.00178 -0.16236
65 24.0591 18.980 5.0791 0.280 7.0543 2.1227 2.74207 2.1833 0.11667 1.36066
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The Mixed Procedure
Influence Diagnostics
Deleted
Obs.
Index COVRATIO
Likelihood
Distance
61 0.9974 0.1900
62 1.3534 0.0174
63 1.4182 0.1170
64 1.5790 0.0327
65 0.5966 1.9564
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Abstract: Development of safe and efficient radiotherapy routines requires quantification of the 
delivered absorbed dose to the cancer tissue in individual patients. In vivo dosimetry can provide 
accurate information about the absorbed dose delivered during treatment. In the current study, a 
novel silver-nanogel formulation based on poly(vinylpyrrolidinone)-coated silver nanoparticles 
formulated in a gelation matrix composed of sucrose acetate isobutyrate has been developed for 
use as an in vivo dosimeter for external beam radiotherapy. In situ photonuclear reactions trigger 
the formation of radioactive 106Ag, which enables post treatment verification of delivered dose using 
positron emission tomography imaging. The silver-nanogel was investigated in a tissue equivalent 
thorax phantom using clinical settings and workflow for both standard fractionated radiotherapy (2 
Gy) and stereotactic radiotherapy (10- and 22 Gy). The developed silver-nanogel provided high 
radiopacity on the planning CT-scans sufficient for marker position use in modern radiotherapy and 
provided dosimetric information about the absorbed dose with a 10% and 8% standard deviation 
for the stereotactic regimens, 10 and 22 Gy, respectively.  
 
Keywords: Silver nanoparticles, in vivo dosimetry, external beam radiotherapy, positron emission 
tomography, sucrose acetate isobutyrate 
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The global burden of cancer continues to increase due to the increasing aging of the population 
and adoption of cancer-causing behaviors.1 Cancer treatment includes surgery, radiation, 
chemotherapy, hormone therapy and immune therapy. Among these, radiotherapy is a cost-
effective treatment modality and approximately 50% of all cancer patients receive radiotherapy 
either alone or in combination with other interventions.2,3,4,5 Safe and efficient radiotherapy requires 
verification of the delivered absorbed dose to each individual patient6,7,8 and is compulsory by law 
in many European countries9. Ideally, radiotherapy should be verified using a detector or a set of 
detectors that can be placed inside the patient, i.e. in vivo, and thus, provide relevant information of 
the absorbed dose delivered. Dosimetric readout should be feasible in a non-invasive manner and 
the dosimeter should be reusable, as radiotherapy is delivered in a series of smaller fractions over 
days to several weeks. Furthermore, placement of the detector itself should be as non-invasive as 
possible to ensure patient compliance. 
Traditionally, in vivo dosimetry was commonly employed by using either silicon based diodes or 
radiothermoluminescent chips placed externally on the patient.8 Silicon based diodes suffer from 
batch-to-batch variations,8 drift in sensitivity over clinical lifetime,10 temperature sensitivity11 and 
require an electrical connection during irradiation. Radiothermoluminescent chips are based upon 
the ability of imperfect crystals to absorb and store the energy of ionizing radiation, which upon 
heating is re-emitted in the form of electromagnetic radiation, mainly in the visible part of the 
spectrum. The light emitted is then detected by a photomultiplier tube and the signal correlated to 
the absorbed dose. Radiothermoluminescent dosimeters placed internally have to be removed 
from the patient before readout is possible which limits its use in anatomical positions not readily 
accessible.12 Following the clinical introduction of modern radiation delivery technology, such as 
intensity modulated volumetric arc therapy (VMAT),13,14 the use of in vivo dosimeters has fallen into 
disuse in radiotherapy clinics. For radiation treatment using VMAT, dose measurements performed 
at the patient’s skin surface cannot practically be used to estimate the radiation dose delivered to a 
deep-seated tumor or organ at risk. Further, intra cavitary placement of in vivo dosimeters is 
impractical for routine clinical use. This creates an urgent need for development of internal 
dosimeters, which can provide dosimetric information about the absorbed dose in a non-invasive 
manner.    
Radiotherapy exploits the use of high-energy photon beams to induce DNA damage to cancerous 
tissue hereby killing or controlling tumor growth. High-energy photon beams can also be exploited 
to remove neutrons from the nucleus of stable elements by photonuclear reactions.15,16 Neutron 
removal in certain elements results in the formation of radioactive isotopes, which can be detected 
using positron emission tomography (PET) imaging. In order to efficiently detect the radioactive 
decay using PET imaging, a positron-emitting radionuclide with sufficient half-life (T½) must be 
formed during the photonuclear reaction. Photonuclear reactions using high-energy photon beams 
on various elements, including Ag, Cr, Cu, Ni, Sn, Ti and Zn, have been evaluated by Hansen et. 
al.17 who concluded that only Ag, Cu and Zn, in which the positron-emitting radionuclides; 108Ag, 
106Ag, 64Cu 62Cu 65Zn and 63Zn are being formed, resulted in detectable PET signals. Among these, 
Ag displayed the highest activity (28 Bq/mm3) compared to Cu (17 Bq/mm3) and Zn (1.1 Bq/mm3), 
hence, less material was required for obtaining a detectable PET-signal.  
We recently described the concept of an injectable liquid fiducial marker for use in image-guided 
radiotherapy (IGRT) by exploiting the use of polymer-coated gold nanoparticles.18,19 In this present 
paper, we describe the proof-of-principle of a liquid injectable dosimetric silver nanogel marker, 
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which enables dual use as an IGRT fiducial marker as well as an internal in vivo dosimeter through 
readout of the radiation induced activation.20,21 The silver nanogel is based on 
poly(vinylpyrrolidinone) (PVP) coated silver nanoparticles (AgNPs) in a nonsolvent-induced phase 
separation (NIPS) gelation matrix based on sucrose acetate isobutyrate (SAIB), further referred to 
as Ag-nanogel. SAIB, a fully acylated derivative of sucrose, is a biodegradable nonpolymeric 
compound, which has been approved for oral consumption and is generally regarded as safe 
(GRAS) by the FDA. SAIB mixtures with ethanol (EtOH) behaves as Newtonian liquids and have a 
low viscosity (50–200 mPa∙s) suitable for injection with thin hypodermic needles.22,23,24 Upon 
hydration, a highly viscous (gel-like) liquid is formed, which efficiently encapsulate high 
concentrations of PVP-coated AgNPs.  
Results and Discussion 
External radiotherapy relies on the ability to deliver high radiation doses to tumor cells with minimal 
exposure to surrounding tissues. Verification of the delivered absorbed dose to each individual 
patient is a requisite for developing new and safe treatment regimens, especially with the 
increasing focus on stereotactic radiation procedures. Here, we report an injectable Ag-nanogel for 
use as an internal in vivo dosimeter that can be placed intratumorally and detect therapeutic levels 
of ionizing radiation using PET for direct dosimetric readout. The Ag-nanogel have been evaluated 
in a tissue equivalent thorax phantom using clinical settings for both standard fractionated 
radiotherapy (dose of 2 Gy) and stereotactic radiotherapy (doses of 10 - and 22 Gy), which is often 
the standard treatment for inoperable cancers, with 33, 5 or 3 treatment fractions, respectively. 
Based on in situ induced photonuclear reactions the Ag-nanogel enabled post treatment 
verification of delivered dose using PET-imaging.  
Ag-Nanogel Formulation and Performance. Ag-nanogel solutions were formulated as a 
homogenous dispersion composed of SAIB and EtOH (80:20) including PVP-coated AgNP (100 
mg/mL). SAIB has previously been reported as an efficient and biocompatible gelation matrix for 
encapsulation of hydrophobic colloids18,19 and the amount of EtOH was chosen to ensure that the 
Ag-nanogel formulation could be injected using thin hyperdermic needles (≤25G) to ease handling 
and possible patient compliance. PVP-coated AgNPs (50-80 nm, ζ-potential = 28.64±1.29 mV) 
were chosen as the apparent hydrophobicity of these colloids was found to be compatible with the 
hydrophobic SAIB based gelation matrix, a parameter previously identified as critical to prevent 
rapid burst release of colloids solution upon injection.18,19  
Upon hydration, a highly viscous dark colored Ag-nanogel was formed with no apparent AgNP 
release despite the high colloid concentration (100 mg/mL) of PVP-coated AgNPs (Figure 1A).  
In vitro release kinetics of encapsulated PVP-coated AgNPs from the formed Ag-nanogels was 
examined by placing small droplets of Ag-nanogels into MQ-H2O at physiological temperature. 
Small aliquots of MQ-H2O were removed over a period of 7 days and replaced with fresh MQ-H2O 
to mimic the sink effect in vivo. AgNPs potentially undergo dissolution in aqueous environment due 
to oxidation by dissolved oxygen,25,26 hence, in order to evaluate both the amount of PVP-coated 
AgNPs and possible Ag+-ions formed by AgNP-dissolution inductively coupled plasma mass 
spectrometry (ICP-MS) was used to quantify the total amount of Ag released from the Ag-nanogels 
in vitro (Figure 1D). No detectable release of Ag0/Ag+ was observed confirming the high colloidal 
stability of the PVP-coated AgNP within the hydrophobic SAIB-based gel matrix. The Ag-nanogel 
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stability is an important feature, as the total amount of Ag within the Ag-nanogel is a decisive factor 
for subsequent dosimetric readout based on PET. Loss of Ag over time would potentially cause a 
drift in Ag-nanogel sensitivity and accuracy. 
 
Figure 1. A) Ag-nanogel formulation based on SAIB, EtOH and PVP-coated AgNPs; B) 
Scanning electron microscope image of PVP-AgNP (re-printed with permission from US 
Research Nanomaterials Inc. Texas, USA); C) Dynamic light scattering analysis of the 
hydrodynamic diameter of PVP-coated AgNP and D) Total Ag (Ag+ and Ag0) release from 
Ag-nanogels in vitro as analyzed by ICP-MS. 
 
In Vitro Evaluation of Ag-Nanogel Biocompatibility. In order to evaluate the biocompatibility of 
the Ag-nanogel, cell viability of fibrosarcoma cells (HT 1080) in presence of Ag-nanogels were 
examined in vitro. Ag-nanogels and control gels based on SAIB:EtOH without PVP-coated AgNP 
were incubated with HT 1080 cells over a period of 24h to evaluate the Ag-nanogel influence on 
cell growth pattern and cell viability. Following incubation, cells were stained using the HCS 
Live/Dead Green Kit and fixed with 4% paraformaldehyde prior to visualization by confocal 
microscopy. EtOH treated cells were included as a positive control to monitor cell death (Figure 2). 
As evident from the in vitro biocompatibility assay no change in cell viability could be visualized 
when incubated in presence of control gel (SAIB) or Ag-nanogels. All visualized cells in close 
proximity to the Ag-nanogel and throughout the dish were alive and exhibited the expected cell 
morphology, hence, no acute toxicity indicating poor biocompatibility of the Ag-nanogel was 
observed. This observation is in good correlation with the undetectable release of Ag0/Ag+ when 
incubated at physiological temperature over a week.  
141
5 
 
The in vitro and in vivo biocompatibility of PVP-coated AgNP, with comparable physicochemical 
properties as the PVP-coated AgNPs used for Ag-nanogel preparation, has recently been 
thoroughly investigated by Ahlberg et al.27 in a multi-center study. Adverse effects following PVP-
coated AgNP exposure was predominately observed at high concentrations and in a cell-type 
specific manner. However, conflicting evidence in the literature regarding AgNP toxicity exist 
possibly due to tremendous variation in particle size, surface charge, coating methods, exposure 
route and exposure levels, hence, evaluation of biocompatibility must be evaluated on a case-by-
case basis before clinical translation is considered feasible.28,29,30,31 
 
 
Figure 2. In vitro cell viability of fibrosarcoma cells (HT1080) in presence of Ag-nanogels. A) 
HT1080 cells only (negative control), B) Ethanol treated HT1080 cells (positive control), C) 
Control gel composed of SAIB and D) Ag-nanogel containing 100mg/mL PVP coated AgNP. 
Cells were stained with the HCS LIVE/DEAD Green Kit. Red: all cells, green: dead cells, 
scale bar: 150 µm. 
 
Ag-Nanogel in External Beam Radiotherapy. Ag-nanogels with 10.0 w/w% PVP-coated AgNPs 
and control gels composed of the gelation matrix without PVP-coated AgNPs were casted into 
gelatin inside low-density polyethylene tubes. The phantom inserts were placed centrally in the 
mediastinum part of a tissue equivalent thoracic phantom (Figure 3A) after which the phantom was 
CT-scanned (Figure 3B) for subsequent radiotherapy treatment preparation and treatment planning 
in line with current clinical practice (Figure 3C). Ag-nanogels were easily detected on the planning 
CT-scan due to the high concentration of PVP-coated AgNPs within the Ag-nanogels. Ag has a 
high absorption coefficient of X-rays (e.g. at 100 keV; silver: 1.47 cm2/g; bone: 0.186 cm2/g and 
soft tissue: 0.169 cm2/g),32 which results in a high radio-opacity on the planning CT-scans. The 
obtained contrast level of approximately 1400-1600 HU (Table 1) is comparable to other liquid 
fiducial markers reported for use in image-guided radiotherapy (IGRT).19,33 Hence, the Ag-nanogel 
142
Injectable Silver Nanogels: In Vivo Dosimetry for External Beam
Radiotherapy using Positron Emission Tomography
6 
 
may in addition to its use as dosimeter, simultaneously be used in IGRT as a surrogate for tumor 
localization. In contrast, the control gel composed of SAIB was barely identified on the CT-scans 
due to low radiopacity of approximately 70 HU comparable to that of soft tissue.34 
 
Figure 3. A) CIRS IMRT throrax phantom consisting of three tissue equivalent materials 
(lung (pink), soft tissue (green) and bone (white) used for Ag-nanogel dosimetry evaluation; 
B) Planning CT-scan of throrax phantom with Ag-nanogel inserted into the mediastinal part 
and visible Ag-nanogel and C) Planning target volume contoured as the entire mediastinal 
part of the phantom exposed to a single fraction of either 2-, 10- or 22 Gy. 
 
Table 1. Measurements of contrast levels (HU) for each individual Ag-nanogel using 300 HU 
as lower threshold for automatic Ag-nanogel delineation. The CT-scans were acquired with 
12-bit depth and the maximum Hounsfield Units measureable is 3071 HU. 
Ag-nanogel # Mean contrast level (HU) STDDev Max contrast level (HU)  
1 1399 832 3071  
2 1526 982 3071  
3 1585 881 3071  
4 1391 886 3071  
Control 69 14 96  
6 1397 957 3071  
7 1397 952 3071  
8 1519 917 3063  
9 1409 793 3069  
Control 69 15 103  
 
Ag-Nanogel Dosimetric Readout using Positron Emission Tomography. During external beam 
radiotherapy with photon energies above 10 MV, a photonuclear reaction (n) may take place 
where, following the absorption of the photon, a neutron is emitted from the target nucleus. 
Naturally occurring Ag consists of two isotopes 107Ag (51.8%) and 109Ag (48.2%), and therefore the 
(n)-process may form the two radioactive Ag-isotopes; 106Ag (T½ = 23.96 min) and 
108Ag (T½ = 
2.37 min) (Figure 4). The activation cross-section of the two isotopes can be assumed identical35. 
The combined β+ decay from both 106Ag and 108Ag can be detected in a PET scanner, however, as 
108Ag has a half-life of 2.37 minutes and only 0.23% of the decay from 108Ag is β+ the contributing 
signal from 108Ag can be ignored17. After 14 minutes, the activity from the 108Ag is less than a 
hundredth of that from 106Ag. Additionally, as the number of formed 106mAg nuclei is negligible 
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compared to the total number of 107Ag nuclei present within the Ag-nanogel, depletion caused by 
multiple irradiation incidences can be ignored. 
Additional isotopes can be generated during radiotherapy namely 15O (T½ = 2.037 min) and 
11C (T½ 
= 20.33 min), however, the photonuclear cross sections for these processes are relatively small  (< 
20 MeV). The influence of 15O and 108Ag can be minimized by allowing time for them to decay. By 
only using the last 20 minutes of the PET scan, we thus allow 10 minutes plus the transport time 
from radiotherapy to scanner for it to decay. The possible generation of 11C is more problematic, as 
the half-life is comparable to 106Ag. However, as seen from Figure 5, the control gel is not activated 
to any measurable degree and it would, thus, seem that a negligible amount of 11C is produced.  
Irradiation of the Ag-nanogel within the human equivalent thorax phantom was conducted using an 
approximately constant dose rate (600 monitor units/min). The dose rate is only approximate as 
the dose rate can change in VMAT treatments, due to occlusion by the multi-leaf collimator system. 
The formation of 106Ag can therefor also be assumed approximately constant. The number of 
produced 106Ag nuclei at the end of irradiation; 𝑁(𝑡) can be calculated as17; 
𝑁(𝑡) =
𝐾𝐹
𝜆
(1 − 𝑒−𝜆𝑡) 
Where 𝐾𝐹 is the formation rate of 
106Ag, 𝜆 is the decay constant of 106Ag, and 𝑡 the time from 
irradiation start. As a fraction of the total number produced 𝑁𝑇 we then get: 
𝑁(𝑡)
𝑁𝑇
=
𝑁(𝑡)
𝐾𝐹𝑡
=
𝐾𝐹
𝐾𝐹𝜆𝑡
(1 − 𝑒−𝜆𝑡) =
1 − 𝑒−𝜆𝑡
𝜆𝑡
. 
This fraction can be used to correct the dose delivered during external beam radiotherapy to an 
irradiated dose based on the amount of 106Ag present at the end of irradiation. 
PET-imaging of the irradiated Ag-nanogels clearly identified the Ag-nanogels due to the β+-decay 
of predominately 106Ag, whereas, the control gel composed of SAIB was not rendered radioactive 
during external radiotherapy (Figure 5C). Co-localization of the PET/CT scans showed excellent 
agreement of the Ag-nanogels in both the axial and sagittal plane (Figure 5B).  
 
Figure 4. Nuclear transformation of naturally occurring silver; 107Ag (51.8%) and 109Ag 
(48.2%) following irradiation with a >10MV photon beam.17 
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Figure 5. Coronal- and right sagittal view of 3D reconstructions of CT (left), PET/CT (middle), 
and PET (right) images. The gel positions are labelled on the CT reconstruction. The 
underlying PET images were reconstructed with a 3D iterative method for better 
visualization. 
 
Statistical Analysis. With the experimental set-up, the measured activity is naturally influenced by 
the irradiation dose, however, potential effects caused by differences in Ag-nanogel position within 
the thorax phantom and variations due to inhomogeneity of the Ag-nanogel could also be present. 
Any differences caused by Ag-nanogel position within the thorax phantom would greatly limit the 
clinical potential of the Ag-nanogel as a dosimeter, as corrections would have to be applied on a 
patient-to-patient basis. Variations due to inhomogeneity of the Ag-nanogels could potentially be 
minimized by tightly controlled preparation methods.  
A statistical analysis (see Supporting Information) was conducted to evaluate the potential effect of 
Ag-nanogel position within the phantom and any variations due to inhomogeneity of the Ag-
nanogels. Initially, a general linear model was considered, where the measured activity was 
depending on the irradiated dose, the Ag-nanogel position within the phantom and the Ag-nanogel 
variations, including their pairwise interactions. Using this model, 99.32% of the total variation 
could be explained. However, as this model had multiple parameters, sub-models without 
interactions were proposed, based on; a) irradiated dose, Ag-nanogel position, Ag-nanogel 
variations and an intercept; b) irradiated dose and an intercept, and c) irradiated dose only (strict 
proportionality). These models were found to explain 99.16%, 98.25%, and 98.16% of the 
variability in the measured activities, i.e. only a modest loss in the ability to describe the dosimetric 
readout by going from the complicated to the very simple model. 
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In order to validate the simple model, the data set was divided into two, one containing the 9 
control measurements on the same control gel in the same position within the thorax phantom and 
the other comprising the remaining 36 measurements recorded with varying irradiation dose, 
different Ag-nanogels and changing positions within the thorax phantom. As the control gel has no 
variability from either position or differences in gel composition, it represents an estimate of the 
experimental error. By comparing the estimates of the standard error for these two groups by using 
the F-test,36 acceptance of the hypotheses that the “honest” error estimate based on repeated 
measurements of the control gel, is equal to the error estimate based on deviations from the 
proportional model (p-value=0.6458) was obtained. Therefore, it was concluded that the simple 
model just taking the irradiated dose (strict proportionality) into account was an adequate and valid 
description of the relationship between the measured activity (kBq/mL) and the irradiated dose 
(Gy); 
𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = 0.0113 ∙ 𝑖𝑟𝑟𝑎𝑑𝑖𝑎𝑡𝑒𝑑 𝑑𝑜𝑠𝑒 + 𝑒𝑟𝑟𝑜𝑟 𝑡𝑒𝑟𝑚, ?̂?𝑒𝑟𝑟𝑜𝑟 = 0.01240. 
This linear relationship between the measured activity and the irradiated dose is illustrated in 
Figure 6, including the 45 measurements conducted for the Ag-nanogels and the control gel. When 
calculating the real dose delivered to the gels from the activation using the simple proportionality 
model and the irradiation time, standard deviations of 0.6233 Gy (31.1 %), 1.0033 (10.0 %) and 
1.7217 (7.8 %) for the 2, 10 and 22 Gy fractions regimes, respectively, are obtained. For the 2 Gy 
level the standard deviation is clearly too high for practical use, while it is within the acceptable 
range of ≤10% for 10 and 22 Gy fractions.  
A possible way to reduce the standard deviation would be to increase the amount of Ag within the 
irradiated area either by increasing the concentration of PVP-coated AgNP within the Ag-nanogels 
or by increasing the volume of the Ag-nanogel. The latter could be problematic for smaller tumors 
with limited size. Using AgNPs composed of only 107Ag would also reduce the observed standard 
deviation as only this isotope contributes to the signal; however, the practicality of this approach is 
limited.  
Current commercial in vivo dosimetric systems are divided into two types; external- (skin) and 
internal (intra cavitary) dosimeters. The external in vivo dosimeters have been shown to have a 
standard deviation of up to 3%,37 however their use in especially IMRT and VMAT is rather limited, 
as they require a fixed gantry position and never fully estimates the tumor dose. Intra cavitary 
dosimeters commonly have a standard deviation of 3.5-5%12,37,38,39, similar to a novel colorimetric 
plasmonic nanosensor based on gold nanoparticles described by Pushpavanam et al.40 for 
dosimetric use in endorectal balloons. Intra cavitary dosimeters in general do not provide 
information about the intra tumoral dose, as readout is only given for the cavity in which the 
dosimeter is placed (e.g. rectum or nasal cavity).  
Compared to the commercial intra cavitary dosimeters the observed standard deviation for the 
developed Ag-nanogel is slightly higher, however, it has the possibility to be placed intratumorally, 
thereby providing valuable information about the actual delivered dose to the tumor. Additionally, 
the Ag-nanogel may simultaneously be used in IGRT as a tumor surrogate for motion 
management, and can furthermore be repeatedly used with no additional patient discomfort or 
added treatment time despite the PET/CT-scan required for non-invasive dosimetric readout. 
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Figure 6. Correlation between irradiated dose (Gy) delivered during external radiotherapy 
and average measured activity (kBq/mL) recorded post-irradiation using PET-imaging.  
 
Conclusion 
A novel Ag-nanogel based on PVP-coated AgNPs formulated in a mixture of SAIB/EtOH has been 
developed for use as in vivo dosimeter for external beam radiotherapy. Irradiation of the Ag-
nanogel with high-energy photon beams used clinically during treatment of cancer patients 
triggered the formation of 106Ag and the subsequent β+-decay could non-invasively be recorded 
using PET-imaging. Using a simple proportionality model, the relationship between the measured 
activity and the irradiated dose could be described. A high standard deviation (30.6%) was found in 
Ag-nanogels irradiated in the normal fractionated region (2 Gy) due to low activation of the Ag-
nanogel. The low degree of 106Ag formation translates into relatively higher uncertainty, which limits 
it’s use in such treatment regimens.  Irradiation of the Ag-nanogel in the stereotactic radiotherapy 
(10- and 22 Gy) region efficiently activated the Ag-nanogel, thereby reducing the observed 
standard deviation in the dosimetric readout to 10.0% and 7.8%, respectively.  
In conclusion, proof-of-principle applying Ag-nanogels as in vivo dosimeters for external beam 
radiotherapy has been established. The developed Ag-nanogel non-invasively provided dosimetric 
information about the exposed dose and simultaneously provided high radio-opacity (1400-1600 
HU) on the planning CT-scans sufficient for use in image-guided radiotherapy. The Ag-nanogel 
may provide radiation oncologist with a new tool for improving planning, precision and verification 
of the delivered absorbed dose and thereby provide a more precise, efficient and safer delivery of 
radiation to tumors.  
 
Materials and Methods 
General. PVP-coated AgNP (Ag, 99.99 %, 50-80 nm, 0.2 % w/w% PVP) was purchased from US 
Research Nanomaterials Inc. (Houston, TX, USA). All other chemicals were purchased from 
Sigma–Aldrich (Schnelldorf, Germany) and used as received from the manufacturer. 
AgNP Characterization. The hydrodynamic diameter of the PVP-coated AgNPs (100 μg/mL) was 
analyzed using a Zeta PALS Analyzer (Brookhaven Instruments, NY, USA). Data was fitted using 
built-in software to calculate the hydrodynamic size of the AuNP-colloids. The ζ-potential was 
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measured in the same sample as the DLS analysis using a Zeta PALS Analyzer (Brookhaven 
Instruments, NY, USA) with a pre-conditioned electrode with 10 sub-runs while observing a fitting 
model residual less than 0.04. 
Ag-Nanogel Formulation. SAIB (12.44 g, 90 w/w% in EtOH) and anhydrous EtOH (1.56 g, 
1.98mL) were thoroughly mixed and added to PVP-coated AgNP (1400 mg) in a glass vial. The 
Ag-nanogel formulation was extensively vortexed and sonicated for 10 min at 50°C to form a dark 
colored homogeneous colloid dispersion with a final composition of SAIB/EtOH (80:20) with 10.0 
w/w% PVP-coated AgNPs. The formed Ag-nanogel dispersion was stored at room temperature 
and used within 4h from preparation with vortexing prior to use. 
In Vitro AgNP Release. Ag-nanogels were prepared as described above. Ag-nanogels (n = 3, 
200μL) were added to glass vials containing MQ-H2O (10.0 mL, 37°C) and aliquots (1.0 mL) were 
removed as a function of time (0.5 h, 1 h, 2 h, 3 h, 6 h, 24 h, 48 h, 72 h and 7 days) and replaced 
with an equal amount of MQ-H2O. Release of Ag
0 and Ag+ from the Ag-nanogels were measured 
using ICP-MS.  
Ag Quantification Using ICP-MS. The Ag-concentration in aliquots removed over time from the 
Ag-nanogel release assay was determined by ICP-MS using a iCAPQ ICP-MS (Thermo Scientific, 
MA, USA) using the following settings; RF Power: 1550 W, Plasma Gas Flow: 14L/min, Nebulizer 
Gas Flow: 0.945 L/min, Dwell Time: 0.01s, Sweeps: 300, Replicates: 3, Delay Time: 60 s, Wash 
time: 60 s. Aliquots samples (50 μL) were digested for 15 min at 25°C in an open glass vial using 
70% HNO3 (1.20 mL) and diluted 25 fold with 2 % HNO3 + 1ppb Pt as internal standard. An Ag 
standard curve covering the concentration range of 12.5 ppb ─ 100 ppb in HNO3 (2 % HNO3 + 1 
ppb Pt) was prepared using an Ag-standard for ICP-MS (10 ppm Ag). The intensity of 107Ag (m/z = 
106.9050) was measured and the concentration of Ag in the aliquots determined based on the 
corresponding standard curve (R2 > 0.99). 
Ag-Nanogel Biocompatibility. MatTek 35 mm petri dishes (n = 6) with cover glass bottoms were 
plated with 2.0×104 cells/cm2 HT1080 cells in 4 mL media and incubated overnight at 37°C. 
Premade Ag-nanogels (50 μL, n = 3) and SAIB based control gels (50 μL, n = 3) were added to the 
center of the wells. Following incubation for 24 h at 37°C the cells were stained using the HCS 
LIVE/DEAD Green Kit (H10290, Invitrogen, New York, USA) according to the manufactures 
instructions. Untreated- and ethanol treated cells (25 vol/vol% for 10 min) were included as a 
positive and negative control. After staining, all cells were fixed using 4 % paraformaldehyde for 15 
min at 5°C, washed twice in PBS and kept in PBS for imaging using confocal microscopy (Leica 
TCS SP5 AOBS confocal microscope, Leica Microsystems, Wetzlar, Germany). Images were 
collected by simultaneously line scanning with excitation at 488- and 633 nm (green/red) and 
emission 493-600 nm and 638-850 nm, respectively, obtained by tunable high-reflectance mirrors. 
Thorax Phantom Insert Preparation. Ag-nanogels were prepared as previously described. Ag-
nanogels (1.00 mL, n = 8) giving 100 mg Ag per Ag-nanogel and control gel (1.00 mL, n = 1) 
(SAIB/EtOH (80:20)) were prepared by injecting the respective solutions into MQ-H2O (20 mL) in 
glass vials (26 mL) at 25°C. After 5 days, a 10 w/w% solution of gelatin from bovine skin (225 G 
Bloom strength) was prepared by dissolving gelatin (80.0 g) and sodium azide (800 mg) in MQ-
H2O (720 mL). The mixture was heated to 80°C with stirring on a water bath until the gelatin was 
completely dissolved after which the solution was cooled to 40°C. Gelatin solution (10 mL) was 
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added to low-density polyethylene tubes (d = 24.8 mm, h = 74.5 mm) and allowed to set at 5°C for 
30 min. Once set, Ag-nanogels and control gel were individually placed in each polyethylene tube 
and gelatin (10 mL) was added to fixate the Ag-nanogels. Thorax phantom inserts were stored at 
5°C until use and in between irradiation experiments. 
Thorax Phantom Setup. An IMRT Throrax Phantom (Model# 002LFC, CIRS, NJ, USA) consisting 
of three tissue equivalent materials (lung (pink), soft tissue (green) and bone (white)) was used for 
Ag-nanogel dosimetry evaluation (Figure 4A). The thorax phantom inserts, prepared as described 
above, were positioned in the mediastinal part of the phantom by removing the existing 
exchangeable cylinders. Ag-nanogels (n = 8) were randomly divided into two sets of four. For each 
experiment, one set was inserted into the thorax phantom. A control gel based on SAIB/EtOH 
(80:20) was additionally inserted into the mediastinal part of the phantom. Three irradiations were 
performed for each dose level (2-, 10- or 22 Gy), for a total of 36 measurements of the Ag-nanogel 
and 9 measurements of the control gel (see Supporting Information) 
External Beam Radiotherapy Planning and Delivery. Radiotherapy treatment preparation and 
planning were performed in line with current clinical practice. The tissue equivalent thorax phantom 
with inserted Ag-nanogels was subject to a planning CT-scan using a Siemens Somatom Definition 
AS Scanner (Siemens, Forchheim, Germany) using a slice thickness of 2mm and tube voltage of 
120 kVp. The planning target volume was contoured as the whole mediastinal part of the phantom 
and treatment planning was performed with volumetric-modulated arc therapy41 with a single 
fraction with prescribed doses of either 2, 10 or 22 Gy. Each Ag-nanogel was contoured to retrieve 
contrast information of the samples and calculated dose. Each dose level was optimized 
individually with 18 MV photon beam using one full arc rotation (358 degrees). External beam 
irradiation was performed on a clinical iX Triology linear accelerator (Varian, Palo Alto, CA, USA). 
Prior to start of irradiation the tissue equivalent thorax phantom was positioned using image 
guidance to ensure a correct phantom and insert alignment. 
Positron Emission Tomography Dosimetric Readout. Directly following irradiation the thorax 
phantom was transported to a PET/CT scanner (Biograph TrueV, Siemens, Erlangen, Germany) 
while carefully timing the delay time from start of irradiation to start of PET/CT-acquisition. A CT-
scan was acquired for attenuation correction followed by a 30 minute PET scan in list mode. The 
PET-scanning was divided into three time frames; 0-2, 2-10, and 10-30 minutes and reconstructed 
using Filtered Back Projection (FPB) using a 4mm Hann filter and both attenuation and scatter 
correction. The time from irradiation end to scan start was used to correct the measured activity for 
decay, assuming only 106Ag was present. The activity from the third frame within a sphere with a 
radius 20 mm centered on each gel was averaged (PMOD, PMOD Technologies Ltd., Zürich, 
Switzerland) and used for calculation of the dosimetric measured absorbed dose.  
Statistical Analysis. Statistical analysis of the intra Ag-nanogel variance was conducted using 
Levene’s test for equal variance42. Furthermore, a statistical analysis investigating the effect of Ag-
nanogel position within the thorax phantom, the effect of differences in the Ag-nanogels and the 
delivered absorbed dose levels were conducted. All statistical analyses were performed in SAS 
version 9.4 (SAS Institute Inc., Raleigh, USA).  
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1. Thorax Phantom Setup Plan 
Irradiation of the thorax phantom was performed by using two different Ag-nanogel configurations 
where Ag-nanogel #1-4 was used in the first configuration (I) and Ag-nanogel #5-8 was used in the 
second configuration (II) (Table ). Each dose level was irradiated and measured with the PET/CT 
three times. Delay between individual irradiations was minimum 24h equal to 60.1 half-lives of 
106Ag to prevent carry-over of radioactivity. In total 45 individual measurements were conducted, 
which were divided into 36 of Ag-nanogels and 9 of the control gel. 
Table 1: Experimental plan with gels configuration.  
Scan\Dose [Gy] 2 10 22 
1 I II I 
2 I II I 
3 II I II 
 
2. Statistical Analysis  
2.1 Ag-Nanogel Variance Analysis   
To analyze possible effects of the individual gels, the position in the phantom, and the irradiated 
dose, a model with second order interactions was considered: 
𝑀1 ∶        𝑌𝑖𝑗𝑘𝜈 = 𝜇 + 𝑝𝑜𝑠𝑖 + 𝑔𝑒𝑙𝑗 + 𝑑𝑜𝑠𝑒𝑘 + {𝑝𝑜𝑠 ∙ 𝑔𝑒𝑙}𝑖𝑗 + {𝑝𝑜𝑠 ∙ 𝑑𝑜𝑠𝑒}𝑖𝑘 + {𝑔𝑒𝑙 ∙ 𝑑𝑜𝑠𝑒}𝑗𝑘 + 𝜖𝑖𝑗𝑘𝜈 
Where 𝑌𝑖𝑗𝑘𝜈 was the measured activity of position i, gel j, dose k and repetition 𝜈. 𝜖𝑖𝑗𝑘𝜈 was the 
error and 𝜇 the overall mean. Backwards elimination was performed down to the model only 
including main effects: 
𝑀2 ∶        𝑌𝑖𝑗𝑘𝜈 = 𝜇 + 𝑝𝑜𝑠𝑖 + 𝑔𝑒𝑙𝑗 + 𝑑𝑜𝑠𝑒𝑘 + 𝜖𝑖𝑗𝑘𝜈 
Then a testing of the main effects was performed, down to having only the dose included, as the 
hypothesis was, that the activity measured was only dependent on the irradiated dose: 
𝑀3 ∶        𝑌𝑖𝑗𝑘𝜈 = 𝜇 + 𝑑𝑜𝑠𝑒𝑘 + 𝜖𝑖𝑗𝑘𝜈 
𝑀4 ∶        𝑌𝑖𝑗𝑘𝜈 = 𝑑𝑜𝑠𝑒𝑘 + 𝜖𝑖𝑗𝑘𝜈 
Normality was evaluated by inspecting the residual/quantile plots. To test for equal variance the 
Levene’s test was used [1]. 
Nothing suspicious was found in the residual/quantile plots and normality was accepted. Using 
Levene’s test for equal variance1, the four dose levels 0-, 2-, 10- and 22 Gy, were found to have 
equal variance P=0.0989. Please note that the dose was not completely homogeneous within each 
group, so equal variance was accepted. 
Four models were considered M1-M4 (see equations above), ranging from complex to very simple 
(Table 2). 
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Table 2. Statistical analysis of results for each model. DF: Degress of Freedom, RSS: 
Residual sum of squares, MS: Mean squared error, F: F-test value 
Model No. par. DF RSS MSE F P(F>f) R2 
M1 19 26 0.00247935 0.00009536   0.9932 
M2 11 34 0.00297182 0.00008741 0.645 0.733 0.9916 
M3 2 43 0.00643799 0.00014972 4.406 0.001 0.9825 
M4 1 44 0.00676092 0.00015366 2.157 0.149 0.9816 
 
The step from M1 to M2 was not significant. The step from M2 to M3 was significant, however the 
decrease in R2 was miniscule. Taking statistical methodology very literally, one should thus accept 
M2. The step from M3 to M4 was also not significant. Since the decrease in variance explained 
were so small, we choose to accept the simplest possible model M4 as it still maintains a R2 of 
0.9816. This can be interpreted as the activity measured can be adequately explained by the 
effective dose alone and that position in the phantom and the individual gels has a negligible effect. 
To evaluate the error the irradiated dose was calculate from the activity using the model, which 
was grouped into the four dose levels (Table 3).. 
Table 3: Error in calculated dose 
Dose group [Gy] 
Standard 
deviation [Gy] 
Maximum lower error 
[Gy] 
Maximum upper error 
[Gy] 
0 0.927 -1.905 1.161 
2 0.612 -1.419 0.822 
10 0.963 -1.543 2.189 
22 1.575 -2.462 3.606 
 
References 
[1] M. B. Brown and a B. Forsythe, “Robust Tests for Equality of Variances,” J. Am. Stat. 
Assoc., vol. 69, no. 346, pp. 364–367, 1974.  
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Abstract 
Background: Studies on healthy elderly have shown that aerobic exercise has a positive effect on both brain structure and function. So far studies in patients with Alzheimer's disease (AD) are few and results have been inconsistent. In this study, we wanted to assess the relationship between aerobic exercise, brain changes measured by MRI and cognitive functioning in patients with AD.  
Methods: As part of a larger randomized controlled trial this MR-sub-study included forty-two patients. For both control and exercise group MR and cognitive assessment was performed at baseline and after 16 weeks with 60-minutes exercise sessions three times a week. Both attendance and intensity were monitored providing a total exercise load. Changes in regional brain volumes and cortical thickness were analysed using Freesurfer and volume of white matter hyperintensities (WMH) quantified. 
Results: Exercise load showed a positive correlation with changes in volume in the hippocampal subfields, as well as frontal, cortical thickness in the exercise group. Changes in frontal, cortical thickness correlated with measures of mental speed and attention (SDMT) and verbal fluency in both groups. Volume of WMH were associates with changes in hippocampal volume. 
Conclusion: In patients with AD the effect of exercise on hippocampal volume appear to depend on training attendance and intensity. The extent of WMH may modify the effect of physical training but further studies are needed.  
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Introduction Alzheimer's disease (AD) is a neuro-degenerative disease, characterized by progressive impairment of memory [GM84] and atrophy of specific brain regions, in particular the hippocampus [JB07]. Atrophy of the anterior hippocampus can be observed in patients with mild cognitive impairment (MCI) as early as three years prior to onset of AD, with increasing involvement of the hippocampus as the symptoms progresses [JW07]. In addition, atrophy has been observed in the amygdala, entorhinal cortex and fusiform gyrus in MCI, progressing to the middle temporal gyrus, posterior temporal lope and parietal lobe in patients with AD [JW07].  The effect of current pharmacological treatments of AD are at best symptomatic [RC12] but recent studies suggest that non-pharmacological approaches such as physical exercise may have a beneficial effect on cognitive functioning as well as brain structure. In healthy elderly both cognition, physical functioning and performance in activities of daily living were improved when given a home training program consisting of daily exercises and walking [AV12].  Studies including MRI suggest that physical training is associated with increased whole brain volume [SC06], less atrophy in frontal, parietal and temporal cortex [SC03] and even an increase in grey matter volume in pre-frontal and cingulate cortex [RR11]. In preadolescent children Chaddock et al [LC10] showed a relation between basal ganglia volume, enhanced cognitive functioning and aerobic fitness while in healthy elderly improvement in memory function were associated with increase hippocampal volume [KE11]. In patients with AD Andrade et al reports an increase in frontal cognitive function, after following a multimodal exercise program for 16 weeks [LA13]. Increasing evidence support that exercise benefits brain function and structure but also that there are multiple pathways and that age and concurrent pathological processes may modify the effect. In a recently published study exercise had a positive effect on neuropsychiatric symptoms and cognition in a relatively large group of patients with mild to moderate (KH 2016). To our knowledge, this is the first to investigate the effect of continuously supervised moderate to high-intensity exercise program in patients with mild to moderate AD. In a sub-study, MRI was performed at baseline and 16-week follow-up in order to assess the effect on regional brain volumes. The primary outcome measure is hippocampal volume and we hypothesize that in AD patients a moderate to intense exercise program will preserve hippocampal volume. 
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Methods 
Participants and study design The primary objective of the ADEX study was to assess the effect of moderate-to-high intensity aerobic exercise on cognitive and physical functioning, quality of life and ADL in two-hundred community-dwelling patients with mild to moderate AD. The participants were randomized into a control and exercise group, the latter performing 60 minutes of moderate-to-high-intensity aerobic exercise three times weekly for sixteen weeks. Psychological, cognitive and physical performance was assessed before and after the sixteen week period for both groups. The trial ran for 5 rounds from 2012 to 2014.  The procedure for screening, as well as inclusion and exclusion criteria, is described in a recent publication [KH13]. In brief, key inclusion criteria included age between 50 and 90 years and a Minimal Mental State Examination (MMSE) score of more than 19, whereas exclusion criteria included presence of medical and psychiatric diseases, alcohol abuse and regular, weekly high-intensity exercise. A subgroup consisting of seventy-one patients from memory clinics in Copenhagen, Roskilde and Odense was invited for brain MRI at baseline and 16 week follow-up. Thirteen of these patients left the study prematurely, and sixteen patients were excluded due to poor MRI data quality (movement artefacts) (9), data processing problems (6) or notable error in data processing outcomes (1), leaving 42 patients for the present study.  The ADEX trial was approved by the The Committees of Biomedical Research Ethics for the Capital Region (Protokol no.: H-3-2011-128) and by the Danish Data Protection Agency (j.no.: 30-0718). 
MRI acquisition Both baseline and follow-up MRI was performed at Hvidovre Hospital, Denmark, using a 3.0-T Siemens Tim Trio scanner and included T1-weighed magnetization-prepared rapid gradient echo (MPRAGE) (TE 3.04ms, TR 1550ms, FoV read 256mm, FoV phase 100%,  192 slices), T2-weighed fast spin echo (TE 354ms, TR 3000ms, FoV read 282mm, FoV phase 76.6%, 192 slices) and fluid attenuated inversion recovery (FLAIR) (TE 353ms, TR 6000ms, FoV read 282mm, FoV phase 85.9%, 192 slices) sequences. 
Data processing 
Regional, cortical thickness and hippocampal volume The T1-weighed data was gradient unwarped to correct for spatial distortions [JC06], and then processed with version 5.3 of the cross-sectional [BF02] and longitudinal [MR12] Freesurfer stream, in order to obtain segmentations of cortical regions defined according to the Destrieux atlas [CD10] as well as the hippocampal subfields [KL09],  caudate and putamen. The pipeline was specifically tuned to correct for intensity inhomogeneity that can be observed at 3T [RB08, WZ09]. In cases where Freesurfer failed to properly delineate the white matter and pial surface, the pipeline were manually guided following the steps outline in the Freesurfer documentation (http://freesurfer.net/fswiki/FreeSurferWiki). This specifically involved correcting the skull stripping to better delineate the pial surface, insertion of control points to guide white matter normalization for the purpose of improving white matter segmentation, and finally editing the white matter segmentation itself. Two trained readers edited the pipeline; to avoid segmentation bias, one was responsible for skull stripping and white matter editing, while the other was responsible for control point insertion.  
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Finally, overall quality of the longitudinal segmentation output were asserted by experienced raters (CTL, KSF, EG). Specifically, the pial and white matter surface outlines, as well as the hippocampal subcortical segmentation were visually inspected and consensus reached for all. One volume was excluded due to significant segmentation error in the hippocampus. To explore regional, cortical effects, gyri and sulci thickness measures obtained from Freesurfer  were divided into four categories (early, middle, late, and very late) each including areas reported to be progressively affected by atrophy from mild cognitive impairment MCI to full AD diagnosis [JW09]: 'early' (temporal, precuneus, cingulate), 'middle' (parietal, temporal-occipital, occipital, fusiform, parahippocampus) and 'late' (frontal). A 'very late' region composed by the pre and postcentral cortex were also defined (supplementary material, table 4).  
Whole and parenchymal brain volume Freesurfer also provides measures of brain volume (BV), brain parenchymal volume (BPV), white matter volume (WM) and intracranial volume (ICV). Whole brain volume included all segmented structures, excluding background and the brain stem. Parenchymal volume further excluded the ventricles (lateral, inferior lateral, 3rd, 4th and 5th), CSF and choroid plexus. Brain parenchymal fraction (BPF) was obtained by dividing BPV with ICV. 
White matter hyperintensities For delineation of white matter hyperintensities (WMH), MPRAGE and T2-weighted images were co-registered and re-sliced to the corresponding FLAIR image using a 6 parameter rigid transformation. WMH were defined as clearly hyperintense areas relative to surrounding white matter on both FLAIR and T2-weighted images and identified by simultaneous inspection of both aligned images. For WMH volume local thresholding was applied and WMH volumes for the whole brain quantified automatically using the Jim image analysis package, Version 6.0, (Xinapse Systems Ltd., Northants, UK, www.xinapse.com). Visual identification and delineation was carried out by a single trained rater blinded to clinical information. For nine subjects (five control, four intervention) WMH could not delineated due to movement artefacts. 
 Longitudinal and normalized measures Longitudinal measures of brain volume, cortical thickness and cognitive scores for each subject were computed as the relative change between baseline and follow-up by subtracting baseline from follow-up, and dividing the difference with the baseline measure, thereby canceling out within-subject correlations, as well as accounting for between-subject differences in brain size. Throughout the paper, we will refer to the relative change simply as change. A normalized WMH measure was obtained by dividing WMH volume with white matter volume. 
Cognitive outcome measures Cognitive assessment included the Minimal Mental State Examination (MMSE) for global cognitive impairment [MF75], the Symbol Digit Modalities Test (SDMT) for mental speed and attention [AS82] (only measurements at 120 seconds included in the analysis), and the Stroop Color and Word Test (Stroop) incongruent score for reaction time.  Verbal memory performance was assessed by the Alzheimer's Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) [WR84], and verbal fluency (VFT) as number of words produced over 1 minute each ([KH15] for details). 
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Exercise load (attendance and intensity) To assess training attendance and intensity a training log was created. Attendance was logged, and attendance ratio defined as number of attended exercise sessions over total number of offered sessions. Exercise intensity was based on the per-session average heart rate (HR) recorded using continued monitoring during exercise (including rest). Average HR for all sessions was calculated, and intensity defined as average HR over maximum expected HR (220 minus subject age).  To obtain total exercise load, measures for attendance ratio and intensity was multiplied. 
Statistical analysis 
Brain volume measures Separate multivariate models were used to compare changes in volume between groups for the hippocampal subfields (model 1), para-hippocampus (model 2), caudate and putamen (model 3). Similarly, separate models were used to compare changes in thickness of the cortical gyri and sulci respectively for each of the ‘early’, ‘middle’, ‘late’ and ‘very late’ categories previously described.  For all group tests, Hotellings T2 multivariate test [HH31] was applied. Hotellings T2 eliminates the need for testing each individual measure in a model (e.g., each of the hippocampal subfields), and consequently the need for performing a multiple comparisons test. This makes the test more sensitive and less prone to type II error (false negatives) than e.g., univariate tests with Bonferoni correction.  Since outliers were detected in scatter plots of the variables, a further non-parametric Oja rank test [HO04] were performed, using 10.000 permutations, to confirm validity of p-values from Hotellings T2 test. 
Correlation tests The relationship between changes in hippocampal subfield volume and verbal memory (ADAS-Cog measure) was tested with caudate and putamen as a control regions. Also, the relationship between changes in frontal and cingulate cortical thickness, and verbal memory, mental speed and attention (SDMT, VFT, Stroop) were assessed with pre- and postcentral cortex as a control region. The relationship between cognitive measures and changes in volume of caudate and putamen were explored with hippocampus as a control volume. Finally, relationship between exercise load and changes in hippocampal subfield volume as well as frontal cortical thickness were also investigated for the exercise group only. (Details on cortical labels can be seen in the supplementary material, table 5). All correlation tests were performed by computing the covariance matrix between changes in test scores and brain measures, and then testing the nul-hypothesis of zero covariance between the two. This yields an overall p-value for the full covariance matrix, but not an r-value. If the overall p-value was significant, a post-hoc analysis of the correlation for each single brain measure was performed, yielding individual r- and p-values.  Six subjects were excluded from the correlation tests due to missing cognitive scores (one subject lADAS-Cog; three subjects SDMT; one subject VFT; six subjects Stroop). For all tests, the significance level was 0.05.  Gender, age and baseline WMH were used as covariates. Statistics were obtained with SAS Statistical Software version 9.4 and Rstudio 2.15.2 
Results No significant differences were found for any baseline characteristics between the control and 
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intervention group (Table 1).  
Brain volumes In the hippocampal subfield model a significant difference were found for the left fimbria (p=0.012) and CA2_3 (p=0.016) which however, could not be found when correcting for multiple comparisons (figure 1, table2).  No difference between groups was observed for the parahippocampal or caudate and putamen models (table 2). No significant between-group difference in changes in regional cortical thickness was found (table 3). The normalized WMH measure did not change significantly from baseline to follow-up (p=0.996). In both groups WMH was associated with changes in the hippocampal subfield volume (p=0.002), specifically presubiculum (r=-0.345, p=0.031), and CA4_DG (r=-0.406, p=0.010), (supplement, table 6) as well as changes in both gyri (p=0.048) and sulci (p=0.002) thickness in the 'very late' category, and also sulci thickness in the 'middle' category (p=0.0495). Inspection of the individual significant gyri and sulci showed the largest correlations with the right post-central gyri (r=0.221, p=0.170) in the ‘very late’ gyri, the right post-central sulci (r=0.467, p=0.002) in the ‘very late’ sulci category, and the right occipital superior and transversal sulci (r=0.460, p=0.003) in the ‘middle’ category. 
Cognitive performance correlations Change in the frontal and cingulate cortical thickness correlated significantly with both SDMT (p=0.025) and VFT (p=0.026), (table 7, supplement). Specifically, for SDMT a moderate correlation was found with change in cortical thickness of the right frontal inferior-orbital gyri (r=0.464, p=0.004) and right frontal inferior-triangular gyri (r=0.386, p=0.020). Per-group investigation (figure 2) revealed moderate correlations in both regions for the exercise group but not the control group. For VFT, correlations was found with cortical thickness changes in the left (r=0.384, p=0.017) and right (r=0.328, p=0.044) frontal mid-posterior gyri and sulci. Per-group investigation of this relationship (figure 3) revealed significant correlations in both regions for the control group but not the exercise group. (table 8, supplement).  A separate analysis of the correlation between normalized WMH and each cognitive performance measure showed a significant correlation with Stroop (r=0.394, p=0.023). Inspection of the scatterplot of the measures revealed the correlation to be dominated by two points with no apparent overall trend. No significant correlations were found between WMH and the SDMT/VFT measures. 
Exercise load correlations Exercise load was found to associate significantly with changes in cortical thickness in the frontal cortex (p=0.0106), especially for the right frontal inferior sulci (r=0.514, p=0.034). Similarly, a significant correlation with changes in volume in the hippocampal subfields (p=0.0091) was found, the strongest correlation showing in the right subiculum (r=0.443, p=0.086). 
Discussion To our knowledge, this is the first study to explore the effects of supervised moderate-to-high intensity aerobic exercise on regional brain atrophy measures in patients with mild to moderate AD.  Main findings in this study are three-fold. First, exercise load shows a positive correlation with changes in volume in the hippocampal subfields, as well as frontal, cortical thickness which support that exercise does stimulate brain growth, which agrees with previous findings, e.g., [SC03], [SC06] and [KE11]. The group differences in changes in the left fimbria and CA2_3 hippocampal subfield volume 
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disagree (figure 1). While changes in the left fimbria could suggest that exercise stimulates brain growth with measurable effects already after 16 weeks in patients with AD, the opposite trend in CA2_3 suggest that the effects are spurious.  We performed a post-hoc qualitative inspection of changes in hippocampal, caudate and putamen volume and regional cortical thickness. Our observations suggested only a minor loss of tissue across subjects across a four month period, and furthermore that loss of tissue seems to be less in exercise participants. In some cases, the data suggested a slight increase. However, given the variation in data and the inability to show significant differences between groups, this remains only partially indicative of the effects of exercise.  Previous literature, e.g., Erickson et al, who showed an effect in global hippocampal volume in healthy elderly after 1-2 years of PE [KE11]. Our findings suggests that 16 weeks may not be enough to effect duration as well as intensity should be considered when planning exercise programs. An alternative explanation for the disagreement is that the control group may have been exercising outside of the study, thereby diminishing group differences. Second, for all participants, changes in frontal, cortical thickness were associated with SDMT and VFT. Cortical thinning have previously been shown to associate with cognitive impairment, e.g., in Parkinson’s Disease [BS14], which suggests that a decline in cortical thickness can be used as an indicator of progressive cognitive impairment. Our finding that frontal, cortical thickness associates with SDMT/VFT cognitive performance measures, is in agreement with this, and more generally with literature on the role the frontal cortex has in mental speed, attention and verbal fluency [JA06].  Given that AD is a neuro-degenerative disease, it would be expected that changes in cortical thickness and cognitive measures would be primarily negative. However, no particular decline or increase in cortical thickness or cognitive performance were observed for changes in frontal, cortical thickness and the SDMT/VFT scores (figure 2 and 3). Further inspection reveals a stronger relationship between changes in cortical thickness and SDMT for the exercise group, while the control group exhibits the strongest correlation with VFT. Third, interestingly, normalized WMH values were associated with changes in hippocampal volume as well as regional, cortical thickness in both groups, suggesting that pathology other then AD may influence brain structure. WMH are generally regarded a marker of small vessel disease and severe WMH an indicator of poor vascular health. Recent findings (presented at AAIC 2015) suggest that the presence of WMH may modify the effect of exercise intervention but also that exercise may enhance vascular health as well as connectivity. A recent study [EL15] have shown that the rate of change in WMH are strongest during conversion from MCI to AD diagnosis, and follows the rate of change in hippocampal volume suggesting that WMH may play a part in the conversion process. Similarly, Caso et al [CF15] conclude that WM degeneration may be an early marker of pathological changes in atypical AD. In line with these studies, our finding that the severity of WMH associates with relative changes in the hippocampal subfields implies a relationship between WMH and the rate of neuro-degeneration in AD.  WMH has also been shown to associate with cognitive decline [OC10] and more specifically medial temporal atrophy, attention and frontal executive functions [YS11] as well as frontal atrophy and reduced delayed recall performance [IM12]. Here, we observed positive correlations between WMH and changes in cortical thickness, which is not what we would expect. The finding was made predominantly in the cortical control regions, where effects due to AD would be expected to show very late. As such, the finding could be spurious, and may again suggest that a four month period is not be 
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enough to measure significant differences with controls.  Although the underlying mechanism is still not completely understood animal studies indicate that physical exercise stimulates neurogenesis and formation of brain-derived neuro-protective factor (BDNF) [HP05][KN09][MM13]. This relationship between exercise and BDNF has also been reported in humans [CC02]. 
Methodological considerations  The disagreement between findings in the left fimbria and left CA2_3 hippocampal subfields, the positive correlations between WMH and regional, cortical thickness suggest some level of uncertainty in the statistics, one explanation being noise. Furthermore, the population size after drop-outs, data processing and quality assurance in this study was quite small, which affects statistical power and consequently increases the likelihood of spurious results. From a clinical perspective, sixteen weeks of exercise are likely not enough to measure effects on the same level as e.g., Erickson et al [KE11]. Furthermore, previous findings have been in healthy elderly subjects, with a presumably small pathological load. It is very likely the effects of an exercise intervention on the brain might be different in patients with AD.   The subjects in this study were recruited from three different memory clinics. This could pose a potential bias in statistics, given that subjects may be treated differently at each center. We did not control for this, due to the already mentioned statistical concerns. Furthermore, there is a good agreement between the statistics of the control and intervention group as shown in Table 1. Given that subjects from all centers using a controlled, randomized process, it seems reasonable to assume that differences between subjects due to memory centers even out. As described in [MR12], the longitudinal Freesurfer pipeline utilizes cross-sectionally processed time points to generate a common template, which is then used as a point of initialization for an unbiased analysis of each individual timepoint. This procedure helps to avoid potential bias in the outcome measures due to e.g., registration to the baseline time point, as pointed out in [NF11]. Furthermore, it increases statistical power because inter-subject variation is reduced. 
Conclusion A sixteen week intervention of moderate-to-high aerobic exercise clearly translated to observable changes in hippocampal subfield volume and cortical thickness in a group of patients with AD. The finding supports evidence that exercise stimulates exercise, which may potentially have a negating effect on neuro-degeneration. Furthermore, correlations between changes in the frontal cortex and mental speed and verbal fluency show that changes in brain volume and cortical thickness does relate to changes in cognition. As such, it seems likely that exercise for prolonged periods of time may increase the extent to which brain growth is stimulated, thereby leading to a positive effect on cognition and ADL in patients with AD. Finally, an observed association between the extent of WMH and changes in the hippocampus suggest that WMH may be indicative of the rate of neuro-degeneration. It is further suggested that this may have a limiting effect on the effectiveness of exercise. Future studies should explore the effect of aerobic exercise focusing on a prolonged duration of the intervention period, as well as an increase in the number of participants receiving MRI, in order to increase statistical power.  
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Table 1: Baseline demographics for all participants and basic volumetric measures for participants in the 
MR sub-study.  MR-substudy Main study  Control 
(N=20) 
Exercise 
(N=22) 
p-values Control 
(N=93) 
Exercise 
(N=107) Age (years), mean (±SD) 69 (7.5) 68 (7.7) 0.681 71.3 (7.3) 69.8 (7.4) Gender, male/female (N) 12 / 8 14  / 8 0.809 57/36 56/51 MMSE, median (±SD) 26.0 (2.3) 26.0 (3.4) 0.712 24.1 (3.8) 23.8 (3.4) Hypertension*, N (%) 5 (25) 4 (18) 0.591 35 (37.6) 48 (44.9) WMH (mm3 ·103), median (±SD)  1.94 (6.1) 1.16 (6.3) 0.116 N/A N/A WMH/WM (10-3),  median (±SD) 6.00 (15.8) 2.80 (12.2) 0.085 N/A N/A BV (mm3 ·106), mean (±SD) 1.01 (0.13) 1.11 (0.12) 0.489 N/A N/A BPV (mm3 ·106), mean (±SD)  1.00 (0.11) 1.05 (0.11) 0.226 N/A N/A BPF, mean (±SD) 0.63 (0.03) 0.64 (0.03) 0.456 N/A N/A * Hypertension was defined as ≥140/90 mmHg. WMH: White matter hyperintensities, WM: white matter, BV: brain volume, BPV:brain parenchymal volume, BPF: brain parenchymal fraction.   
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Table 2: Difference between control and exercise group in change in volume measures.  Left side  (p-value) Right side (p-value) Test 1 Hippocampus     Total hippocampus volume *  0.930 0.266     Presubiculum 0.747 0.817     Subiculum 0.485 0.469     Fimbria 0.012 0.423     Hippocampal fissure 0.240 0.583     CA1 0.470 0.237     CA2_3 0.016 0.299     CA4_DG 0.120 0.184 Test 2   Parahippocampus 0.462 0.962 Test 3  Caudate 0.128 0.071 Putamen 0.289 0.779  * Includes the ’hippocampus’ class, which captures voxels that were not put in the other subfield categories. 
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Table 3: Difference between control and exercise group in change in cortical, regional thickness.  Gyri 
(p-value) 
Sulci 
(p-value) Early 0.255 0.187 Middle 0.112 0.623 Late 0.687 0.126 Very late 0.121 0.506 
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Figure 1: Boxplots showing the changes in volume in the left fimbria and left CA2_3 hippocampal 
subfields for the control and exercise groups. 
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Figure 2: Correlation between change in the right frontal inferior-orbital/inferior-triangular gyri 
thickness and relative change in SDMT measured at 120 seconds. 
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Figure 3: Correlation between relative change in the left and right cingulate, mid-posterior gyri and sulci 
thickness and relative change in VFT. 
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Supplementary 
Cortical regions (Freesurfer, Destrieux atlas nomenclature)     
Table 4: Gyri and sulci according to known progression of AD partitioned into categories of 'early', 
'middle', 'late' and ‘very late’.  
Gyri 
Early temporal (inferior, medial, superior lateral),  temporal (transversal, plan-polar, plan-tempo),  precuneus,   cingulate (transversal+ventral) 
Middle parietal (inferior-angular+supramar, superior),  occipital-temporal medial (parahippocampal, fusiform)  
Late frontal (inferior-opercular/orbital/triangular, medial, superior)  
Very Late precentral,  postcentral  
Sulci 
Early temporal (inferior, superior, transverse),  cingulate-marginalis  
Middle parieto-occipital,  occipital-temporal lateral,  occipital (anterior, middle-lunatus, superior-tranversal)  
Late frontal (inferior, middle, superior)  
Very Late precentral (inferior, superior),  postcentral   
177
   
Table 5: Gyri and sulci of the frontal and cingulate cortex, as well as the precentral and postcentral 
cortex.   
Effect frontal (inferior, middle, superior) gyri and sulci,  cingulate (mid-posterior, mid-anterior, anterior) gyri and sulci 
Control precentral gyri,  postcentral gyri,  postcentral sulci, precentral (inferior, superior) sulci 
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Results, additional tables 
    
Table 6: Correlations between baseline normalized WMH and change in volume in the hippocampal 
subfields, parahippocampus, caudate and putamen for all study participants.  Left side  Right side 
r-value p-value r-value p-value 
Test 1 Hippocampus     Sum of all subfields -0.263 0.106 0.147 0.373     Presubiculum -0.345 0.031 0.238 0.145     Subiculum -0.295 0.068 0.263 0.106     Fimbria 0.281 0.083 0.009 0.956     Hippocampal fissure -0.225 0.169 -0.313 0.053     CA1 -0.098 0.552 0.058 0.726     CA2_3 0.042 0.802 0.085 0.607     CA4_DG -0.406 0.010 0.132 0.423 
Test 2  
 Parahippocampus -0.058 0.721 0.135 0.407 
Test 3  Caudate 0.301 0.059 0.204 0.208 Putamen -0.140 0.390 0.012 0.941  
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Table 7: correlations between changes in caudate, putamen volume/frontal, cingulate cortical thickness 
and changes in SDMT/VFT/Stroop outcome measures for all participants. 
 
 Effect 
(p-value) 
Control 
(p-value) 
Frontal, cingulate cortex    SDMT  0.0246 0.6749 Stroop 0.8873 0.5966 VTF 0.0259 0.4788 
Caudate, Putamen   SDMT 0.7042 0.1978 Stroop 0.8424 0.7530 VTF 0.0801 0.3846  
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Table 8: Correlations between relative changes in frontal/cingulate cortical thickness and VFT/SDMT 
outcome measures for all participants.   VFT 
(r-value) 
VFT 
 (p-value) 
SDMT  
(r-value) 
SDMT  
(p-value) 
Left: Frontal inferior sulci 0.037 0.825 0.103 0.549 Frontal middle sulci 0.182 0.275 0.187 0.275 Frontal superior sulci 0.249 0.132 0.099 0.566 Frontal inferior-opercular gyri 0.297 0.071 -0.069 0.690 Frontal inferior-orbital gyri 0.164 0.326 -0.057 0.743 Frontal inferior-triangular gyri 0.319 0.051 -0.032 0.854 Cingulate mid-posterior gyri and sulci 0.384 0.017 0.118 0.494 
Right: Frontal inferior sulci 0.174 0.297 0.167 0.324 Frontal middle sulci 0.276 0.093 -0.179 0.296 Frontal superior sulci 0.227 0.170 0.208 0.224 Frontal inferior-opercular gyri 0.269 0.103 0.279 0.104 Frontal inferior-orbital gyri 0.114 0.494 0.464 0.004 Frontal inferior-triangular gyri 0.277 0.092 0.386 0.020 Cingulate mid-posterior gyri and sulci 0.328 0.044 -0.126 0.463  Significant p-values have been highlighted in orange, bold and the corresponding correlations in blue, bold. P-values for the individual gyri and sulci regions have not been corrected for multiple comparisons.  
 
181
182
Eﬀect of moderate-to-high intensity aerobic exercise on hippocampus and
cortical regions in patients with mild to moderate Alzheimer's disease
Appendix E
Software-Package for
Automated Bias-Field
Correction and
Quantifcation of Abdominal
Fat using MRI with
Preliminary Evaluation in
Overweight Subjects
Technical Report - DTU Compute
Software-Package for Automated
Bias-Field Correction and
Quantiﬁcation of Abdominal Fat
using MRI with Preliminary
Evaluation in Overweight
Subjects
Anders Nymark Christensen, Christian Thode Larsen,
Martin Bæk Petersen, Knut Conradsen, Vedrana Dahl Andersen
December 1, 2015
1 Abstract
The abdominal distribution of fat is investigated in many clinical studies. A
major limitation is the time-consuming quantiﬁcation of the fat, if done man-
ually. We present an automatic and robust package for MRI, that performs
both bias-correction and segmentation of both the sub-cutaneous fat and
visceral fat. The method uses various image-derived energies, and by tuning
them it can be applied to other body parts, such as the thighs. Preliminary
assessment on overweight subjects showed few errors when evaluated by a
trained medical doctor.
1
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2 introduction
The abdominal distribution of fat is of great clinical interest. Multiple stud-
ies [Miyazaki et al., 2002, Fujioka et al., 1987, Rosito et al., 2008] has shown
a correlation between abdominal fat, insulin resistance and other metabolic
risk factors. The longitudinal changes has also been studied, in e.g. children
[Tinggaard et al., 2015] and pre-/post menopausal women [Kanaley et al., 2001,
Franklin et al., 2009].
To analyse the distribution of abdominal fat three techniques have seen wide
spread use. Dual X-ray absorptiometry (DEXA), Computed Tomography
(CT), and Magnetic resonance Imaging (MRI). DEXA is fast and cheap,
and only has a very low dose of ionising radiation. However, it does not
allow for diﬀerentiation between sub-cutaneous fat and visceral fat. CT is
fast and gives quantitative measures making the post-processing easier. The
drawback is, that it incurs a signiﬁcant radiation dose. MRI is slow and more
diﬃcult to analyse, as it is not quantitative and suﬀers from a bias-ﬁeld. As
it is free of ionising radiation and has superior contrast it is often the chosen
technique. It is also the technique evaluated in this report.
Several algorithms for abdominal fat segmentation has been proposed. SliceO-
matic (Tomovision, Inc., Magog, Canada) is a commercial program that
allows for segmentation in a supervised fashion. [Armao et al., 2006] used
region growing with mixed results. [Leinhard et al., 2008] used an automatic
morphon based approach [Knutsson and Andersson, 2005] on a Dixon se-
quence [Dixon, 1984, Ma, 2008]. While the results are very convincing the
article is very sparse with regards to implementation details. Further, it is un-
likely that an atlas based on a single subject, as they use, will perform reliable
across the wide variety seen in the population. [Zhou et al., 2011] proposes
supervised segmentation based on chain-coding [Baruch and Loew, 1988].
Unfortunately the details are omitted for a later publication. [Thörmer et al., 2013]
presents a software package available on request for supervised segmentation.
The method is based on localised region-based contous [Lankton and Tannenbaum, 2008].
[Liou et al., 2006] proposed an automatic method using binary operations
with added heuristics for segmentation. It seems a promising methods, but
does not diﬀerentiate between visceral fat and internal non-visceral compart-
ments. [Kullberg et al., 2007] proposed a automatic heuristical method that
requires the scan to be centred on the L4-L5 vertebra. [Mosbech et al., 2011]
used active contours for automatic segmentation. Further, dynamic program-
ming was used to ﬁnd the fascia of Scarpa, dividing the subcutaneous fat in
a deep and superﬁcial part.
We present an integrated package that contains both fully automated bias-
2
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correction and segmentation. The bias ﬁeld correction method was previously
presented in [Larsen et al., 2014], and has been found to perform well across
a range of sequences. For the segmentation we implemented the graph-cut
based method proposed by [Li et al., 2006], which can be used to perform a
global segmentation, thus taking advantage of information in adjacent slices.
The method is robust and by weighting diﬀerent energies, it can be made
to work across diﬀerent sequences and even diﬀerent body parts. For the
exclusion of non-visceral fat some information of the anatomical location of
the slice is needed. Except for that it is fully automatic.
3 Materials and Methods
All code was written in Matlab (The MathWorks Inc., Natick, USA).
3.1 Bias-correction
The bias ﬁeld correction method employs a generative model, where the
bias ﬁeld is assumed to be multiplicative, smooth and slowly varying over
the image. The generative model is composed of a mixture of Gaussians that
models the underlying uncorrupted signal intensities and a linear combination
of cubic b-spline basis functions with regularization on the bending energy
for the bias ﬁeld eﬀect.
Parameter estimation of the generative model is carried out in the log-
transformed data domain using a generalized expectation maximization al-
gorithm [Van Leemput et al., 1999]. The following hyper-parameters were
used: 8 Gaussians, smoothing distance 25, smoothing regularisation 0.5, as
they were found to perform well across a range of MRI sequences.
The implementation of our generative bias ﬁeld correction method was pre-
viously presented in [Larsen et al., 2014]. Here it was shown how perfor-
mance of the method is comparable to the popular N3 bias ﬁeld correction
method [Sled et al., 1998], and also how it is important that involved hyper-
parameters are tuned properly, depending on scanner and ﬁeld strength.
3.2 Segmentation
The segmentation of the images is based on the method by [Li et al., 2006],
were the problem is formulated as a graph to be cut. The scan is unrolled for
3
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Figure 1: (a) Surface orientation. (b) Two adjacent columns with edges.
Copyright c© 2006, IEEE
the segmentation. If we have an orientation as in ﬁg. 1 (a), the surface will
only pass through each (x,y)-column once. To ensure connectivity we have
intra-column edges in each column and to incorporate smoothness constraints
∆x, ∆y we have inter-column edges, see ﬁg. 1 (b). This can be generalised to
4D if we have multiple surfaces and want to impose constraints ∆l, ∆u on the
distance between them. The node weights (energy used) are set depending
on the problem. If it is layers in a 3D volume, it could e.g. be the inverse
of the gradient, as we cut in the minimum value. To cut the graph we use
[Boykov and Kolmogorov, 2004].
3.2.1 Subcutaneous fat
The inner and outer surface of the subcutaneous fat are found together, with
∆l = 5, ∆u = 150. The volume needs to be unrolled. This is done by
ﬁnding the centroid and then sample radially. As the inner surface of the
subcutaneous fat changes distance to the centroid signiﬁcantly in the lateral
areas, we have a denser sampling in those. See ﬁg. 2. The resulting unrolled
image, see ﬁg. 3, can then be used to estimate energies for the segmentation.
Diﬀerent energies are used to ﬁnd the inner and outer surface. A gradient
based G, a gradient based of the median ﬁltered scan Gm, a gradient based
4
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Figure 2: Radial sampling
Figure 3: Unrolled image
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of the median ﬁltered scan with additional Gaussian smoothing Gs and a
surface cost S.
With the slices along the x-direction, the gradient based energy is deﬁned as
G = sign(Gz) · (|Gz|+ |Gx|) (1)
Where Gz and Gx are the gradients in the z- and x-direction.
The gradient of the median ﬁltered scan Gm is a more robust measure-
ment. It is obtained by median ﬁltering the scanning with a kernel of size
round(10/pixel size in mm) and then taking the gradient measure.
The gradient of the median ﬁltered scan with additional Gaussian smoothing
Gs used the same kernel as above for the median ﬁlter and for the Gaussian
a kernel of size 1.5 times the one used in median smoothing with a standard
deviation of 3/pixel size in mm.
The surface cost S is a product of two energies. The ﬁrst S1 is given by
setting all values in G less than zero to zero and then taking the cumulative
sum in the z-direction. The second S2 is given by taking the cumulative sum
in z-direction of the unrolled image. The two energies are normalised and
multiplied. This energy is then ﬁltered with a median ﬁlter with the kernel
[round(70/pixel size in mm) round(4/pixel size in mm)] (x,z).
To ﬁnd the outer surface normally only Gs is used, but it can be weighted
with the other energies if necessary. The values ∆x, ∆y are set to 10 and 10.
For the inner surface a weighting of G, Gm, and S is used, speciﬁcally:
Ei = 0.5 ·G + 0.1 ·Gm + 0.4 · S (2)
The found inner surface is median ﬁltered with a kernel of 5, except in the
anterior region were a kernel of 35 was used. This was due to problems with
visceral fat being segmented as subcutaneous. An example of the obtained
segmentation is shown in ﬁg. 6. The values ∆x, ∆y are set to 3 and 7.
3.2.2 Visceral fat
Using the inner surface of the subcutaneous fat as a mask, the visceral fat
was segmented. We use a threshold value based on k-means clustering with
5 classes. Ordering the clusters after mean value in ascending order, we used
the value of the 4th cluster as threshold. Empirically we discovered that the
threshold obtained by using Otsu threshold [Otsu, 1979] were too low, see
ﬁg. 7.
6
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(a) G
(b) Gm
(c) Gs
Figure 4: The three gradient based energies
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(a) S1
(b) S2
(c) S
Figure 5: The three surface cost based energies
8
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(a) Original
(b) Unrolled
Figure 6: Segmentation of the subcutaneous fat
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Figure 7: Histogram showing the diﬀerence between Otsu and k-means
threshold
Figure 8: The visceral fat, with the spinal column area extracted
10
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3.2.3 Spine extraction
The spine extraction is optional. Without it, the fat in the non-visceral
compartment around the spine will be classiﬁed and counted as visceral fat.
It needs some user input, as it needs to be centred approximately on the
spine. In the lover parts of the spinal column it is nearly centred in the slice.
When moving caudally the spine shifts more posterior. The user can input
either a vector describing the displacement or a single number used for all
slices.
Centred on the spine the scan is unfolded radially as before. The energies,
however, are diﬀerent. For all of them, except the surface cost, the anterior
part (1/4 radially) of the scan was set to zero.
The ﬁrst is simply the raw image im. The second is the gradient of the raw
imageGspine. The third is the gradient of the scan ﬁltered with a median ﬁlter
Gspinem using a kernel of size round(10/pixel size in mm). The surface costs
are a bit more complicated. The cumulative sum is taking in the z-direction.
For the ﬁrst Sspine1 starting from the bottom, for the second S
spine
2 starting
from the top. For Sspine1 the lower 1/30 of the z-axis are set to inﬁnity. For
Sspine2 the upper 3/4 are set to inﬁnity. This constrains the possible solution.
The weighting of the diﬀerent energies is as follows:
Espine = 0.1 · im + 0.2 ·Gspine + 0.25 ·Gspinem + 0.4 · Sspine1 + 0.1 · Sspine2 (3)
3.3 Test subjects
10 healthy subjects included in the project `Active Commuting To Improve
Wellbeing and health in Everyday life' (ACTIWE) was randomly chosen.
The subjects were 20-45 years of age and overweight with a BMI of 25-35.
Imaging was performed on a Biograph mMR (Siemens, Erlangen, Germany)
using a T1 weighted sequence with water suppression. 5 slices centred on
the L5 vertebra were chosen for analysis. The slices were segmented, and an
experienced medical doctor (MD) manually annotated any errors.
3.4 Earlier studies
During the development of this software, 2 other projects have been analysed.
11
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(a) im
(b) Gspine (c) Gspinem
(d) Sspine1 (e) S
spine
w
Figure 9: The energies used for the spine extraction
12
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(a) Original
(b) Unrolled
Figure 10: Extraction of the spine
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3.4.1 MRI scans of children using Dixon
197 children between 10 and 15 years of age were examined in a longitudinal
study at Department of Growth and Reproduction, Copenhagen University
Hospital Rigshospitalet. The imaging sequence used was Dixon.
The bias-correction was performed using an older method [Mosbech et al., 2011].
The segmentation was performed using an early iteration of the method de-
scribed here. A single study was re-examined, to evaluate the robustness of
our software package on diﬀerent patient groups and imaging sequences.
3.4.2 Abdominal and thigh scans of adult men using T1
In the study `Testosteron treatment of men with type 2 diabetes' conducted
at Department of Endocrinology at Odense University Hospital segmenta-
tion was performed on both abdominal slices and thigh slices. 27 men were
scanned twice and imaging were recorded using a T1 sequence without water
suppression.
The analysis was also performed using an earlier iteration of the method
described here. A single study was reexamined to evaluate the robustness
of our software package on diﬀerent patient groups, imaging sequences and
body parts.
4 Results
The segmentation results evaluated by a MD is presented in table 1. The
error was evaluated with Matthews Correlation Coeﬃcient [Matthews, 1975]
and The Dice coeﬃcient. The overall misclassiﬁcation was 0.233 % and 0.101
% for visceral and subcutaneous fat respectively.
A number of repeated errors were identiﬁed. For the subcutaneous fat, the
outer surface was placed inside the fat in a right lateral position. The error
was minor but systematic. Anterior laterally there was often a minor error
at the intersection of the subcutaneous fat, the abdominal compartment and
the lateral muscle compartments. A larger error but not as common, was a
chunk of visceral fat being classiﬁed as subcutaneous in the anterior part.
For the visceral fat, the spine extraction has to some degree errors. These
errors go both way, both too much and too little extracted. Further, the vis-
ceral fat seems to be underestimated. The false positives are predominantly
from the lateral muscle compartments.
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Table 1: Segmentation results from the ACTIWE study. TP = True Posi-
tive, TN = true Negative, FP = False Positive, FN = False Neg-
ative, MCC = Matthews Correlation Coeﬃcient, DICE = Dice
coeﬃcient
Visceral fat Subcutaneous fat
TP TN FP FN MCC DICE TP TN FP FN MCC DICE
34154 564085 497 304 0.988 0.988 48230 550508 197 105 0.997 0.997
57548 540147 890 455 0.987 0.988 55125 542257 1203 455 0.984 0.985
45159 552659 770 452 0.986 0.987 90325 508564 0 151 0.999 0.999
10253 587165 754 868 0.925 0.927 71477 527469 68 26 0.999 0.999
20920 577270 595 255 0.979 0.980 98872 499985 136 47 0.999 0.999
54534 542924 1255 327 0.984 0.986 66935 532050 0 55 1 1
34358 563359 1202 121 0.980 0.981 48936 548819 437 848 0.986 0.987
45115 553113 658 154 0.990 0.991 87724 510035 1044 237 0.992 0.993
17371 579254 1947 468 0.934 0.935 57395 540716 312 617 0.991 0.992
17809 579269 1313 649 0.946 0.948 69356 529544 0 140 0.999 0.999
The analysis of a scan of a child using Dixon, is shown in ﬁg. 11. The bias-
correction has worked ﬁne, as well as the segmentation of the subcutaneous
fat. The visceral fat is, however underestimated.
The analysis of a man in the testosteron study is shown in ﬁg. 12. No
problems were encountered with the bias-correction. For the thigh it was
necessary to change the outer surface energy to
Eo = 0.75 ·Gs + 0.25 · S2 (4)
as the femur had a very strong gradient. Some errors are apparent in the
outer surface, overestimation in the top, and a minor underestimation to the
right. The inner surface lacks support in the lower right part, but except for
that performs acceptable.
For the abdominal slices the ∆y for the inner surface was changed to 70, as
the slices were very far apart and changed considerably. The spine extraction
has failed, and is apparently sensitive to changes in sequence. Except for that
the segmentation is satisfactory.
5 Discussion
We have presented a fully automatic bias-correction and segmentation method
that works robustly across diﬀerent sequences.
15
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Figure 11: Scan of a child using Dixon
As seen from the results the method works very well in general. Our valida-
tion method where a MD marks errors is likely to be biased to some degree, as
the answer is already given by the scan. However, using blind segmentations
is not without problems, as this suﬀers from both intra and inter observer
variance. Even with these drawbacks blinded manual segmentation is often
used as the `ground truth' in comparisons.
This said the bias-correction and segmentation works well, but some problems
persist. Sometimes the visceral fat and subcutaneous fat present with no
visible demarcation. To ﬁx that a heavier smoothing of the inner surface
is used in the anterior part, but even that is not suﬃcient to adequately
correct the problem. The threshold for the visceral fat may need to be
tuned slightly downwards and certainly needs to be sequence dependant. The
current threshold works well in T1 and T1 with water suppression, but not
in Dixon. The original analysis of the Dixon images used Otsu threshold and
this could easily be incorporated. The spine extraction is rather complicated
and not suﬃciently robust. In ﬁg. 10 it misses the right erector spinae muscle
compartment. In the T1 images it fails completely. In many studies the non-
visceral fat is, however, counted as visceral and depending on the study the
lack of this feature may not be critical.
An issue not mentioned before is the lateral muscle compartments. While
16
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(a) Thigh
(b) Abdomen
Figure 12: Segmentation of a man from the testosteron study using T1
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they normally contain very little fat, they should ideally be classiﬁed as a
non-visceral compartment, and the fat present in them counted separately.
6 Conclusion
We have presented a robust, easy to use routine, that performs all the nec-
essary steps for segmentation of abdominal fat. Some work remains before
the software is ready to be made public. See future work below.
7 Future Work
In addition to a rigorous validation across diﬀerent sequences and population
groups, some features should be incorporated.
7.1 Fascia of Scarpa
The fascia of Scarpa partitions the subcutaneous fat. The blood from the
inner part drains to the liver, and it is hypothesised that it is thus too
simpliﬁed to look at the subcutaneous fat as one compartment. The fascia of
Scarpa is ﬁckle and not easily identiﬁed on many slices. Some work has been
done see e.g. [Mosbech et al., 2011]. The segmentation of this fascia should
be incorporated in the package although it is only feasible in T1 with water
suppression and maybe T1 images. A signiﬁcant problem is how to handle
the segmentation in the slices with no support. Especially in the anterior
part, it is often impossible to identify the fascia.
7.2 Non-visceral compartments
The spine extraction needs to be more robust. Moreover, the lateral muscle
compartments should also be extracted and counted separately.
7.3 Automatic spine detection
Instead of relying on user input the spine should be identiﬁed automatically
from the scan. As it has a speciﬁc repeating structure it should be possible,
but may be quite challenging.
18
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7.4 Modify the graph-cut problem
Especially in the anterior part, visceral fat is often located adjacent to the
subcutaneous fat, without a visible demarcation on the scans. By making
the constraints on the graph-cut radially dependant, it would be easier to
achieve a better segmentation in those cases.
7.5 Processing time
The processing time, can be around half an hour for larger scans with around
40 slices. This should be brought down, e.g. by cropping the data-set and
excluding the air voxels around the subject. This would also reduce the
memory requirements.
7.6 Bias-correction
Needs to be validated rigorously across the diﬀerent sequences. Although
problems have not been encountered, it is probable that a lower number of
Gaussians will perform more robustly.
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Appendix F
Lung disease classiﬁcation
in mice using x-ray
phase-contrast and
dark-ﬁeld imaging
  
Abstract—Pulmonary diseases are among the leading causes of 
lowered life-quality and morbidity worldwide. Using 
conventional x-ray imaging, common pulmonary disorders like 
emphysema and fibrosis are difficult to diagnose in their early 
stages.  
In contrast to conventional x-ray imaging, dark-field is more 
sensitive to morphological changes in lung. However, due to 
similar characteristic behavior of x-ray dark-field for both 
emphysema and fibrosis, it has been questioned if it is possible to 
correctly classify the disorders.  
We present a method based on a combination of absorption 
and dark-field signals and incorporation of regional information 
through a healthy lung model that is shown to classify pixel-wise 
between healthy, emphysema and fibrosis with an accuracy of 
84.05 % in a murine model. An easy way to visualize the 
probabilistic results is presented using a colour coded image. 
Finally, the possibility of including the phase-contrast signal for a 
better classification is analysed.  
 
Index Terms— Phase contrast x-ray, dark-field, classification, 
pulmonary disease, fibrosis, emphysema 
 
I. INTRODUCTION 
Lung diseases such as emphysema and fibrosis are among the 
leading causes of lowered life-quality and morbidity 
worldwide [1], [2]. 
Despite substantial histological changes in the architecture 
of the lungs, these diseases are difficult to diagnose in their 
early stage using conventional x-ray radiography [3]–[6]. 
It has been shown in recent studies [7]–[9] that a superior 
sensitivity for the detection of these maladies can be obtained 
using the dark-field radiography. This imaging modality can 
be acquired additionally to differential phase-contrast and 
conventional absorption imaging if a three grating Talbot-Lau 
interferometer is introduced into the beam [10], [11]. The 
dark-field is a measure for the non-resolvable x-ray small-
angle scattering occurring at the air-tissue interfaces in the 
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lung, whereas the phase-contrast visualizes the x-ray beam 
refraction on directly resolved structures.  
The morphological changes, associated with the 
aforementioned disorders lead to a loss of air-tissue interfaces 
and consequent loss of x-ray dark-field signal [12]. Due to 
similar characteristic behavior for different disorders of the 
dark-field it has been questioned whether x-ray grating-based 
imaging is suitable for correct classification of the different 
pulmonary disorders. A prior study [8] has demonstrated 
proof-of-principle feasibility of classification of the disorders 
globally using shape parameters of the lung in addition to the 
mean signal values. In this study we report a method to obtain 
a direct pixel-wise classification probability using only the 
signal values. In particular, we investigate the differences 
between healthy, emphysematous and fibrotic lungs and 
analyze how much we can improve the classification  by 
incorporating local information through a lung model with 
respect to the global signal values. Finally, we assess whether 
the phase image holds additional information that helps the 
classification. 
II. METHODS AND MATERIALS 
A. Imaging 
All animal experiments were approved by the relevant 
authorities. Emphysema and fibrosis were induced in animals 
using an orotracheal instillation with a solution of pancreatic 
elastase or bleomycin in a sterile phosphate-buffered saline, 
respectively. The successful induction of the disorders was 
confirmed by histological analysis. The in vivo imaging was 
performed using a prototype small-animal x-ray phase-
contrast and dark-field scanner [13], [14]. The phase-contrast 
and dark-field radiographies were obtained from 5 images 
acquired at different positions of the source grating, with an 
exposure time of 3.3 seconds per step. The x-ray source was 
operated at 35 kVp and 18 W. The image resolution is 
approximately 60 µm (10% MTF). During image acquisition 
the animals were breathing freely after being anesthetized 
using intraperitoneal injection of medetomidine (500 μg/kg), 
midazolam (5 mg/kg), and fentanyl (50 μg/kg). 
 
B. Dataset 
In total, 31 healthy, 13 fibrotic and 14 emphysematous mice 
were analyzed. The mice were from prior studies, e.g. [9], 
[15], [16] . An expert radiologist, experienced with phase-
contrast and dark-field imaging, annotated the fibrotic and 
Lung disease classification in mice using x-ray 
phase-contrast and dark-field imaging 
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emphysematous mice by marking regions that were very likely 
to be diseased. The images were partitioned into a training set 
with 6 healthy, 6 fibrotic and 6 emphysematous mice, and a 
test set of 6 healthy, 7 fibrotic and 8 emphysematous mice The 
remaining 19 healthy mice were used to build a model of the 
healthy mouse lung. 
C. Image Processing 
1) Active Appearance Model 
To segment the lung, we used an active appearance model 
(AAM) [8], that automatically delineates the lung using the 
dark-field image, as shown in Figure 1. It then deforms the 
lung to a standard shape. In this way direct comparisons can 
be made across different mice.  
 
Figure 1: The AAM used for lung segmentation on a dark-field image 
2) Rib Extraction 
The ribs were masked and excluded from the analysis, since 
they are visible on the absorption but not on the dark-field 
image. To find them we used a histogram equalization of the 
absorption image. The equalized image was filtered by a 
Laplacian of Gaussian (kernel size: 25x25 pixels, standard 
deviation of 8 pixels) and a threshold (values above 0.0004) 
applied. Finally, areas smaller than 500 pixels were removed, 
see Figure 2.  
 
Figure 2: Identified ribs for exclusion 
3) Spine extraction 
The spine was also masked and excluded from the analysis, 
see Figure 3. It was localized by median filtering the 
absorption image, and downsampling it to one fourth of the 
original size. The gradient was taken in the horizontal 
direction and added to the image. Finally a graph-cut 
algorithm [17] was used to find the two minimum value paths 
from top to bottom of the image, with the constraint that the 
two paths must have a distance of 20 to 55 pixels between 
them.  
 
Figure 3: Absorption image of a mouse with spine identified for exclusion 
D. Features used 
The absorption, dark-field and differential phase images were 
used directly. 
Further, we investigated three possible ways to extract 
additional information from the differential phase image. 
These were based on different texture filters: a range filter, a 
standard deviation filter, and an entropy filter to the image. 
For each pixel in the image we apply a mask of a certain shape 
and size. For the range filter, the difference between the 
maximum and minimum pixel value within the mask is found, 
and that value is returned to the pixel the mask is centered on. 
The standard deviation filter returns the standard deviation, 
while the entropy filter uses the entropy defined by (1). 
𝑒𝑒𝑒𝑒𝑒𝑒𝑒 =  −∑  𝑒 ∙ 𝑙𝑒𝑙2(𝑒)𝑚𝑚𝑚𝑚        (1) 
where – for each pixel in the mask - p is the probability of the 
pixel value of the pixel. The probability is estimated as the 
relative frequency of the pixel value in the entire image. 
We used disk shaped masks for all three filters with radius 
ranging from 3 to 25 pixels. See Figure 4 for an example. 
 
E. Healthy lung model 
Using the 19 healthy mice, a model of the healthy lung was 
generated. The ribs and spine were excluded and the AAM 
was used for segmentation and deformation to a standard 
shape. Then the mean and standard deviation in each pixel 
were calculated across the 19 mice. This was done for the 
absorption, dark-field, differential phase and the 3 times 23 
different images resulting from applying the above filters to 
the differential phase-contrast image. The healthy lung model 
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was used as a way to incorporate regional information and 
thus the varying signal intensity across the lung, see Figure 5.  
 
Figure 5: Average dark-field image of the masked lung of 19 healthy mice 
F. Histograms 
Using the mice from the test set, normalized histograms were 
calculated for each of the absorption, dark-field, phase and the 
3 times 23 different filtered phase images. This gives us 72 
different estimated marginal probabilities of a given value 
belonging to either healthy, emphysematous or fibrotic tissue.  
Further we calculated the histograms for the same values 
but after we have subtracted for each pixel the corresponding 
healthy lung average and then divided with the pixel standard 
deviation from the normal lung. An example of the histograms 
for absorption and dark-field after subtraction and division of 
the healthy lung can be seen in Figure 6. 
 
 
G. Classification and model selection 
By evaluating the histogram value in each pixel, we can 
classify by selecting the disease with the highest probability 
(value in the histogram). When using more than one measure, 
e.g. both absorption and dark-field, the obtained probabilities 
from each histogram are simply multiplied. The final 
classification is then the label: healthy, emphysema or fibrotic, 
that has the highest probability in a given pixel. Calculated 
maps for the whole lung can be visualized using a RGB color 
space, to give a direct impression of how certain a 
classification is, see Figure 7, 8 or 9. The brighter the color the 
more certain the classification is and an uncertain 
classification between e.g. fibrosis and emphysema is 
highlighted by purple color. 
 
Figure 6: Absorption and dark-field signals histograms obtained from the 
lung model.  
 
The absorption image, dark-field, differential phase image, 
and the 23 different filtered images for both range, standard 
deviation and entropy were tested to see which yielded the 
best classification. 
The model was based on forward selection. All features 
were tested and the best included. Keeping that chosen feature 
all the rest was tested and the best included. This procedure 
was repeated.  The measure for success was accuracy (Acc) 
defined as: how large a fraction of the lungs in the test set that 
was classified correctly. The accuracy was determined for 
each mouse in the test set, and the mean of all accuracies was 
used. 
To penalize complex models, the Bayesian information 
criterion (BIC) [18] and Akaikes information Criterion, 
corrected for small sample size (AIC) [19] was used. 
They are defined respectively: 
𝐵𝐵𝐵 = 𝑒 ∙ ln(1 −𝐴𝐴𝐴) + 𝑘 ∙ ln (𝑒)      (2) 
𝐴𝐵𝐵 = 2𝑘 + 𝑒 ∙ ln(1 −𝐴𝐴𝐴) + 2𝑚(𝑚+1)
𝑛−𝑚−1
     (3) 
where n is the number of samples (mice), and k the number of 
parameters in the model (features included). The model 
yielding the smallest value is then preferred. 
 
III. RESULTS 
A. Training set 
We tested four separate sets:  
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• Raw image values: using only the raw values with no 
lung model.  
• Lung model: where the pixel values have been 
corrected by subtraction of the mean and division 
with standard deviation of the lung model. 
• Combined model: Using the lung model on 
absorption and dark-field and the raw values of the 
phase and filter images. 
• Phase filters: With only the differential phase and 
filter images 
 
The results for the training set are presented in Table 1. 
Moving right from the first column additional features are 
included. I.e. the highest scoring model for ‘Raw values’ is the 
one based on Drk, Abs and R(25). Abs stands for absorption, 
Drk for dark-field, R is range filter, S is standard deviation 
filter, and E is entropy filter; the number given in brackets () 
denotes the radius of the filter. Highest accuracy is marked 
with blue, and the model selected by BIC and AIC – which in 
all cases coincided - is marked with green. 
B. Test set 
The models selected by BIC and AIC were tested on the test 
set. Results are presented in Table 2. The best method, based 
on the use of a lung model, yielded an accuracy of 84.05 %. 
Using the raw signal values results in a somewhat worse 
classification. Surprisingly, combining the lung model with 
phase information actually performs worse, and using the 
phase information alone is only a little better than guessing. 
An example for the classification algorithm for an 
emphysematous and a fibrotic mouse that showed good 
agreement with the findings of a radiologist are shown in 
Figure 7 and 8 respectively. 
The lung model performed particularly poorly for two mice – 
one emphysematous and one fibrotic shown in Figure 9. The 
emphysema mouse revealed significantly lower dark-field 
values than expected.  
 
 
IV. DISCUSSION 
Using the raw values alone gives an acceptable classification 
in most cases, but incorporating regional information through 
a lung model yields superior results. The differential phase-
contrast information did not improve classification. 
The raw values give a decent accuracy of 76.42 %, with a 
clear outlier in one fibrotic animal. Excluding that, the 
accuracy level increases to 80.15 %. 
Using only absorption and dark-field combined with local 
information by terms of the lung model, has an overall 
accuracy of 84.05 %. In one emphysema mouse the model 
fails due to very high values in the dark-field. The reason for 
this could be additional lung injury (e.g. blood accumulation) 
in the lung. The one misclassified fibrotic animal (Figure 9) 
has a very early stage of fibrosis that looks akin to 
emphysema. Both fibrosis and emphysema start by an acute 
inflammation of the lung, therefore, classification of the two 
disorders at an early stage without prior clinical knowledge is 
challenging. 
Incorporating the phase features does not increase the 
accuracy nor the robustness of the methods. This is surprising 
as there is discriminatory power in the features when 
inspecting the histograms. It is however likely that the 
variance from mouse to mouse is too large, making the phase 
features less useful. Using a more sophisticated classification 
method than simply multiplying the histogram values it might 
be possible to use this information. To test if the joint 
probabilities yielded better results, we tried to classify using a 
Quadratic Discriminant Analysis [20]. This did not yield better 
results. 
A big advantage of our classification method is the 
associated probability of the classification and the easy to 
interpret visual results. 
The phase features might have other applications as well. In 
[21] the aeration of the lungs was correlated with the power 
spectrum. A more direct measure could have been one of the 
phase features we employed, which would have yielded 
information of the local aeration. 
V. CONCLUSION 
Healthy, emphysematous, and fibrotic mice can be 
discriminated and classified using absorption and dark-field 
images. The classification is improved by incorporating 
regional information through a lung model, and can be 
presented as easy to interpret images. The differential phase-
contrast information was useless in the classification, but 
might be useful if a more advanced classification scheme is 
employed. 
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Figure 4: Segmented lungs from healthy mouse. A) absorption, B) dark-field, C) differential phase, D) range filter, E) STD filter, F) entropy filter. All filters 
with radius 15 pixels. 
A B C 
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Figure 7: An emphysematous lung (mouse: Emphysema 4) showing good agreement with classification. Green: healthy. Blue: Emphysema. Red: 
fibrosis. The yellow line is the region demarcated as fibrosis by an expert. 
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Figure 8: A fibrotic lung (mouse: Fibrosis 4) showing good agreement with classification. Green: healthy. Blue: Emphysema. Red: fibrosis. The yellow 
line is the region demarcated as fibrosis by an expert. 
 
  
215
  
Figure 9: A fibrosis lung (mouse: fibrosis 1), relatively poorly classified using lung model. Green: healthy. Blue: Emphysema. Red: fibrosis. The yellow 
line is the region demarcated as fibrosis by an expert. 
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Table 1. Training set results 
 
 
 
Table 2: Accuracy values obtained for test set 
Disease Labelled 
Mice 
Raw  
[Drk Abs] 
Lung model  
[Drk Abs] 
Combined  
[Drk Abs R (25)] 
Phase measures 
[R (25)] 
Healthy 1 75.66 94.10 93.15 28.63 
Healthy 2 87.13 94.53 93.66 33.01 
Healthy 3 50.39 76.70 76.98 28.80 
Healthy 4 48.99 85.61 82.41 27.45 
Healthy 5 82.96 98.26 97.34 30.65 
Healthy 6 64.47 96.52 95.15 27.98 
Emphysema 1 84.33 82.15 67.78 27.54 
Emphysema 2 96.49 95.96 97.63 83.63 
Emphysema 3 91.83 92.95 36.18 0.47 
Emphysema 4 99.59 94.60 84.99 20.19 
Emphysema 5  80.66 65.80 44.31 9.80 
Emphysema 6 79.36 33.89 57.03 66.49 
Emphysema 7 95.01 84.80 62.29 9.57 
Emphysema 8 84.99 58.22 80.56 83.51 
Fibrosis 1 1.84 51.67 27.94 2.50 
Fibrosis 2 98.59 84.98 91.71 90.97 
Fibrosis 3 60.94 96.04 98.96 97.11 
Fibrosis 4 98.04 98.93 23.69 22.96 
Fibrosis 5 82.51 86.59 96 82.54 
Fibrosis 6 41.00 92.84 66.47 1.08 
Fibrosis 7 100 99.96 99.96 82.02 
All Healthy 68.27 90.953 89.78 29.42 
All Emphysemous 89.03 76.05 66.35 37.65 
All Fibrotic 68.99 87.29 72.10 54.17 
Total 76.42 84.05 74.96 40.80 
  
Raw values Drk Abs  R(25) Phase E(3) R (20) R(3) S(25) S(3) R(22) 
Accuracy % 66.91 79.57 81.24 81.22 80.23 78.98 77.77 76.75 75.64 74.66 
Lung model Drk Abs  Phase R(25) R(24) R(23) R(22) R(21) R(20) R(19) 
Accuracy % 78.38 88.63 88.77 66.66 63.40 61.37 59.81 58.51 57.46 56.53 
Combined Drk Abs R(25) Phase S(25) Ent(3) R(3) E(25) S(3) R(20) 
Accuracy % 78.37 88.63 90.63 90.71 90.48 89.95 88.78 87.04 85.26 83.30 
Phase filters R(25)  Phase R(23) R(24) R(3) S(25) R(20) R(22) S(3) R(21) 
Accuracy % 61.05 62.26 62.56 62.27 62.12 62.14 62.01 61.83 61.68 61.56 
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